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1 Introduction 
1.1. The immune system 
Defense against a vast range of different pathogens encountering an individual during its lifetime 
is accomplished through the well coordinated action of the innate and adaptive branches of the 
immune system. Innate immunity provides a rapid and relatively unspecific first response to 
pathogens. In contrast, adaptive immunity contributes features as individual antigen specificity, 
self-non-self discrimination, receptor diversity, and immunological memory to a pathogen. In 
mammals, all cells of the immune system are derived from pluripotent stem cells and they 
develop during hematopoiesis in the bone marrow in adults. Hematopoietic stem cells 
differentiate either into myeloid or lymphoid progenitor cells. Myeloid progenitors are the 
precursors of granulocytes and macrophages, which play a major role within the innate branch of 
the immune system. Common lymphoid progenitors either give rise to B and T lymphocytes or 
to natural killer (NK) cells. Whereas NK cells are also considered to be part of innate immunity, 
B and T cells are key players of the adaptive arm of the immune system. Via a series of sequential 
differentiation steps and selection processes, B and T lymphocytes acquire unique variants of 
antigen receptors that are not self-reactive, but highly specific for a certain antigen. Thus, the 
lymphocyte population of an individual harbors a large repertoire of receptors that are highly 
diverse in their antigen binding site. An adaptive immune response is subdivided into humoral 
and cell-mediated immunity. The latter is performed by specialized cytotoxic T cells and is risen 
against intracellular pathogens, such as viruses, as well as against aberrant cells of the body, like 
tumor cells. Humoral immune response is based on the effect of antigen-specific antibodies, 
which are secreted by antigen-activated B cells. Additionally, a set of plasma proteins known as 
the complement system enhances recognition and destruction of encountered pathogens. As the 
expansion of cell populations in response to antigens followed by subsequent downregulation of 
the response occur permanently in the immune system, a tight control of these processes is 
essential to prevent dangerous developments such as autoimmunity or cellular transformation.  
1.1.1 T cell development  
Lymphocyte development is initiated in the bone marrow with the commitment of a 
hematopoietic stem cell to a common lymphoid precursor cell (CLP), which may give rise to B 
and T lymphocytes or NK cells. CLPs that receive signals via the Notch1 receptor are committed 
to the T cell lineage and migrate to the thymus, where they further develop into T cells before 
emigrating to the periphery. The earliest stages of immature T cells are designated as double 
negative (DN), as these cells lack the expression of both the T cell receptor (TCR) and the co-
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receptor molecules CD4 and CD8. Via a series of sequential differentiation steps, the 
rearrangement of the TCR genes occurs over four stages (DN1-4) that are differentiated based 
on their CD25 and CD44 surface expression. T lymphocytes are distinguished into αβ or γδ T 
cells, depending on whether their TCR is formed by αβ or γδ chains. The β, γ, and δ TCR loci 
rearrange almost simultaneously during DN2 to 3 stages and the decision that a precursor 
commits to the αβ or γδ lineage is thought to depend on whether a functional γδ receptor is 
produced before a functional β chain, which can pair with a pTα to form the pre-TCR (βpTα). 
Mostly, αβ T cells are generated. At a checkpoint known as β-selection, only DN3 cells that 
express a functional pre-TCR in association with CD3 are selected to mature to proliferating 
DN4 cells. These pass through a transient immature CD8+ single positive (ISP) stage before 
maturing into CD4+CD8+ double positive (DP) T cells. At the DP stage, TCR α chain 
rearrangement is completed, resulting in the expression of the TCR. The TCR binds its cognate 
antigen exclusively when it is presented via a major histocompatibility complex (MHC) molecule 
on an antigen-presenting cell. DP thymocytes are then subjected to a serial selection process 
ultimately yielding single positive (SP) T cells. These thymocytes either express CD4 or CD8 in 
combination with a TCR that displays a moderate affinity to self-MHC. Mature, SP T cells exit 
the thymus and migrate to the periphery, where they operate either as CD8+ cytotoxic T cells in 
cellular immunity or provide antigen-activated B cells during humoral immunity with additional 
signals as CD4+ helper T cells (TH). 
1.1.2 Early B cell development 
During embryogenesis, B cell development starts in the fetal liver, and is continued in the bone 
marrow in adults. Thereby, B lymphocytes are generated via a series of sequential differentiation 
steps, yielding the surface expression of a functional, non-self-reactive B cell receptor (BCR). The 
BCR complex consists of an immunoglobulin heavy chain (IgH), an immunoglobulin light chain 
(IgL), and two associated signaling molecules, Igα and Igβ (cp. Fig. 3). Whereas antigen specificity 
and binding are provided by the variable regions of IgH and IgL, Igα and Igβ mediate 
downstream BCR signaling into the cell (reviewed in Janeway, 2007). 
B cell development is initiated with the commitment of lymphoid precursor cells to the B cell 
lineage, what critically depends on the transcription factors E2A, EBF, and Pax5. While E2A and 
EBF activate B cell-specific gene expression and induce the initiation of immunoglobulin (Ig) 
gene rearrangement, Pax5 restricts any further development to the B cell lineage by repressing 
lineage-inappropriate genes like Notch1 and simultaneously activating the expression of B cell 
signaling molecules (Busslinger, 2004). In the earliest B lineage cells, known as pro-B cells, 
expression of two enzymes encoded by the recombination-activated genes rag-1 and rag-2 induces 
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the rearrangement of the Ig heavy chain locus. This process is known as somatic recombination 
and involves the rearrangement of variable (V), diversity (D), and joining (J) gene segments 
encoding for the variable Ig regions. By individual VDJ joining, each B cell acquires a unique 
receptor specificity and thus a limited number of inherited gene segments can give rise to a 
greatly divers antibody repertoire. DH to JH joining at the early pro-B cell stage is followed by VH 
to DH joining at the late pro-B cell stage (Tonegawa, 1993). Another enzyme, terminal 
deoxynucleotidyl transferase (TdT), contributes to the diversity of the BCR by adding N-
nucleotides at the rearrangement joints (Gilfillan et al., 1993). Following successful rearrangement 
of the Ig heavy chain locus, a pre-BCR is expressed on the cell surface of large pre-B cells. The 
pre-BCR complex consists of the rearranged Igμ heavy chain and a surrogate Ig light chain, 
which is composed of VpreB and λ5. Pre-BCR signaling promotes light chain rearrangement in 
small pre-B cells. As soon as an Ig light chain has been successfully rearranged and can pair with 
the heavy chain, it replaces the surrogate light chain to form a complete IgM molecule. Once a B 
cell expresses the BCR on its surface, the cell is defined as an immature B cell (Bossy et al., 1991). 
As soon as one Ig heavy or one Ig light chain allele has been productively recombined, a 
mechanism known as allelic exclusion prevents further rearrangements of the second Ig allele to 
guarantee that a single B cell only expresses Ig molecules of a single specificity (Alt et al., 1984). 
Cells lacking a productive Ig heavy or light chain rearrangement after the first recombination 
process have the possibility to undergo a further rearrangement process of the second Ig allele. In 
case of a still unproductive rearrangement, cells undergo apoptosis. A series of selection events in 
the bone marrow guarantees that only B cells that have gained a non-self-reactive BCR enter the 
peripheral B cell pool. Cells that are self-reactive are eliminated by clonal deletion, become 
anergic or are reprogrammed through a mechanism known as receptor editing. The latter changes 
the BCR specificity by further rearrangements to ablate autoreactivity (Edry and Melamed, 2004).  
Anergic cells can enter the periphery but cannot be further activated and possess only a short 
half-live. Cells that are autoreactive but escape this negative selection in the bone marrow can 
cause autoimmune diseases. While about 2x104 IgM+ immature B cells are generated daily in the 
murine bone marrow, only about 10 % of these cells are able to survive these series of selection 
events (Gay et al., 1993; Radic et al., 1993; Tiegs et al., 1993). Those B cells exit the bone marrow, 
enter the circulation, and migrate to the spleen to undergo further maturation. 
1.1.3 Late B cell development – Marginal zone versus follicular B cell differentiation 
The spleen is divided into two compartments known as red and white pulp. The splenic 
lymphocytes are mainly harbored in the white pulp, which is organized in follicles with respective 
B and T cell areas, surrounded by the marginal sinus and the marginal zone. A detailed scheme of 
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the follicular microarchitecture is illustrated in figure 1. Immature B cells that are “in transit” 
from the bone marrow to the periphery are referred to as “transitional” B cells when entering the 
spleen. These cells comprise a distinct short-lived developmental transition from immature into 
mature B cells. Thereby these cells develop via several differentiation stages (1 to 3). Transitional 
type 1 (T1) B cells are subjected to an additional selection process, allowing only about one third 
of T1 transitional B cells to further differentiate via the T2 and T3 transitional stage, ultimately 
giving rise to mature B cells (Chung et al., 2003). At all stages, B cell survival critically depends on 
signals of the BCR (Lam et al., 1997; Kraus et al., 2004), delivered presumably in a tonic (ligand-
independent) fashion in the periphery when no antigen is encountered. From the T2 transitional 
B cell stage, also survival signals via the B cell activating factor (BAFF) receptor are required 
(Moore et al., 1999; Hsu et al., 2002). Only cells that gain excess to the splenic follicles within days 
have the ability to develop into long-lived B cells. 
 
 
 
 
 
 
 
In the spleen, two major subsets of mature B cells, follicular (Fo) and marginal zone (MZ) B cells 
are discriminated. With about 75 %, Fo B cells constitute the majority of peripheral B cells in 
adults. Circulating with the blood stream, Fo B cells continuously pass the peripheral lymphoid 
tissues. With about 5 %, MZ B cells are less abundant. Together with specialized macrophages, 
MZ B cells line the marginal sinus at its outer border and form the marginal zone, separating the 
red from the white pulp. In contrast to Fo B cells, MZ B cells do not circulate to other lymphoid 
organs and can therefore exclusively be found in the spleen. The marginal zone is constantly 
exposed to large amounts of blood that exit the circulation through the marginal sinus. By 
trapping pathogens that have reached the blood stream, MZ B cells provide a first and rapid 
immune response to various blood-borne bacteria. For that specialized function, MZ B cells are 
pre-activated and highly express special surface receptors like the complement receptors 
CD21/35. Whereas homing of B cells to the follicular B cell zone is dependent on the 
Figure 1 Immunohistochemical analysis of a murine 
splenic cryosection. Follicular B cells (bright red) form the 
follicular B cell zone, which is located next to the T cell zone 
(white). Germinal centers (blue) as hallmark structures of a T 
cell-dependent (TD) immune response are formed at the 
border between B and T cell zone by proliferating B cells 
upon TD activation. A splenic follicle is surrounded by the 
marginal sinus (indicated by an arrowhead), which is lined by 
specialized macrophages and marginal zone B cells (dark red), 
forming the marginal zone. Follicles form the white pulp of 
the spleen. These are surrounded by the splenic red pulp that 
consists mainly out of connective tissue and vasculature. In 
this compartment, filtration of the blood and removal of old 
erythrocytes are accomplished. Staining: α-IgM (red), PNA 
(blue); 14 days after TD immunization; Bar: 250 µm. 
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engagement of the CXCR5 receptor by the chemokine CXCL13, which is expressed by follicular 
dendritic cells, B cells are attracted to the MZ by the engagement of their S1P1 and S1P3 
receptors through lysophospholipid-shingosine-1-phosphate, which is available in the blood. MZ 
B cells highly express these receptors in comparison to Fo B cells. Adhesion of MZ B cells within 
the MZ is further mediated through the interaction with MARCO receptors, expressed on MZ 
macrophages, and via binding of integrins like LFA-1 and α4β1 on MZ B cells to adhesion 
molecules on stroma cells (Pillai and Cariappa, 2009).  
A third population of mature B cells that has not been discussed yet is known as B1 B cells. 
These cells do not conform to the developmental pathway that is described above and have to be 
distinguished from the conventional B2 cells, like Fo and MZ B cells. The main parts of the B1 B 
cells are thought to arise early in ontogeny and to be derived from stem cells in the fetal liver. B1 
cells form the predominant B cell population in the peritoneal and pleural cavities and share both 
some phenotypic and functional analogies with MZ B cells. Both populations have the capacity 
for self-renewal (Tarakhovsky, 1997) and express only a restricted primary antibody repertoire. 
MZ and B1 B cells are regarded as major source of IgM antibodies and are thus rather considered 
as players of innate immunity (Martin and Kearney, 2002; Martin et al., 2001). 
1.1.4 B cell activation 
Mature B cells are referred to as resting and naïve, until they interact with their specific antigen 
and become activated. Depending on the nature of the antigen, B cell activation can either occur 
with or without the involvement of helper T cells (TH cells), known as T cell-dependent (TD) and 
-independent (TI) immune response, respectively. Cross-linking of the BCR by TI antigens, for 
example bacterial polysaccharides, initiates clustering of the BCR and subsequently signaling, 
leading to B cell activation without T cell help. In this way, activated B cells undergo clonal 
expansion and form extrafollicular foci, where they differentiate into plasma cells, secreting low-
affinity IgM or IgG1 antibodies (Gray et al., 1996). In contrast to TD antigens, TI antigens 
neither trigger affinity maturation of the BCR nor the generation of memory B cells. The TI 
immune response is predominantly accomplished by MZ B cells and B1 B cells and leads to a 
prompt, but rather unspecific immune response.  
TD immune responses are mainly performed by Fo B cells, though they also have the ability to 
respond to TI antigens (Rajewsky, 1996). After the binding of a TD antigen by the BCR, the 
antigen is internalized, processed, and presented on major histocompatibility complex (MHC) II 
molecules. CD4+ TH cells that express a TCR specific for the same antigen and have been 
activated by dendritic cells before interact with these B cells at the border between follicular B 
and T cell zone. The TCR binds to both the MHC class II molecule and the presented antigen, 
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initiating internal signaling in both B and T cells. Thus, B cells are provided with co-stimulatory 
signals, which include the interaction between CD40 receptors on B cells and the CD40 ligand, 
displayed on activated TH cells, as well as the stimulation by cytokines, which are released by TH 
cells. Those activated B cells undergo clonal expansion and can either take part in the germinal 
center reaction or migrate to extrafollicular foci, where they differentiate into low affinity 
antibody-secreting plasma cells.  
Germinal center (GC) formation is the hallmark of a TD immune response and is a prerequisite 
for the generation of high affinity antibodies. GCs are structures that are formed by proliferating 
B cells in the follicles of secondary lymphoid tissues like the spleen, lymph nodes, and Peyer’s 
patches within days upon contact with TD antigens. In the GC, B cells undergo somatic 
hypermutation and Ig class switch recombination. Thereby, the enzyme activation-induced 
cytidine deaminase (AID) plays an essential role during both processes (Revy et al., 2000; 
Muramatsu et al., 2000). Somatic hypermutation changes the immunoglobulin variable region 
genes with a mutation rate of 10-3/nt, increasing the antigen specificity of the BCR (Liu et al., 
1997). B cells accomplishing high affinity binding to antigens, displayed on the surface of 
follicular dendritic cells, and simultaneously receiving survival signals from antigen-specific TH 
cells are positively selected. Cytokines released by TH cells induce Ig class switch recombination 
in B cells, leading to the replacement of the μ and δ constant regions with further constant 
regions as γ, ε, and α, while maintaining the same antigen specificity. This process is known as 
isotype switching and leads to the production of IgG1, IgG2a, IgG2b, IgG3, IgE, and IgA 
antibodies, which possess different effector properties and operate at different sites. Central 
functions of secreted immunoglobulins are the neutralization and the opsonization of pathogens, 
followed by phagocytosis through macrophages or lysis mediated by the complement system.  
B cells that have been positively selected during the GC reaction leave the follicle and enter the 
peripheral circulation either as long-lived antibody-secreting plasma cells or memory B cells. 
Plasma cells migrate to the bone marrow, where they reside and secrete high affinity antibodies 
that bind to the specific antigen. Memory B cells remain resting in the peripheral lymphatic 
tissues until they are activated again by a second antigen challenge, allowing a rapid and specific 
secondary immune response and thus long-lasting protective immunity. Interestingly, MZ B cells 
have also been reported to show the ability to form GC structures in splenic follicles after TD 
activation (Song and Cerny, 2003). 
1.2 Central signaling pathways in B lymphocytes 
B cell activation during TD immune response is based on BCR signaling upon binding of cognate 
antigen and on additional signals provided by the contact with CD4+ TH cells. This B-T cell 
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interaction is commonly referred to as “immunological synapse” and includes contacts of various 
cell surface molecules, eliciting internal signaling in both B and T cells. Binding of CD40 ligand 
by the CD40 receptor on B cells is a crucial interaction within that immunological synapse to 
allow B cell activation during a TD immune response. 
1.2.1 CD40 receptor signaling 
CD40 is a member of the tumor necrosis factor receptor (TNFR) family. Its expression was 
initially noted on B cells, but is also found on other antigen-presenting cells like monocytes or 
dendritic cells as well as on non-hematopoietic cells such as epithelial or endothelial cells. The 
engagement of CD40 by the CD40 ligand (CD40L, CD154) triggers clustering of the receptor 
and the recruitment of a set of adaptor proteins known as TNFR-associated factors (TRAFs). 
TRAF proteins interact with the cytoplasmic domain of CD40 and mediate signaling into the cell, 
most prominently by activating the canonical and non-canonical NF-κB pathway as well as the 
mitogen-activated protein (MAP) kinases p38, extracellular signal-regulated kinase (Erk), and c-
Jun N-terminal kinase (Jnk). In addition, JAK-STAT (Janus-activated kinase - signal transducer 
and activator of transcription) as well as phosphoinositol 3-kinase (PI3K) and phospholipase Cγ2 
(PLCγ2) signaling can be triggered in response to CD40 activation (Hanissian and Geha, 1997; 
Harnett, 2004) (Fig. 2). CD40 ligation on B cells in vitro promotes B cell activation, reflected in 
the upregulation of activation and adhesion molecules, and promotes proliferation, survival, and 
cytokine secretion (Dallman et al., 2003; Harnett, 2004). In concert with certain cytokines such as 
IL4, CD40 stimulation of B cells in vitro induces class switch recombination. In vivo, the CD40-
CD40L interaction is essential for a TD immune response. This became evident with the finding 
that patients with “X-linked hyper IgM syndrome” who suffer from diminished generation of 
IgG, IgE, and IgA antibodies including memory B cells harbor mutations in their CD40L gene 
(DiSanto et al., 1993; Korthauer et al., 1993). Later it was shown that mice with inactivated CD40 
or CD40L do neither form GCs nor perform class switch recombination after TD immunization, 
underlining the important role of the CD40-CD40L interaction for the GC reaction (Kawabe et 
al., 1994; Xu et al., 1994).  
1.2.2 NF-κB signaling 
NF-κB/Rel is a family of inducible transcription factors with essential functions during 
lymphocyte development, activation, proliferation, and survival. In mammals, the NF-κB family 
consists of five genes coding for NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB, 
and c-Rel (Bonizzi and Karin, 2004). In resting cells, NF-κB dimers are retained in the cytoplasm 
by the interaction with proteins of the inhibitor of the NF-κB (IκB) family, which mask 
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respective nuclear localization sequences and prevent nuclear transport of NF-κB components. 
In B cells, the canonical NF-κB pathway is rapidly but only transiently activated in response to a 
wide range of stimuli inducing signaling of different receptors including the BCR, Toll-like 
receptors, the IL1 receptor, as well as members of the TNFR family. Upon activation, IκBα, 
which is the most prominent inhibitor of the canonical NF-κB pathway, is phosphorylated and 
ubiquitin-dependently proteasomally degraded, followed by nuclear translocation of p50/c-Rel or 
p50/p65 heterodimers. Activation of non-canonical NF-κB signaling is kinetically slower but 
more sustained. In B cells, its activation is triggered predominantly by engagement of CD40, 
BAFF, or lymphotoxin β receptors and depends on the proteolytic cleavage of the inhibitory 
precursor p100, releasing mainly p52/RelB heterodimers for nuclear translocation (cp. Fig. 2).  
 
 
 
Figure 2 Simplified illustration of CD40 signaling, modified from (van Kooten and Banchereau, 
2000; Elgueta et al., 2009). Upon engagement of the CD40 receptor, TRAFs1,2,3,5, and 6 as well as 
JAK3 are recruited to the cytoplasmic tail of CD40 and drive the activation of the MAPKs Erk, p38, and 
JNK, the canonical and non-canonical NF-κB pathways, PI3K, PLCγ2, as well as JAK-STAT-signaling. 
MAPKs activate transcription factors like Elk1, ATF2, or Jun/Fos that activate gene transcription in the 
nucleus. Activation of canonical and non-canonical NF-κB signaling is initiated with the activation of 
specific kinases (IKKs, NIK), mediating phosphorylation and subsequent ubiquitin-dependent 
proteasomal degradation of inhibitors of NF-κB (IκBα, p100). p50 is constitutively generated by 
processing of p105. NF-κB dimers (RelB:p52, cRel/p65:p50) translocate into the nucleus to activate gene 
transcription. Of note, recruitment of TRAF2 and 3 to CD40 releases otherwise cooperatively degraded 
NIK, allowing NIK accumulation and subsequent activation of non-canonical NF-κB signaling. PLCγ2 
(phospholipase Cγ2), JAK (Janus kinase), TRAF (tumor necrosis factor receptor-associated factor), PI3K 
(phosphoinositol 3-kinase), STAT (signal transducer and activator of transcription), Erk (extracellular 
signal-regulated kinase), Jnk (c-Jun N-terminal kinase), NIK (nuclear factor κB-inducing kinase), IKK (IκB 
kinase), IκBα (inhibitor of NF-κBα), P (phosphorylation), U (ubiquitination).  
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In summary, canonical and non-canonical NF-κB signaling cause the formation and nuclear 
translocation of distinct NF-κB heterodimers that activate NF-κB target genes (Bonizzi et al., 
2004; Dejardin et al., 2002; Derudder et al., 2003). 
1.2.3 B cell receptor signaling 
The successful generation of a functional, non-self-reactive B cell receptor (BCR) is the 
prerequisite for positive selection and survival of B cells during early development in the bone 
marrow. But also the survival of resting, peripheral B cells critically depends on signals delivered 
by the BCR (Lam et al., 1997; Kraus et al., 2004). However, these signals are considered to be 
mediated ligand-independently, and thus to be of a “tonic” nature. During immune response, B 
cells become activated by binding of the cognate antigen to their BCR, initiating BCR signaling 
within minutes. In the BCR complex, a surface Ig molecule that binds an antigen is associated 
with two transmembrane molecules, Igα and Igβ that harbor immunoreceptor tyrosine-based 
activation motives (ITAMs) in their cytoplasmic tails to mediate BCR signaling downstream. 
Upon BCR ligation by antigens, signaling is initiated by phosphorylation of these ITAMs via 
various Src family tyrosine kinases, most prominently through Lyn (Kurosaki, 1999). This allows 
SH2 domain-containing proteins such as Syk to bind to the phosphorylated ITAMs (Rowley et al., 
1995). Syk in turn recruits and phosphorylates SLP65 as well as other adaptor proteins that 
mediate further downstream signaling (Wienands et al., 1998). Thereby, PLCγ2 and PI3K are 
crucial effector molecules. BCR signaling results in the activation of the MAP kinases Erk, Jnk, 
and p38, as well as of canonical NF-κB and Akt signaling (Marshall et al., 2000) (Fig. 3).  
On the cell surface, BCR complexes are constitutively localized in lipid rafts (Bannish et al., 2001; 
Guo et al., 2000). In addition, the BCR is associated with co-receptors that positively or negatively 
influence BCR signaling. CD19 functions as a positive co-receptor, since it lowers the threshold 
of BCR signaling (Pezzutto et al., 1987; Carter et al., 1991). CD19 is present on the cell surface 
with two other transmembrane proteins, CD21 and CD81. CD21 is the complement receptor 2, 
which can be co-ligated with the BCR by complement-coated antigens. CD81 is required to 
stabilize the co-receptor complex, whereas CD19 mediates signaling. PI3K, Lyn, and Vav were 
shown to interact directly with the cytoplasmic tail of CD19 and transmit signaling to PLCγ2, 
Akt, and the MAP kinase Erk (Buhl et al., 1997; Otero et al., 2001; Li and Carter, 1998; Wang et 
al., 2002). As deficiency for Pten, which is a negative regulator of PI3K, was shown to fully 
restore the phenotype of CD19 knock-out mice (Anzelon et al., 2003), CD19 is suggested to 
signal most prominently via PI3K. PI3K/Akt signaling is widely known to promote B cell 
survival and proliferation (Harnett et al., 2005). Recently, PI3K was identified as key mediator of 
tonic BCR signaling (Srinivasan et al., 2009). 
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Figure 3 Simplified illustration of B cell receptor (BCR) signaling, modified from (Dal Porto et 
al., 2004). The BCR complex consists of an Ig surface molecule associated with the signaling proteins Igα 
and Igβ and is linked to a co-receptor complex of CD81, CD19, and CD21. Upon BCR engagement, Src 
family tyrosine kinase Lyn is recruited and phosphorylates the ITAMs of Igα and Igβ, thereby creating 
docking sites for SH2 domain-containing proteins such as Syk. Syk mediates downstream signaling via the 
adaptor proteins SLP65, Vav, and BCAP and activates Btk. Through Vav and Rac, the MAPK cascade 
MEKK-MEK-p38/Jnk is activated, while PKC and Ca2+ also contribute to p38/Jnk activation. A 
complex of SLP65, Grb2, and SOS activates the Ras-Raf-MEK-Erk signaling cascade. MAPKs p38, Jnk, 
and Erk activate transcription factors that activate gene transcription in the nucleus. The lipid-mobilizing 
enzyme PI3K generates PIP3, serving as substrate for PLCγ2 to generate DAG and IP3. Latter induces 
Ca2+ release from the endoplasmatic reticulum and results in the activation of Calmodulin and PKC, 
which is also activated by DAG. PKC activates a complex of Carma1, Malt1, and Bcl10, which activates in 
turn an IKK complex mediating degradation of the inhibitor IκBα, allowing the nuclear translocation of 
canonical NF-κB dimers (c-Rel/p65:p50) to activate gene transcription. PI3K activation is mostly 
triggered by the co-receptor CD19, which binds in addition Vav and Lyn through phosphorylated tyrosine 
residues in its cytoplasmic domain. PIP3 generated by PI3K activates Akt, Btk, Bam 32, and PLCγ2. Akt 
kinase activates Bcl-XL and mTor and inhibits GSK3, an inhibitor of NFAT. Btk kinase activates PLCγ2. 
The adaptor protein Bam32 integrates PI3K and PLCγ2 signaling. Pten negatively regulates PI3K activity 
by degrading PIP3. Ig (Immunoglobulin), H (heavy chain), L (light chain), BCAP (B cell adaptor for 
PI3K), Btk (Burton’s tyrosine kinase), PIP3 (Phosphatidylinositol-trisphosphate), DAG (Diacylglycerol), 
IP3 (Inositol-trisphosphate), PKC (protein kinase C), CaM (Calmodulin), CaMK (Calmodulin-dependent 
kinase), GSK3 (Glycogen synthase kinase 3), Pten (phosphatase with tensin homology), P 
(phosphorylation), U (ubiquitination).   
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1.3 The role of the Notch pathway in lymphocytes 
1.3.1 The Notch signaling cascade 
In 1917, Thomas Hunt Morgan described fruit flies with notches at the edges of their wing 
blades (Morgan, 1917). Decades later, haploinsufficiency in the Drosophila Notch gene, which was 
cloned in the mid eighties, was taken as the basis for that phenotype (Kidd et al., 1986; Wharton et 
al., 1985). Notch signaling is an evolutionarily conserved pathway, which is involved in the 
regulation of cell fate decisions, differentiation processes, cell survival, and proliferation in a wide 
variety of biological systems. In mammals, the Notch family of transmembrane receptors 
comprises four different members, Notch1, 2, 3, and 4 that are bound by different ligands of the 
Delta-like (Dll) or Jagged family (Dll1, 3, 4, Jagged1, 2). Receptor-ligand interaction results in the 
activation of the Notch signaling pathway.  
Notch receptors are heterodimers that are encoded by one gene and that consist of a N-terminal 
extracellular and C-terminal transmembrane and intracellular domain, which are non-covalently 
linked to each other (Blaumueller et al., 1997; Logeat et al., 1998). The extracellular part harbors 
epidermal growth factor (EGF)-like repeats that mediate ligand binding, followed by cysteine rich 
Lin12/Notch repeats (LIN) that prevent ligand-independent activation. A hydrophobic stretch of 
amino acids mediates heterodimerization. The intracellular part contains diverse elements that 
mediate signal transduction. These include the RAM domain and ankyrin repeats, necessary for 
the interaction with downstream effector proteins, nuclear localization signals, and a 
transactivation domain. Furthermore, a PEST (proline-glutamine-serine-threonine-rich) 
sequence, regulating protein stability, is located at the C-terminus (Fig. 4A). Ligand binding to the 
extracellular domain of Notch (NotchEC) results in a regulated set of proteolytic cleavage events, 
liberating the Notch intracellular fragment (NotchIC). Firstly, metalloproteases of the ADAM 
family cleave Notch extracellularly. Shed NotchEC is endocytosed together with the ligand by the 
ligand-expressing cell. A multiprotein complex with γ-secretase activity induces a second cleavage 
of Notch within the transmembrane region. Released NotchIC translocates into the nucleus, 
where it complexes with the DNA binding protein CSL/RBP-Jκ (CBF in human, Suppressor of 
Hairless in Drosophila, Lag1 in C. elegans, RBP-Jκ in mice) and induces the recruitment of co-
activators such as Mastermind. Thus, CSL/RBP-Jκ is converted from a transcriptional repressor 
to a transcriptional activator, ultimately triggering the transcription of Notch target genes (Fig. 
4B). These include most prominently members of the Hes and Hey family (Kopan and Ilagan, 
2009).   
Notch signaling is regulated at multiple levels. Downstream, the Notch activation complex is 
short-lived, as the PEST domain targets nuclear NotchIC for ubiquitin-dependent proteasomal 
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degradation. In addition, negative regulators as the MINT (Msx2-interacting nuclear target) 
protein can compete with NotchIC for complexing with CSL/RBP-Jκ (Kuroda et al., 2003). At 
the level of ligand binding, the Fringe glycosyltransferase modifies NotchEC by adding sugar 
moieties, in a way that preferentially Delta-like (Dll), but not Jagged ligands will initiate Notch 
signaling (Moloney et al., 2000). Recently, it was discovered that the pairing of Notch receptors to 
different ligands influences the outcome of Notch signaling (Besseyrias et al., 2007; Santos et al., 
2007). Moreover, cell type-specific and spatial expression of Notch receptors and Notch ligands 
can limit Notch signaling to a certain cell population and determine its nature.  
 
 
 
Figure 4 Notch primary structure and signaling cascade. (A) The N-terminal, extracellular part of 
Notch (NotchEC) contains 29 to 36 epidermal growth factor (EGF)-like repeats and three cysteine-rich 
Lin12/Notch repeats (LIN). The intracellular part of Notch (NotchIC) harbors a RAM domain (RAM), 
six ankyrin repeats (ANK), two nuclear localization signals (NLS), a transactivation domain (TAD), and a 
proline-glutamine-serine-threonine-rich (PEST) sequence at the C-terminus. NotchEC and NotchIC are 
non-covalently linked; TM (transmembrane); (B) The interaction of NotchEC with ligands of the Delta-
like or Jagged family induces sequential proteolytical cleavages. Notch is extracellularly cleaved by 
members of the ADAM family of metalloproteases, while γ-secretase (GS) cleaves Notch within the 
transmembrane region. Liberated NotchIC translocates into the nucleus to interact with RBP-Jκ 
(recombination signal binding protein for Ig kappa J region) and to recruit a co-activator complex 
containing besides others MAML (mastermind-like), p300 and pCAF (p300-associated factor). SKIP can 
be part of both the co-activator and the co-repressor complex, while the latter contains MINT (Msx2-
interacting nuclear target protein), HDAC1 (histone deacetylase 1) and is displaced from RBP-Jκ by the 
co-activator complex to ultimately activate the transcription of Notch target genes. 
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The outcome of Notch signaling is diverse. While Notch regulates lineage decisions at 
developmental branch points in some circumstances, Notch may maintain cells in 
undifferentiated states or promote differentiation of cells in other contexts. Thus, the outcome of 
Notch signaling is thought to be dependent not only on the nature of ligand pairing, but also on 
the cellular context and signaling strength. 
1.3.2 Notch signaling in lymphocytes 
Both Notch1 and Notch2 have been shown to be expressed on lymphocytes, where they 
function non-redundantly. The essential role of Notch in T cell lineage commitment and 
development is the best-characterized function of Notch in hematopoiesis, whereas the impact of 
Notch on B cell development is not so accurately defined. In bone marrow progenitors, ablation 
of Notch1 or RBP-Jκ results in a block of T cell development and the appearance of ectopic B 
cells in the thymus (Han et al., 2002; Radtke et al., 1999). In contrast, retroviral expression of 
Notch1IC causes a block in B cell development at the pre-/pro-B cell stage and the simultaneous 
development of ectopic T cells in the bone marrow (Pui et al., 1999). These data evidence that 
Notch1 signaling is necessary and sufficient to induce T cell development. Once the T cell lineage 
has been committed, Notch1 is thought to influence the choice of αβ or γδ T cell fates 
(Washburn et al., 1997). Whereas γδ T cells appear to develop Notch-independently, Notch1 
signaling is continuously required for the development of αβ T cells up to the DN3 stage (Wolfer 
et al., 2002). Thereby, Notch1 seems to cooperate with pre-TCR signaling for successful β-
selection (Ciofani et al., 2006; Maillard et al., 2006; Allman et al., 2001a). Notch2 is in contrast 
dispensable for T cell development, but influences lineage commitment during peripheral B cell 
development. While both Notch1 and Notch2 are expressed on early B cell subsets in the bone 
marrow, mainly Notch2 is expressed in mature B cells (Walker et al., 2001; Saito et al., 2003; Witt 
et al., 2003b). In detail, Notch2 expression is predominantly found in transitional type 1 (T1) and 
marginal zone (MZ) B cells (Tan et al., 2009). Since these data revealed Notch expression during 
different stages of B cell development, several groups attempted to study the impact of Notch on 
B cell development and proliferation. Retroviral expression of Notch2IC in all hematopoietic 
stem cells was shown to block B cell differentiation at the large pre-B cell stage and to induce 
ectopic T cell development in the bone marrow. In addition, enhanced B1 B cell differentiation 
was found in the spleen when Notch2IC was expressed at lower levels (Witt et al., 2003b).  
1.3.3 The role of Notch in marginal zone B cell development 
It is well established that Notch2 signals influence the cell fate decision between follicular (Fo) 
and MZ B cells. This has been demonstrated by the B cell-specific inactivation of Notch2 or 
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RBP-Jκ that results in the loss of MZ B cells, while Fo B cells develop in a Notch-independent 
manner (Saito et al., 2003). In addition, the deletion of MINT, a negative regulator of Notch 
signaling, leads to increased MZ B cell development (Kuroda et al 2003), whereas the inactivation 
of MAML1, a co-activator component within the Notch-RBP-Jκ complex, results in defective 
MZ B cell generation (Wu et al., 2007). The crucial Notch ligand for MZ B cell development is 
Dll1 (Hozumi et al., 2004)). Thus, commitment to the MZ B cell compartment is thought to 
depend upon the non-redundant, competitive interaction between the Notch2 receptor on T1 
transitional B cells with the Dll1 ligand, expressed in a limited nature on non-hematopoietic, in 
particular endothelial cells located in the splenic red pulp and MZ. The Dll1-Notch2 interaction 
is presumably weak and is assumed to be strengthened by modifications of NotchEC through the 
glycosyltransferases Lunatic and Manic Fringe (Tan et al., 2009). The precise mechanism, how 
Notch2 signaling contributes to the generation and/or maintenance of MZ B cells is still elusive. 
It is not known whether Notch2 signaling truly drives MZ B cell differentiation or rather 
provides survival signals for these cells.  
Moreover, it is still controversially discussed at which developmental B cell stage Fo and MZ B 
cells branch from each other. Recent studies indicate that the vasculature of the splenic red pulp 
provides a microenvironmental niche, in which T1 transitional B cells, entering the spleen, are 
committed to the MZ B cell lineage (Tan et al., 2009) by receiving Notch2 signals. T1 transitional 
B cells may thus develop to MZ B cell precursor cells (IgMhighIgDhighCD21/35high CD1dhighCD23+) 
and finally to MZ B cells (IgMhighIgDlowCD21/35highCD1dhighCD23-) (Allman and Calamito, 2009). 
T1 transitional B cells, which do not receive Notch2 signals are thought to develop to T2 
transitional B (IgMhighIgDhighCD21/35intCD1dlowCD23+) and Fo B (IgMlowIgDhigh 
CD21/35intCD1dlowCD23high) cells. However, previous studies in the rat point to an origin of MZ 
B cells from the Fo B cell pool (Dammers et al., 1999), suggesting that each B cell including T2 
transitional and Fo B cells, receiving respective signals as from the Notch2 receptor, may adopt a 
MZ B cell phenotype.  
Besides Notch2, a number of gene ablations in the BCR and NF-κB-linked signaling pathways 
display defects of MZ B cell development in parallel with normal Fo B cell development. 
Particularly S. Pillai and A. Cariappa have postulated that the BCR signaling strength is a critical 
determinant for the MZ vs. Fo B cell lineage decision. While strong BCR signals are supposed to 
induce commitment to the Fo B cell pool, weak BCR signals may allow MZ B cell differentiation. 
This hypothesis is supported by various mouse mutants displaying decreased or increased BCR 
signaling strength (Pillai and Cariappa, 2009). Additionally, PI3K signaling seems to be critically 
involved in the generation of MZ B cells. Thus, the deletion of CD19, which signals mainly 
through PI3K, as well as the ablation of the PI3K signaling component p110δ lead to decreased 
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numbers of MZ B cells (Otero et al., 2001; Clayton et al., 2002), whereas enhanced MZ B cell 
formation is observed in mice deficient for Pten, a negative regulator of PI3K signaling (Suzuki et 
al., 2003). Moreover, the inactivation of various NF-κB components, predominantly of the 
canonical NF-κB pathway, resulted in impaired MZ B cell generation (Pillai et al., 2005). Various 
cross-talks between Notch and NF-κB signaling either enhancing or inhibiting NF-κB activity 
have been described (Osipo et al., 2008). However, it is unclear how Notch2, BCR, and NF-κB 
signals are integrated during the commitment of a Fo or MZ B cell fate. It is still in question 
whether Notch2 signaling could be sufficient for the generation of MZ B cells or requires the 
involvement of further signaling pathways.  
1.3.4 Notch signaling in lymphomagenesis 
Notch has been linked to cancer for the first time almost 20 years ago, when a chromosomal 
translocation was identified in T cell acute lymphoblastic leukemia (T-ALL) patients that resulted 
in the overexpression of a constitutive active Notch1 receptor (Ellisen et al., 1991). That 
translocation was later named TAN1 (translocation-associated Notch homologue) and its 
oncogenic effect was proven when bone marrow reconstitution with progenitors expressing 
TAN1 rapidly caused T-ALL in mice (Pear et al., 1996). Meanwhile, deregulated Notch signaling 
has been associated with diverse malignancies (Koch and Radtke, 2007). In the hematopoietic 
system, aberrant Notch signaling is preferentially oncogenic for T cells since constitutive 
activation of Notch1, 2, or 3 have been shown to induce T cell leukemia (Pui et al., 1999; Bellavia 
et al., 2000; Rohn et al., 1996). Moreover, more than 50 % of human T-ALLs suffer from 
activating mutations within the Notch1 gene (Weng et al., 2006). However, the effect of 
deregulated Notch signaling in B lymphocytes in regard to the development of B cell 
malignancies is still controversial. Notch1 and Notch2 are highly expressed in B cell chronic 
lymphatic leukemia and Hodgkin lymphomas and were suggested to promote proliferation and 
survival of these tumors (Hubmann et al., 2002; Jundt et al., 2002a; Jundt et al., 2004; Rosati et al., 
2009). Recently, gain-of-function mutations of Notch2 have been reported in marginal zone and 
diffuse large B cell lymphomas (Troen et al., 2008; Lee et al., 2009). Nevertheless, a direct 
oncogenic effect of activated Notch in B cells has not been described so far. Other studies even 
indicate that Notch itself may rather induce apoptosis in B cells (Morimura et al., 2000; Romer et 
al., 2003; Zweidler-McKay et al., 2005). However, activated Notch has been recently reported to 
synergize with CD40 and BCR signaling to induce proliferation of primary B cells in vitro 
(Thomas et al., 2007). Therefore, the kind of interplay between Notch and other signaling 
cascades is likely to determine the outcome of active Notch signaling in B cells, leading 
potentially either to apoptosis or tumor initiation.  
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1.4 Interplay of signaling pathways in B cell lymphomas 
Notch, CD40, and BCR signaling are all involved in B cell activation and may support B cell 
expansion. Deregulated activation of such signaling cascades may maintain proliferation or 
survival signals inappropriately and may ultimately lead to lymphomagenesis. Therefore, this 
section will pull together the role of these receptors during the development of B cell 
lymphomas. Interestingly, these three signaling molecules are linked to an oncogenic virus, the 
Epstein-Barr virus (EBV). This herpes virus mainly infects human B cells and leads to the 
transformation of B cells in vitro. Thereby, EBV induces the expression of a set of viral latency 
genes in the context of different latency programs. Off note, some of those viral proteins mimic 
constitutive active cellular receptors, including EBNA2, mimicking a constitutive active Notch 
receptor, LMP1, mimicking a constitutive active CD40 receptor, and LMP2A, mimicking a 
constitutive active B cell receptor (BCR).  
Aberrant Notch signaling is clearly transforming for T cells, and the still controversial 
contribution of Notch to B cell malignancies has been described in detail above. More obvious, 
CD40 is involved in the development of B cell tumors. CD40 is not only highly expressed in B 
cell lymphomas like the Hodgkin lymphoma (HL) and B cell chronic lymphatic leukemia 
(O'Grady et al., 1994; Westendorf et al., 1994), but was shown to lead to B cell transformation 
when it is constitutive active (Homig-Holzel et al., 2008). BCR dependency is a main determinant 
of B cell survival over all stages of development including peripheral existence. Many B cell 
lymphomas also seem to be reliant on survival signals mediated by the BCR, thus retaining BCR 
expression. 
One exception is the HL, implicating the interplay of Notch, CD40, and BCR signaling in B cell 
lymphomas. Malignant cells in the HL arise from germinal center B cells and have lost their B 
cell-specific expression pattern including BCR surface expression in the majority of cases 
(Kanzler et al., 1996). To persist, these cells must have activated other survival pathways. In fact, 
constitutive NF-κB activity is a hallmark of HLs (Bargou et al., 1997). Enhanced CD40 and CD30 
signaling have been suggested to contribute to strong NF-κB activity in the malignant cells of this 
tumor. Beside TNFRs, also Notch1 and 2 were reported to be highly expressed in HLs and were 
suggested to promote proliferation and survival of HL cell lines in vitro (Jundt et al., 2002; Jundt et 
al., 2004). Whether HL cells are completely independent of BCR expression is not absolutely 
clear, since all HLs that are truly BCR-negative are infected with EBV and express LMP2A, a 
viral homolog of an active BCR that may substitute for survival signals usually delivered by the 
BCR. EBV-negative HL cells show at least low levels of BCR expression (Kuppers et al., 2005). 
Thus, it is still in question whether these malignant B cells still depend on survival signals from 
the BCR or whether other survival pathways can actually compensate for it.  
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1.5 Model systems 
In this work, various model systems, including transgenic mice and cell lines, were used. In this 
section, the establishment of these systems and previous results will be explained. 
1.5.1 The Notch1/2IC-expressing EREB2.5 cell lines 
The Epstein-Barr (EBV) virus-encoded nuclear antigen 2 (EBNA2) is an important transcription 
factor of EBV, which is not only essential for initiation but also for maintenance of B cell 
immortalization by EBV (Kempkes et al., 1995a). Since EBNA2 is also tethered to promoter 
regions by the interaction with CSL/RBP-Jκ, it is regarded as functional homologue of an 
activated Notch receptor (Henkel et al., 1994; Grossman et al., 1994; Zimber-Strobl et al., 1994). 
Whereas transactivation of genes by Notch depends on previous ligand-receptor interaction, 
EBNA2-mediated transactivation is autonomous and thus constitutive active. Therefore, it is in 
question whether EBNA2 uses the Notch signaling pathway to contribute to B cell 
immortalization.  
To compare the function of NotchIC and EBNA2 in B cells, pRTS-1 expression vectors 
(Bornkamm et al., 2005) encoding for the intracellular parts of human Notch1 and human 
Notch2, respectively, under the control of a doxycycline-inducible, bidirectional promoter were 
generated and stably introduced into human EREB2.5 cells (Kempkes et al., 1995a). EREB2.5 is a 
conditionally EBV-immortalized, human B cell line, in which EBNA2 function and thus the 
EBV program depends on the presence of estrogen. As negative control, the bacterial CAT 
(chloramphenicol acetyl transferase) gene was introduced instead of Notch1IC or Notch2IC 
(Notch1/2IC). These stably transfected cell lines are referred to as Notch1IC/EREB, 
Notch2IC/EREB, and CAT/EREB. In order to identify and sort transgene expressing cells, a 
cDNA coding for a truncated human nerve growth factor receptor (ΔNGFR) was cloned in all 
three cases in the opposite transcriptional orientation. The generation of EREB2.5 cells and 
respective Notch1/2IC- or CAT-expressing cell lines is illustrated in figure 5. In this cell system, 
EBNA2 and Notch1/2IC can be activated separately by adding estrogen and doxycycline, 
respectively. Comparing the kinetics of doxycycline and estrogen induction revealed that in 
EREB2.5 cells, the EBNA2 protein is functionally active and translocated into the nucleus 20 
minutes after the addition of estrogen. In contrast, full expression of Notch is reached four hours 
after the induction through doxycycline. Thus, cells were analyzed at different time points after 
adding estrogen or doxycycline.  
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Figure 5 Generation of EBV-transformed B cell lines expressing doxycycline-regulable, human 
Notch1IC or Notch2IC (Kohlhof et al., 2009). EREB2.5 is a conditionally immortalized 
lymphoblastoid cell line that was established by infecting human primary B cells with an ebna2-deficient 
strain of EBV, while the EBNA2 defect is complemented by an ER-EBNA2 expression plasmid 
(Kempkes et al. 1995a). Thus, EBNA2 function depends on the presence of estrogen. Without functional 
EBNA2, cells exhibit a resting phenotype, while cells proliferate in the presence of estrogen. Notch1IC, 
Notch2IC, and CAT (Chloramphenicol acetyl transferase) were cloned downstream of a bidirectional, 
doxycycline-dependent (Tet-O7) promoter. Transfection of the expression plasmids into EREB2.5 cells 
resulted in the cell lines Notch1IC/EREB, Notch2IC/EREB, and CAT/EREB. ΔNGFR (truncated 
nerve growth factor receptor) serves as marker in order to detect or sort transgene-expressing cells; 
EBNA1 (EBV nuclear antigen 1) ensures episomal maintenance of the expression plasmids; the tet-on 
cassette is coding the reverse transactivator (rtTA) and the KRAB repressor; Hyg (hygromycin expression 
cassette for selection of stably transfected cell clones); ER (estrogen receptor). 
 
Using these cell lines, an Affymetrix GeneChip® analysis was performed by H. Kohlhof, 
revealing that Notch1/2IC and EBNA2 exhibit profound differences in the regulation of target 
genes. Whereas EBNA2 turned out to be more efficient in upregulating genes involved in 
proliferation, survival, and chemotaxis, Notch1IC and Notch2IC were more potent inducing 
genes associated with development and differentiation. Only a small group of not specifically 
classified genes was similarly upregulated by EBNA2 and NotchIC. Since this group contained 
various genes associated with the regulation of cell cycle and proliferation, the question whether 
Notch1/2IC can replace EBNA2 in its function to maintain B cell immortalization, was 
addressed. In vitro studies revealed that Notch1/2IC were not able to maintain survival of 
cultured EREB cells, in contrast to EBNA2. However, Notch1/2IC/EREB cells were still able 
to incorporate BrdU, unlike the negative control CAT/EREB. This indicated that Notch1/2IC 
can drive some cells into the S-phase of the cell cycle although numbers of cultured cells did not 
increase. In addition, annexin staining revealed higher percentages of apoptotic cells in 
Notch1/2IC- compared to CAT- or EBNA2-expressing cells, suggesting that in the absence of 
EBNA2, Notch1/2IC actively induces apoptosis in EBV-infected B cells (Kohlhof et al., 2009). 
Introduction 
 19
In this work, these cell lines were used to study target genes of Notch1/2 in B cells in vitro in 
comparison to gene regulation by EBNA2. 
1.5.2 The LMP1/CD40-transgenic mouse strain 
CD40 plays an essential role during T cell-dependent immune response and is widely expressed 
on tumor cells of diverse B cell malignancies. To study constitutive CD40 signaling in vivo, C. 
Hömig-Hölzel generated a conditional transgenic mouse strain expressing a constitutive active 
CD40 protein in a Cre/loxP-dependent manner. Constitutive activity of CD40 was achieved by 
fusing the signaling domain of human CD40 and the transmembrane domain of the EBV-
encoded latent membrane protein 1 (LMP1/CD40). LMP1 is regarded as a functional equivalent 
of CD40 except that LMP1 signals ligand-independently by self-aggregation of its membrane 
domain. The LMP1/CD40 transgene was targeted into the murine rosa26 genomic locus to 
establish the LMP1/CD40-transgenic mouse strain. LMP1/CD40 signaling in mature B cells 
dependent on CD19-Cre resulted in splenomegaly with a 3.5 fold increase of splenic weight in 
LMP1/CD40 mice compared to controls. Splenic B and T cell numbers of LMP1/CD40 mice 
were strongly increased. LMP1/CD40-expressing B cells displayed an activated phenotype from 
their size and surface expression of activation markers and showed prolonged survival and 
spontaneous cell division in vitro. With one year of age, more than 50 % of LMP1/CD40-
transgenic mice developed B cell lymphomas. C. Hojer further analyzed the activation profile and 
respective importance of signaling pathways in LMP1/CD40-expressing B cells, revealing a 
selective activation of non-canonical NF-κB signaling in LMP1/CD40-transgenic B cells. In 
addition, constitutive CD40 signaling induced the activation of the MAP kinases Jnk and Erk, 
while the increased survival properties of LMP1/CD40-expressing B cells could be assigned to 
this constitutive Erk activation (Homig-Holzel et al., 2008). In this work, these transgenic mice 
were used to study the role of tonic BCR signaling in pre-malignant LMP1/CD40-expressing B 
cells in vivo. 
1.5.3 The Igβ-deficient mouse strain 
The survival of resting, peripheral B cells depends on the expression of a functional BCR. This 
has been initially revealed by the lab of K. Rajewsky, showing that deletion of the BCR or of one 
of its signaling molecules, indeed Igα, lead to a severe diminished mature B cell compartment 
(Lam et al., 1997; Kraus et al., 2004). To investigate the importance of Igβ in the BCR complex 
for mediating survival of mature B cells, N. Uyttersprot generated a knock-out mouse strain 
based on the Cre/loxP system that is conditional deficient for the Igβ C-terminus. The targeting 
strategy she used is detailed in figure 6.  
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In this mouse strain the deletion of the Igβ signaling domain, containing the ITAMs, can be 
traced by concomitant expression of GFP. To allow normal early B cell development and to 
delete Igβ Cre-dependently only in mature B cells, CD21-Cre-transgenic mice were used, deleting 
only from the T2 transitional B cell stage (Kraus et al., 2004). It is not clear, whether the deletion 
of BCR-associated signaling components like Igα or Igβ only severely impairs or entirely 
abrogates tonic BCR signaling. However, such Igβ-deficient mice showed strongly diminished 
peripheral B cell numbers, indicating that the maintenance signal delivered through the BCR 
requires the signaling function of both Igα and Igβ subunits (N. Uyttersprot, personal 
communication). In this work, this mouse strain was used to ablate Igβ and thus to severely 
impair BCR signaling in pre-malignant LMP1/CD40-expressing B cells in vivo. 
 
 
 
Figure 6 Targeting strategy for the generation of the conditional Igβ-deficient mouse strain 
(adapted from N. Uyttersprot). (1) The wild type Igβ locus contains 6 exons, while exon 1 encodes the 
leader sequence, exon 2 and 3 the extracellular (EC) domain, exon 4 the transmembrane (TM) region, and 
exon 5 and 6 the intracellular (IC) domain, containing the ITAMs for signaling. In the 3´ UTR of the Igβ 
gene, a termination sequence is located that contains MAZ (Myc-associated zinc finger) sites. (2) During 
gene targeting, exon 5, 6, and the 3´ UTR region were flanked with loxP sites and a cassette containing a 
truncated exon 5 (5*), an IRES-GFP coding sequence flanked with frt sites, and the wild type 3´ UTR 
sequence including the MAZ sites was placed downstream of the Igβ gene (Igβflox(GFP)). (3) Cre-
mediated excision of the loxP sites-flanked region results in splicing from exon 4 to the truncated exon 5, 
removing the Igβ signaling domain, and ultimately leading to the concomitant expression of a truncated 
Igβ molecule and GFP via the IRES (IgβΔc GFP allele). 
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2 Goal 
Peripheral B cells are resting until they encounter their cognate antigen. Binding of antigens to the B 
cell receptor (BCR) and the interaction with ligands on other cells via specific receptors like CD40 or 
Notch trigger internal signaling, resulting in B cell activation and expansion. Moreover, B cell 
differentiation may be influenced by those signals. Deregulated expression or activation of such 
receptors may inhibit expanding cells to terminate proliferation properly, and may implicate cellular 
transformation. Notch signaling crucially influences lymphocyte differentiation. Whereas Notch1 
signaling is instructive for T cell development, Notch2 signals are essential for the generation of 
marginal zone (MZ) B cells. However, the precise mechanism how Notch2 signaling contributes to 
the generation and/or maintenance of these cells, particularly in interplay with other signaling 
pathways, has not been defined jet. Deregulated Notch signaling is clearly transforming for T cells 
and enhanced Notch expression is also found in divers B cell lymphomas. However, the role of 
Notch in those tumors is still controversial as aberrant Notch signaling has been proposed to 
promote survival and proliferation, but also apoptosis in B cells. A viral homologue of Notch 
interacting as well with RBP-Jκ is EBNA2, an important transcription factor of the Epstein-Barr virus 
(EBV). EBV immortalizes human B cells in vitro, while EBNA2 contributes essentially to that process. 
Since EBNA2 interacts with similar factors as an activated Notch receptor to activate its target genes, 
EBNA2 is suspected to make use of the Notch signaling pathway to contribute to B cell 
immortalization.  
To further specify the role of Notch in B cells, we firstly intended to study target genes of Notch1/2 
in B cells in vitro in comparison to gene regulation by EBNA2, using a cell culture system that allows 
the conditional regulation of EBNA2 and activated Notch. Secondly, we aimed to investigate the 
influence of constitutive Notch2 signaling (Notch2IC) on B cell differentiation, activation, and 
lymphomagenesis in vivo. For that purpose, a conditional transgenic mouse strain allowing B cell-
specific Notch2IC expression should be generated in this work. To study the role of Notch2 in early 
B cells, Notch2IC expression should by activated by mb1-Cre. To analyze the function of Notch2 
predominantly in mature B cells, CD19-Cre should be used for activation. In the latter approach, the 
attention should be particularly turned to the impact of Notch2 on the generation of MZ B cells.   
The CD40 receptor provides B cells with crucial costimulatory signals during TD immune response. 
Moreover, CD40 is highly expressed on divers B cell lymphomas and leads to B cell transformation in 
vivo when it is constitutive active. In developing as well as in mature, peripheral B cells, functional 
BCR signaling is essential for survival. However, it is in question whether aberrantly activated or 
malignant B cells also depend on this tonic BCR signal. In the last part of this work, we therefore 
ablated the BCR-associated signaling molecule Igβ in mature B cells displaying constitutive CD40 
signaling, to study the requirement of tonic BCR signaling in pre-malignant B cells in vivo. 
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3 Results 
3.1 Comparison of Notch1IC, Notch2IC, and EBNA2 target genes in B cells 
in vitro 
We were able to show previously that neither Notch1IC nor Notch2IC (Notch1/2IC) can 
replace EBNA2 in its function to maintain B cell immortalization. Although in the absence of 
EBNA2, Notch1/2IC were able to drive EREB2.5 cells into the S-phase of the cell cycle, cell 
numbers did not increase, presumably due to an increased apoptosis rate in Notch1/2IC-
expressing cells (Kohlhof et al., 2009). To examine whether these biological differences between 
Notch1/2IC and EBNA2 are reflected in the regulation of target genes, mRNA levels of cell 
cycle- and apoptosis-related genes were analyzed by quantitative real-time (q) PCR.  
3.1.1 The experimental setting  
Based on previous kinetic studies, we designed the following experimental approach. In 
Notch1IC/EREB, Notch2IC/EREB, and CAT/EREB cells, EBNA2 function depends on the 
presence of estrogen while the expression of Notch1/2IC or CAT is dependent on doxycycline 
(see 1.5.1 for details). Thus, the cell lines were kept in the absence of estrogen for three days to 
completely abort the effect of EBNA2 on its target gene regulation, before doxycycline or 
estrogen was added. Doxycycline-induced cells were harvested eight and 24 hours and estrogen-
induced cells four and 24 hours after induction (Fig. 7 I.). Since the viability of EREB2.5 cells 
strongly declines after three days of estrogen withdrawal, a modified experimental approach had 
to be applied to analyze long-term effects of Notch signaling. Therefore, cells were induced 
immediately after estrogen withdrawal and were kept in the presence of doxycycline for three 
days before cells were harvested or analyzed (Fig. 7 II.). Sorting of ΔNGFR+ cells by magnetic 
cell separation (MACS) yielded a purity of 87 to 98 % of cells expressing the respective 
transgenes in response to doxycycline. Subsequently, RNA or whole-protein cell extracts were 
isolated for further analyses. To accomplish gene expression monitoring, mRNA was reversely 
transcribed into cDNA. 
3.1.2 Notch1/2 lead to cell cycle entry due to the induction of cell cycle-associated genes 
Firstly, we investigated the regulation of cell cycle- and proliferation-associated genes by 
Notch1/2IC in comparison to EBNA2. Genes to be tested by qPCR were chosen based on an 
Affymetrix GeneChip® analysis performed by H. Kohlhof (Kohlhof et al., 2009). To get further 
insight into the regulation of cell cycle- and proliferation-associated genes, she clustered all 
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differentially expressed genes that had been assigned to these functional groups. Genes were 
arranged in four gene clusters (1 to 4). 
 
 
 
 
 
 
Clusters 1 and 2 contained cell cycle-associated genes that were upregulated late by EBNA2, 
suggesting an indirect regulation. Notch1IC and Notch2IC were able to induce most of these 
genes, however to a lower extent than EBNA2. CCNE1 (CyclinE1), CCNE2 (CyclinE2), CCNA2 
(CyclinA2), and CDK6 from cluster 1 and CDK4 from cluster 2 were selected to confirm their 
regulation by qPCR (Fig. 8A). All genes tested revealed a clear induction 24 hours and three days 
after Notch1/2IC induction as well as 24 hours after EBNA2 activation. In all cases, mRNA 
levels were significantly higher in EBNA2-expressing cells than in Notch1/2IC-expressing cells 
24 hours after induction. Clusters 3 and 4 contained genes which were strongly activated already 
four hours after EBNA2 activation, including some known EBNA2 target genes like CCND2 
(CyclinD2), c-MYC, PIK3R1, and CDK2. qPCR confirmed that regulation by Notch1/2IC behaved 
heterogeneously in clusters 3 and 4. Whereas CCND1, CCND2, and CDK2 were upregulated 
comparably by EBNA2 and Notch1/2IC (Fig. 8B), c-MYC and PIK3R1 were much stronger 
upregulated by EBNA2 than by Notch1/2IC (Fig. 8C). In accordance with the mRNA 
expression data, PIK3R1 protein was detected in EBNA2- but not in Notch1/2IC-expressing 
cells. c-MYC protein expression was induced by Notch2IC and to a higher extent by Notch1IC, 
but did not reach the high peak of c-MYC protein levels as observed early after EBNA2 
induction (Fig. 8D). From that data we draw the conclusion that the entry of Notch1/2IC-
Figure 7 Experimental design for kinetic 
experiments with Notch1IC/EREB, 
Notch2IC/EREB, and CAT/EREB cells. 
Schematic illustration of the experimental 
design that was valid for all kinetic 
experiments. I.) Prior to induction, cells were 
deprived of estrogen for three days. Cells were 
harvested directly after estrogen withdrawal (0 
hours), eight, and 24 hours after doxycycline 
addition (Notch1IC, Notch2IC, CAT), and 
four and 24 hours after estrogen addition to 
CAT/EREB cells (EBNA2). II.) To examine 
the effects of constitutive Notch signaling over 
a period of three days, doxycycline was added 
immediately after estrogen withdrawal and cells 
were harvested three days later. The control 
cell line CAT/EREB was treated in the same 
way as Notch1IC/EREB and 
Notch2IC/EREB cells. Prior to the 
preparation of RNA or to protein isolation, 
ΔNGFR+ cells were purified by MACS 
separation to enrich the cells with a 
transcriptional response to doxycycline. 
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expressing B cells into the S-phase of the cell cycle may be attributed to the induction of several 
cell cycle- and proliferation-associated genes by Notch1/2IC. However, that induction is 
obviously in general lower as the induction by EBNA2, except in case of CCND2, CDK2, and 
CCND1. 
3.1.3 Differential expression of pro-apoptotic and anti-apoptotic genes in Notch1IC-, 
Notch2IC-, and EBNA2-expressing B cells 
Since we observed an increased percentage of apoptotic cells in Notch1IC- and Notch2IC-
expressing cell cultures compared to the negative control CAT/EREB, we were interested in the 
regulation of genes associated with apoptosis. Genes whose expression should be further tested 
were chosen from cluster analysis of apoptosis-related genes, which were at least two-fold 
regulated in the Affymetrix GeneChip® analysis (performed by H. Kohlhof). The cluster analysis 
revealed four different clusters. Cluster 1 contained genes that are mainly induced by 
Notch1/2IC, cluster 2 genes that are regulated by Notch1/2IC and EBNA2, and cluster 3 and 4 
genes that are primarily regulated by EBNA2. Whereas cluster 1 mostly comprised pro-apoptotic 
genes, interestingly we found pro- as well as anti-apoptotic genes in clusters 2 to 4. By qPCR, we 
confirmed that several pro-apoptotic genes like DNASE1L3, BID, and BCL2L11 (BIM) were 
induced by Notch1/2IC and EBNA2 (Fig. 9A). In contrast, most anti-apoptotic genes like 
BCL2A1 (BFL-1), BCL2L1, and BIRC5 (Survivin) were more intensely upregulated by EBNA2 
than by Notch1/2IC (Fig. 9B). Since most of these anti-apoptotic genes are known as LMP1 
target genes (Dirmeier et al., 2005), their high expression in EBNA2-expressing cells is most likely 
due to the high amount of LMP1 protein in EBNA2/EREB compared to Notch1/2IC/EREB 
cells. These data show that Notch1/2IC as well as EBNA2 induce pro-apoptotic genes, implying 
that EBNA2 as well as Notch1/2IC lead to the induction of apoptosis in B cells as long as anti-
apoptotic stimuli, for instance via LMP1, are missing (Kohlhof et al., 2009).  
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Figure 8 Differentially expressed cell cycle- and proliferation-associated genes in 
Notch1IC/EREB, Notch2IC/EREB, CAT/EREB, and EBNA2/EREB cells. Cells were treated as 
outlined in figure 7 and were harvested at indicated time points. mRNA levels were quantified by qPCR 
and are normalized to the expression of ribosomal protein genes. Values represent the fold induction of 
mRNA levels compared to the mRNA levels at 0 hours, which were set to 1. Data represent the average 
of triplicate samples with SD as shown. Coding of the graphs is explained beside the diagram; Notch1IC 
(Notch1IC/EREB), Notch2IC (Notch2IC/EREB), CAT (CAT/EREB), EBNA2 (CAT/EREB after the 
addition of estrogen); The analyzed genes are indicated above each diagram; CCN (cyclins); CDK (cyclin-
dependent kinases); A-C show the results of qPCR analyses of (A) Cell cycle-associated genes, which were 
upregulated late but stronger by EBNA2 than by Notch1/2IC. (B) CCNs and CDKs, which were 
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upregulated early by EBNA2 and similarly by Notch1/2IC. (C) PIK3R1 and c-MYC, which were 
upregulated early and strongly by EBNA2, and only marginally by Notch1/2IC. (D) Protein expression of 
c-MYC and PIK3R1 by Notch1/2IC and EBNA2. Notch1IC/EREB, Notch2IC/EREB, and 
CAT/EREB cells were deprived of estrogen for three days. Whole-cell lysates were harvested from 
growth-arrested cells (0 hours), from cells which were stimulated with doxycycline for eight or 24 hours 
(Notch1IC, Notch2IC, CAT), or from CAT/EREB cells, which were stimulated with estrogen for four or 
24 hours (EBNA2). Additionally, whole-cell extracts were prepared from CAT/EREB cells continuously 
growing in the presence of estrogen (pr). Membranes were stained with antibodies raised against indicated 
proteins. Equal protein loading was controlled by staining with an α-Tubulin antibody.  
 
 
 
 
 
 
Figure 9 Differential expression of pro-apoptotic and anti-apoptotic genes in Notch1IC/EREB, 
Notch2IC/EREB, CAT/EREB, and EBNA2/EREB cells. qPCR analysis of apoptotic (A) and anti-
apoptotic (B) genes. Cells were treated as outlined in figure 7 and were harvested at the indicated time 
points. mRNA levels were quantified by qPCR and are normalized to the expression of ribosomal protein 
genes. Values represent fold induction of mRNA levels compared to the mRNA levels at 0 hours, which 
was set to 1. Data represent the average of triplicate samples with SD as shown. The analyzed genes are 
indicated above the diagrams; The coding of the graphs is elucidated below the diagram; Notch1IC 
(Notch1IC/EREB), Notch2IC (Notch2IC/EREB), CAT (CAT/EREB), EBNA2 (CAT/EREB after the 
addition of estrogen).  
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3.2 The role of Notch2 in B cell differentiation in vivo 
3.2.1 Generation of a transgenic mouse line conditionally expressing Notch2IC  
To further investigate, how Notch2 influences normal B cell development in vivo and whether 
constitutive Notch2 signaling itself promotes B cell lymphomagenesis or rather induces apoptosis 
of mature B cells in vivo, a conditional transgenic mouse strain expressing a constitutive active 
Notch2 receptor (Notch2IC) based on the Cre/loxP system was generated. As we were 
particularly interested to explore the role of Notch in mature B cells, Notch2 was chosen to be 
investigated instead of Notch1, since Notch2 is the Notch family member mainly expressed in 
mature B cells (Saito et al., 2003).  
3.2.1.1 Targeting strategy 
To generate the conditional Notch2IC-transgenic mouse strain, murine notch2IC cDNA was 
targeted into the murine rosa26 locus (Fig. 10, 1). An endogenous ATG-Kozak sequence, located 
at the 5´-end of the notch2IC coding sequence, was used as translational start site. Rosa26 is a 
commonly used locus for transgene expression, as rosa26 is ubiquitously expressed, but can be 
homozygously deleted without phenotypic alterations. 
The used targeting strategy is illustrated in figure 10. The notch2IC cDNA was placed under the 
control of the CAGGS (CMV early enhancer/chicken β-actin/rabbit globin) promoter, which is 
known as very strong and constitutive active promoter, achieving high expression levels in all 
tissues in vivo with the exception of erythrocytes and hair (Niwa et al., 1991; Daly et al., 1999b; 
Daly et al., 1999a). The CAGGS expression module comprises at the 3´-end a short intron 
sequence, flanked by a splice donor and acceptor side, enhancing the transcription rate of the 
otherwise non-spliced transgene cDNA. To restrict the expression of notch2IC in a cell type-
specific manner, a loxP-flanked transcription and translation termination sequence (STOP 
cassette) was placed upstream of the notch2IC coding sequence. To identify cells expressing the 
Notch2IC protein, an IRES-hCD2 cassette was placed downstream of the notch2IC coding 
sequence, leading to the simultaneous expression of a truncated human CD2 (hCD2) molecule 
and Notch2IC. Flanked with frt sites, the IRES-hCD2 sequence may be excised by crossing the 
Notch2IC mouse strain to Flp recombinase-expressing mice, to exclude any alteration of the 
phenotype due to the concomitant expression of hCD2. In the targeting vector, the described 
expression cassette is flanked by rosa26 homologous arms, allowing the insertion into the XbaI 
restriction site of the murine rosa26 genomic locus by homologous recombination (Fig. 10, 2). 
After Cre-mediated excision of the STOP cassette, the notch2IC transgene will be expressed under 
the control of the CAGGS promoter (Fig. 10, 3). 
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Figure 10 Targeting strategy for the generation of Notch2ICflSTOP mice. The conditional notch2IC 
allele (notch2ICflSTOP) was inserted together with an IRES-hCD2 coding sequence into the murine rosa26 
locus. (1) Wild type rosa26 locus with its three exons and the XbaI restriction site in the first intron, where 
the transgene was inserted; (2) Rosa26 locus after homologous recombination of the targeting construct 
(Notch2ICflSTOP); (3) Rosa26 locus after homologous recombination and deletion of the STOP cassette 
upon Cre-mediated recombination (Notch2IC), what leads to the expression of the notch2IC transgene 
under the transcriptional control of the constitutive active CAGGS promoter. The dotted lines illustrate 
the homologous recombination and the excision by Cre. The scheme shows the restriction sites (EcoRI, 
ScaI, KpnI, EcoRV) used for Southern blot digest and the location of the respective probes. The expected 
fragments after the respective digestion and hybridization with the labeled probe are indicated by the thin 
lines. XbaI (site of insertion); CAGGS (CMV early enhancer/chicken β-actin/rabbit globin promoter); 
STOP (STOP cassette); hCD2 (truncated human CD2); NEO (neomycin-geneticin resistance gene); Cre 
(Cre recombinase). 
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For the generation of the transgenic mouse strain, four consecutive steps were required. (1) 
Cloning of the targeting construct; (2) Transfection of the construct in murine embryonic stem 
cells and screening to identify clones, which have inserted the expression cassette into the rosa26 
locus by homologous recombination; (3) Injection of correctly targeted ES cell clones into 
blastocysts followed by implantation into foster mothers; (4) Breeding of resulting chimeric 
offspring with wild type mice to achieve germline transmission of the transgene.  
3.2.1.2 ES cell targeting 
After cloning as described in 8.3.4, the linearized Notch2IC targeting construct was transfected 
into murine IDG2.3 ES cells by electroporation. IDG2.3 is a F1-hybrid cell line that was 
established from a male C57BL/6Jx129/SV (F1) blastocyst (Hitz et al., 2007). 384 G418-resistant 
cell colonies were picked and expanded for further analyses. To identify clones with correct, 
homologous, and single recombination, different Southern blot analyses were performed. The 
different Southern blot strategies are outlined in figure 10. To screen for homologous 
recombination of the targeting vector with the rosa26 locus, EcoRI-digested DNA was hybridized 
to the rosa26 probe, which is externally located at the 5´-end of the targeting vector. This probe 
detects the wild type rosa26 locus as a 15.6 kb fragment and the homologous recombined locus as 
a 6.4 kb fragment (Fig. 11A). 29 out of the 384 screened clones showed homologous integration 
at one rosa26 allele, and out of these, six clones were subjected to further analyses. Non-targeted 
IDG2.3 ES cells were used as negative control. The integration of the entire 9.3 kb expression 
cassette into the rosa26 locus was further confirmed with a ScaI digest and hybridization with the 
rosa26 probe, detecting a 15.4 kb fragment in the recombinant clones and the wild type allele as a 
6.1 kb fragment (Fig. 11B). To prove the complete integration not only from the 5´-site, as 
accomplished by EcoRI and ScaI digests, but also from the 3´-site, a probe recognizing sequences 
of hCD2 was hybridized to KpnI-digested DNA, detecting a 9.2 kb fragment after complete 
integration at the 3´-end (Fig. 11C). To exclude multiple integrations, a probe recognizing a 
sequence of notch2IC was used in combination with EcoRV-digested DNA (Fig. 11D), revealing a 
10.5 kb fragment in the correctly targeted clones and an additional 19.3 kb fragment in all 
examined samples, resulting from the hybridization of the probe with the endogenous notch2 
locus. Moreover, a non-specific signal at the fragment size of 15.0 kb was detected in all 
examined samples including the non-targeted control, what might be due to an unknown 
restriction polymorphism of the notch2 gene in IDG2.3 cells.   
From the Southern blot analyses we concluded that all further examined clones carry the 
Notch2IC expression cassette correctly integrated exclusively in the rosa26 locus. Three out of 
these six clones (NIA5, NIC6, NIIID8) were subjected to sequencing of the notch2IC transgene 
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to exclude any mutations. For this purpose, the transgene was amplified from genomic ES cell 
DNA in two parts by PCR and the sequence integrity of the obtained products was confirmed in 
all clones by BLAST analysis of the sequencing data with the original sequence.  
 
 
 
 
Figure 11 Southern blot analyses of targeted and wild type ES cell clones. Southern blot analyses 
showing the correct and single integration of the Notch2IC expression cassette in the rosa26 genomic 
locus of targeted IDG2.3 ES cells. Genomic DNA from targeted and wild type ES cells was digested with 
the indicated restriction enzymes and subjected to Southern blot analyses with the stated radioactively 
labeled probes; (wt) fragments detect the wild type alleles; expected (rec) fragments are detected after 
homologous recombination. (A) After an EcoR1 digest, a 15.6 kb (wt) and a 6.4 kb (rec) fragment are 
detected by the rosa26 probe. (B) After a ScaI digest, a 15.4 kb (rec) and a 6.1 kb (wt) fragment are 
detected by the rosa26 probe. (C) After a KpnI digest, a 9.2 kb (rec) fragment and no signal in wild type 
ES cells are detected by the hCD2 probe. (D) After an EcoRV digest, the Notch2IC probe detects a 10.5 
kb (rec) fragment, a 19.3 kb (wt) fragment from hybridization with the endogenous notch2 locus, and a 
non-specific 15.0 kb (n.s.) fragment in all lanes. No additional signal down to the size of 2 kb was 
detected, excluding any multiple integrations. 
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Furthermore, the expression of hCD2 was tested by deleting the loxP sites-flanked STOP 
cassette in vitro. For that purpose, targeted ES cells were transiently transfected with a Cre 
recombinase expression plasmid and hCD2 expression was analyzed by flow cytometry after 48 
hours (Fig. 12). 11 to 16 % of hCD2+ cells were detected in the different clones after Cre 
expression, what corresponds approximately to the expected transfection efficiency. Only very 
few (0.35 %) hCD2+ cells were found in the non-transfected control. Thus, we concluded that 
the STOP cassette does not exhibit any leakiness and can be successfully excised via Cre-mediated 
recombination at the loxP sites leading to hCD2 expression via the IRES element in the targeted 
IDG2.3 ES cells. 
 
 
 
Figure 12 Functional testing of targeted ES cell clones for hCD2 expression. Flow cytometric 
analysis of targeted ES cell clones (N1A5, NIC6, NIIID8) 48 hours after transient transfection of a Cre 
recombinase expression plasmid (+ Cre). Non-transfected cells of clone NIA5 served as negative control. 
Numbers display the percentages of TOPRO--gated, hCD2+ cells. 
3.2.1.3 Establishment of the Notch2ICflSTOP mouse line 
In cooperation with the Institute of Developmental Genetics of the Helmholtz Center Munich, 
the clones NIA5 and NIIID8 were injected into C57BL/6-derived blastocysts and were 
implanted into C57BL/6 foster mothers (Fig. 13A). Clone NIA5 gave rise to seven chimeras (Fig. 
13B), showing 95 to 100 % of chimerism, while clone NIIID8 gave rise to four chimeras of 95 % 
of chimerism. To establish the Notch2ICflSTOP mouse strain, chimeras of each clone were bred 
with C57BL/6 mice. Since the notch2IC transgene was passed to the offspring in all cases 
according to Mendelian segregation, 100 % germline transmission of the transgene was obtained 
for each chimera (Fig. 13C).  
As we aimed to investigate the role of Notch2 in B cells, Notch2IC expression was activated 
specifically in B lymphocytes at certain differentiation stages. Notch2ICflSTOP mice were either 
crossed to CD19-Cre (Rickert et al., 1997) or mb1-Cre (Hobeika et al., 2006) mice. Both Cre-strains 
induce deletion of the STOP cassette from the pro-B cell stage on. Whereas the deletion 
efficiency mediated by mb1-Cre is already high in pro-B cells, CD19-Cre leads to a gradual 
increase in Cre-mediated recombination as B cells proceed through their differentiation (Rickert et 
Results 
 32
al., 1997). For simplicity, mice carrying one notch2IC knock-in allele, and one CD19-Cre or mb1-
Cre allele, respectively, are referred to as Notch2IC//CD19Cre+/- and Notch2IC//mb1Cre+/- 
mice, respectively. As controls, either Notch2ICflSTOP and CD19Cre+/-, or Notch2ICflSTOPP and 
mb1Cre+/- mice, were used despite otherwise stated, since these control strains showed an 
identical phenotype.  
 
 
 
Figure 13 Blastocyst injection and establishment of the Notch2ICflSTOPP mouse strain. (A) IDG2.3 
ES cell colonies, cultured on an embryonic feeder cell layer, on the day of injection into blastocysts. ES 
cell colonies are indicated by an arrow. (B) Chimeric mouse with 95 to 100 % of chimerism, resulting 
from the blastocyst injection of clone NIA5. The extent of chimerism is judged from the ratio of black 
and brown coat color. A ratio of 25:75 (brown:black) corresponds to a chimerism of 100 % after injection 
of C57BL/6Jx129/SV (F1) ES cells in C57BL/6-derived blastocysts. (C) Genotyping PCR to prove 
germline transmission of the notch2IC transgene detected by a 560 bp PCR product. Transgene detection 
in about 50 % of offspring corresponds to 100 % germline transmission since 50 % was the expected 
transmission of this breeding according to Mendelian segregation. Genomic DNA from clone NIA5 and 
targeting vector DNA served as positive controls for PCR; (1-7) offspring after germline breeding of 
chimeras from clone NIIID8. 
 
3.2.2 Notch2IC protein is translocated into the nucleus and is functional in B cells of 
Notch2IC//CD19Cre+/- mice 
To prove the functionality of the established transgenic mouse strain, the expression of the 
Notch2IC protein after removal of the STOP cassette was analyzed by Western blots of whole-
cell extracts from splenic B cells (Fig. 14A). High expression levels of Notch2IC protein were 
detected in splenic B cells isolated from Notch2IC//CD19Cre+/- mice but not in B cells of 
Notch2ICflSTOP control mice, evidencing that Notch2IC is expressed in vivo after Cre-mediated 
recombination and proving a tight control exerted by the STOP cassette on transgene expression. 
Since nuclear translocation of Notch is a prerequisite for the interaction with RBP-Jκ and the 
activation of target genes, we studied next whether the transgenic Notch2IC protein can be 
translocated into the nucleus. To this end, we separated protein lysates of splenic B cells isolated 
from Notch2IC//CD19Cre+/- and control mice in cytoplasmic and nuclear fraction and analyzed 
the Notch2IC protein level by Western blot (Fig. 14B). Notch2IC protein was detected in large 
amounts in the nuclear fraction of Notch2IC-expressing B cells as multiple bands of slightly 
different molecular weight. A very low level of Notch2IC, but only the variant of higher 
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molecular weight was found in Notch2ICflSTOP or CD19Cre+/- control B cells. In 
Notch2IC//CD19Cre+/- B cells, the detection of multiple signals for Notch2IC slightly differing 
in size could be due to either lacking posttranslational modifications in comparison to wild type 
Notch2IC or to partial degradation.   
To confirm the functionality of the transgenic Notch2IC protein, we examined the expression of 
hes1 and deltex1 in the mutant mice, as both are classical Notch target genes. Both Hes1 and 
Deltex1 levels were significantly increased in whole-cell extracts from Notch2IC-expressing B 
cells compared to controls (Fig. 14C). These data show that the transgenic Notch2IC protein is 
expressed specifically in B cells at high levels upon Cre-mediated deletion of the STOP cassette, 
and can be translocated into the nucleus, where it exhibits its function in the transcriptional 
regulation of target genes, as shown for hes1 and deltex1.  
 
  
 
Figure 14 Notch2IC protein is expressed, translocated into the nucleus, and functional in B cells 
of Notch2IC//CD19Cre+/- mice. Splenic B cells were purified from Notch2IC//CD19Cre+/- and 
control mice. For experiments shown in A-C, both Notch2ICflSTOP and CD19Cre+/- control mice were 
used and showed an identical phenotype. (A) Whole-cell extracts were subjected to immunoblot analysis 
with an antibody raised against Notch2. Equal protein loading was controlled by an α-Tubulin staining. 
The result is representative for five independent experiments. (B) Cytoplasmic (CP) and nuclear (N) levels 
of Notch2IC were analyzed by immunoblot. The purity of cytoplasmic and nuclear extracts was verified 
by an α-Tubulin staining and by an non-specific (n.s.) signal arising only in the nucleus after staining with 
an α-Bcl3 antibody. Equal protein loading was controlled by a Ponceau S staining. The experiment was 
performed three times. (C) Whole-cell extracts were subjected to immunoblot analysis with antibodies 
raised against murine Deltex1 and Hes1. Equal protein loading was controlled by an α-Tubulin staining. 
The experiment was performed five times. 
3.2.3 Early B cell development is blocked in Notch2IC//mb1Cre+/- mice  
Retroviral high-level expression of Notch2IC in hematopoietic stem cells has been shown to 
block B cell development at the large pre-B cell stage and to result in the development of T cell 
leukemia, whereas lower-level expression of Notch2IC selectively promoted B1 B cell 
differentiation (Witt et al., 2003a). To assess what phenotype is achieved when transgenic 
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Notch2IC is expressed from the early pro-B cell stage on, we analyzed the lymphoid 
compartment of Notch2IC//mb1Cre+/- mice by flow cytometry.  
B cells in the bone marrow can be distinguished in B220+CD43+ pro- and large pre-B cells, 
B220+CD43- small pre- and immature B cells, and B220highCD43- mature B cells, recirculating to 
the bone marrow from the periphery. B220+CD43+ B cells can be further divided into Hardy 
Fraction A (BP1-CD24low), Fraction B (BP1-CD24+), Fraction C (BP1+CD24low), and Fraction C´ 
(BP1+CD24+) (Allman et al., 2001b). Lymphoid cells were isolated, stained for the expression of 
various surface markers, and subsequently subjected to flow cytometric analysis. 
Notch2IC expression induced by mb1-Cre resulted in a complete block of B cell development in 
the bone marrow. No immature and mature B cells were detected and even the B220+CD43+ 
pro-/large pre-B cell population was strongly reduced compared to control mice (Fig. 15, upper 
panel and Tab. 1). A more detailed analysis of the remaining B cell population revealed that 
almost all B220+CD43+ B cells are BP1- and CD24low (Hardy Fraction A). The BP1-CD24+ 
population (Hardy Fraction B) was slightly reduced, whereas the BP1+ fractions C and C´ were 
strongly diminished in Notch2IC//mb1Cre+/- mice compared to controls (Fig. 15, lower panel). 
These results indicate that Notch2IC expression blocks B cell development already at Hardy 
Fractions A and B. Analysis of hCD2 expression showed that only around 15 % of B220+CD43+ 
B cells carry a deletion of the STOP cassette (Tab. 1) suggesting that B cell development is 
blocked as soon as Notch2IC is expressed.   
 
 
3.2.4 Notch2IC expression dependent on mb1-Cre causes an aberrant T cell-like 
differentiation in the bone marrow 
In Notch2IC//mb1Cre+/- mice, 72 % of lymphocyte-gated bone marrow cells expressed hCD2, 
although less than 2 % of these cells were B220+ (Tab. 2). Further analyses of this hCD2+ bone 
marrow population showed that up to 99 % of these cells were CD8+, CD4+, CD43+, CD5+, 
Thy1.2+, CD3low but T cell receptor β- (Fig. 16A and data not shown). Thus, the phenotype of 
Figure 15 Early B cell development is blocked in 
Notch2IC//mb1Cre+/- mice. FACS dot blots from 
representative experiments characterizing B cell populations 
in the bone marrow of Notch2IC//mb1Cre+/- and control 
mice. Numbers display the mean percentages and SD of 
lymphocyte-gated pro- and large pre-B cells (B220+CD43+), 
immature and small pre-B cells (B220+CD43-), and mature, 
recirculating B cells (B220highCD43-) (upper panel) or of 
lymphocyte-gated, B220+CD43+ Hardy Fraction A (BP1-
CD24low), Fraction B (BP1-CD24+), Fraction C 
(BP1+CD24low), and Fraction C´ (BP1+CD24+) (Allman et 
al., 2001b) (lower panel). Values were calculated from 10 
analyzed mice per genotype.
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this cell population is clearly reminiscent of T cells. Forward/side scatter analysis of the hCD2+ 
bone marrow population showed that the major percentage of cells is located in the lymphocyte 
gate. Thereby, a notable fraction of cells displayed an activated phenotype, visible from an 
enlarged size in the forward scatter (Fig. 16B).  
 
 
 
 
 
Figure 16 hCD2+ bone marrow cells from 
Notch2IC//mb1Cre+/- display a CD8+, CD4+, 
CD43+, CD5+, Thy1.2+, CD3low phenotype. (A) 
Bone marrow single cell suspensions were stained and 
analyzed by flow cytometry for the expression of 
indicated surface markers. Histograms show overlays of 
the surface expression of the respective molecules on 
lymphocyte-gated, hCD2+ cells from 
Notch2IC//mb1Cre+/- mice (grey line) and 
lymphocyte-gated bone marrow cells from control mice 
(blue line). Mean percentages and SD were calculated 
from 10 independent experiments. (B) Forward/side 
scatter (FSC/SSC) characterization of hCD2+ bone 
marrow cells of Notch2IC//mb1Cre+/- mice. The blot 
displays FSC/SSC distribution of TOPRO-3-, hCD2+ 
cells representative for 15 independent experiments. 
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In total, B220+ B cell numbers were severely reduced in the bone marrow, while Thy1.2+ T cell 
numbers were extremely increased, leading in summary to an increased number of total 
lymphocytes in the bone marrow compared to control animals (Fig. 17A). B220+ B cells in the 
spleen, lymph nodes, and the peritoneal cavity of Notch2IC//mb1Cre+/- mice were drastically 
reduced (Fig. 17B, Tab. S1, and data not shown). The remaining B220+ lymphocyte population of 
these organs did not express IgM, IgD, CD21, or CD23 (data not shown), pointing to a rather 
immature state of these peripheral B cells. T cell development in the thymus of 
Notch2IC//mb1Cre+/- mice was not altered (data not shown) and also T cell numbers in the 
spleen, lymph nodes, and the thymus were comparable to control mice (Fig. 17B and Tab. S1 ). 
The aberrant hCD2+ population was found only in small amounts in other secondary lymphoid 
organs including the blood of Notch2IC//mb1Cre+/- mice, displaying in 50 to 98 % the 
described immune phenotype (data not shown). The percentages of lymphocyte-gated, hCD2+ 
cells in the various organs with percentages of Thy1.2+ T cells and B220+ B cells within this 
population are displayed in table 2, and do rather not point to an established leukemic disease at 
the time point of analysis. Mice of six, eight, 10, and 11 weeks of age were analyzed and all 
showed an identical phenotype. Mice died with 10 to 12 weeks of age of unknown cause of 
death. In summary, the expression of Notch2IC dependent on mb1-Cre blocked early B cell 
maturation at the pro-B cell stage for unknown reasons and led to the formation of an aberrant 
Notch2IC-expressing population with a T cell-like surface phenotype, mainly located in the bone 
marrow. 
 
Figure 17 Notch2IC//mb1Cre+/- mice show T cell expansion in the bone marrow, but have 
reduced B cell numbers in the bone marrow and the spleen. Absolute numbers of lymphocytes or 
total counted cells, lymphocyte-gated, B220+ B cells, and Thy1.2+ T cells in bone marrow (BM) (A) and 
spleen (SP) (B) of Notch2IC//mb1Cre+/- (blank circle) and control (filled circle) mice. Points represent 
data from individual mice and horizontal bars mark the mean value, indicated in numbers above each 
point column. ** P<0.01, *** P<0.001, as calculated by the two-tailed student’s t-test in comparison to 
control. 
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3.2.5 Early B cell development is normal in Notch2IC//CD19Cre+/- mice  
To overcome the block of early B cell development, Notch2ICflSTOP mice were bred with CD19-
Cre mice. CD19-Cre initiates deletion of the STOP cassette from the pro-B cell stage on, but leads 
to a gradual increase in Cre-mediated recombination as B cells proceed through their 
differentiation. Thereby, negative selection of transgene-expressing cells during early B cell 
development may be overcome by delayed recombination. Expression of Cre recombinase under 
the control of the endogenous CD19 promoter has been reported to result in a deletion 
efficiency of 75 to 80 % in bone marrow B cells and > 95 % in B cells of the periphery (Rickert et 
al., 1997). The analysis of hCD2 expression revealed the deletion of the STOP cassette in 17 % 
of all bone marrow, and in 79 % of all splenic B cells in Notch2IC//CD19Cre+/- mice (Fig. 18A). 
The very low deletion efficiency in B cells of the bone marrow indicates a negative selection of 
developing B cells that express Notch2IC, though the percentages and total cell numbers of pro-, 
pre-, and immature B cells were comparable in mutant and control mice. Only percentages and 
total numbers of mature, recirculating B cells were significantly diminished in 
Notch2IC//CD19Cre+/- mice compared to controls (Fig. 18B and Tab. 3).  
In summary, we observed normal early B cell development in Notch2IC//CD19Cre+/- mice in 
contrast to Notch2IC//mb1Cre+/- mice. In addition, high percentages of peripheral B cells 
expressing the transgene were detected. From these results we concluded that the block of B cell 
development can obviously be overcome by the delayed activation of Notch2IC expression 
dependent on CD19-Cre. 
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Figure 18 Early B cell development is normal in Notch2IC//CD19Cre+/- mice. (A) Deletion 
efficiency of the STOP cassette measured by flow cytometric analysis of hCD2 expression on bone 
marrow (BM) and splenic (SP) B cells from Notch2IC//CD19Cre+/- (grey line) and control (blue line) 
mice. Numbers indicate mean percentages and SD of hCD2 expression on lymphocyte-gated, B220+ B 
cells. Values were calculated from 10 independent experiments. (B) Flow cytometric analysis of bone 
marrow single cell suspensions. Numbers display the mean percentages and SD of lymphocyte-gated pro- 
and large pre-B cells (B220+CD43+), immature and small pre-B cells (B220+CD43-), and mature, 
recirculating B cells (B220highCD43-). Values were calculated from twelve analyzed mice per genotype. 
 
 
3.2.6 Marginal zone B cells are the dominant B cell population in Notch2IC//CD19Cre+/- 
mice 
As the genetic deletion of Notch2 or components of its signaling pathway result in the 
abolishment of the MZ B cell population with normal maintenance of the Fo B cell population, 
we were particularly interested, how the peripheral B cell compartment of 
Notch2IC//CD19Cre+/- mice will be affected by the expression of constitutive active Notch2. 
For that purpose, cell populations, in particular B cell subsets, were analyzed in secondary 
lymphoid organs as the spleen, inguinal lymph nodes, and the peritoneal cavity of 
Notch2IC//CD19Cre+/- and control mice. 
3.2.6.1 Notch2IC//CD19Cre+/- mice show a slight splenomegaly, but normal splenic cell 
numbers  
Conditional expression of Notch2IC induced by CD19-Cre resulted in a slight, but statistically 
significant splenomegaly in eight to 16 week-old mice (Fig. 19A), while the splenic weight of 
Notch2IC//CD19Cre+/- mice was increased on average by 1.5-fold compared to control mice 
(Fig. 19B). B and T cell numbers were normal in Notch2IC-expressing mice compared to age-
matched controls (Fig. 19C and Tab. 3). 
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Figure 19 Slight splenomegaly, but normal splenic cell numbers in Notch2IC//CD19Cre+/- mice. 
(A) Splenic size of eight week-old Notch2IC//CD19Cre+/- mice and littermates. The ruler indicates the 
size of the organs. (B) Splenic weight and (C) absolute numbers of total counted cells, B220+ B cells, and 
CD3+ T cells in the spleen (SP) of Notch2IC//CD19Cre+/- (blank circle) and control (filled circle) mice. 
Points represent data from individual mice and horizontal bars mark the mean value, indicated in numbers 
above each point column. *** P < 0.001, in comparison to control, as calculated by the two-tailed 
student’s t-test. 
 
3.2.6.2 Marginal zone B cells are expanded in Notch2IC//CD19Cre+/- mice to the 
expense of the follicular B cell population 
To determine the distribution of different B cell subsets in the spleen, splenic cells were stained 
with different antibody combinations and were subsequently analyzed by flow cytometry. By 
staining cells with α-IgM and α-IgD antibodies, immature and MZ B cells (IgM+IgDlow) can be 
distinguished from Fo B cells (IgM+IgD+). As shown in the dot plots in figure 20A (upper panel), 
the percentage of IgM+IgDlow B cells was significantly increased in Notch2IC//CD19Cre+/- mice. 
As a consequence, the percentage of the IgM+IgD+ B cell population was dramatically decreased. 
However, the remaining Fo B cell population expressed higher overall levels of IgM. Moreover, 
the analysis of CD21 and CD23 expression revealed that the majority of the mature B cell 
fraction in Notch2IC//CD19Cre+/- mice has adopted a MZ B cell phenotype (CD21highCD23-), 
while the percentage of CD21intCD23+ Fo B cells was dramatically decreased (Fig. 20B, upper 
panel). The absolute B cell numbers of Fo and MZ B cells were five times lower and seven times 
higher, respectively, in Notch2IC//CD19Cre+/- mice than those of controls (Tab. 3). These data 
suggest a strong shift of mature B cells to the MZ B cell compartment at the expense of Fo B 
cells upon constitutive Notch2 signaling. 
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3.2.6.3 B cell subsets are altered in the inguinal lymph nodes of Notch2IC//CD19Cre+/- 
mice 
Fo B cells form the pool of mature B cells that recirculate with the blood through the body and 
the peripheral lymphoid organs. In contrast, MZ B cells are sessile at the margin of splenic 
follicles and can thus exclusively be found in the spleen, but not in other secondary lymphoid 
compartments like the lymph nodes. Therefore, we were interested to investigate how the 
intensive generation of MZ instead of Fo B cells affects the B cell subsets in the inguinal lymph 
nodes of Notch2IC//CD19Cre+/- mice.  
Mainly cells that had not deleted the STOP cassette were found in the inguinal lymph nodes of 
Notch2IC//CD19Cre+/- mice, since only 24 % of B cells expressed hCD2 (data not shown). 
Applying an IgM/IgD as well as a CD21/CD23 staining revealed that the predominant B cell 
population in the inguinal lymph nodes is still formed by Fo B cells. However, percentages and 
numbers of this population were reduced compared to the control, while percentages and 
numbers of B cells displaying a MZ B cell phenotype were significantly elevated (Fig. 20A and B, 
lower panel, Fig. S1, right panel). In addition, a slightly increased CD21-CD23- immature B cell 
population was observed. Total B cell numbers were slightly, but not significantly reduced, 
whereas T cell numbers were almost doubled compared to the wild type (Fig. S1, left panel). The 
diminished B cell number and percentage of Fo B cells may be the consequence of reduced 
numbers of circulating Fo B cells in Notch2IC//CD19Cre+/- mice and is in line with the 
reduction of recirculating B cells in the bone marrow as described in 3.2.5. 
 
 
 
 
Figure 20 Marginal zone B cells are expanded in Notch2IC//CD19Cre+/- mice to the expense of 
the follicular B cell population. (A) Lymphocytes of the spleen (SP) and inguinal lymph nodes (iLN) 
were analyzed by flow cytometry for the expression of IgM and IgD. Numbers indicate mean percentages 
and SD of lymphocyte-gated populations of B220+ B cells displaying a Fo (IgM+IgD+) or MZ and 
transitional (IgM+IgDlow) B cell phenotype. (B) Flow cytometric analysis of Fo (CD21intCD23+) and MZ 
B cells (CD21highCD23-) in the spleen (SP) and inguinal lymph nodes (iLN). Numbers indicate mean 
percentages and SD of lymphocyte-gated, B220+ B cells displaying the respective phenotypes. The 
calculations are based on eleven independent experiments. 
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3.2.6.4 Notch2IC//CD19Cre+/- mice harbor reduced B cells in the peritoneal cavity, with 
a preferential loss of B2 and B1a cells  
In the peritoneal cavity, B1 cells are found besides the common IgM+B220highCD5- B2 cells. B1 
cells are a self-renewing IgM+B220low B cell population that can be divided into B1a (CD5+) and 
B1b (CD5low) cells. B1 cells are also located in the spleen in low numbers (Martin and Kearney, 
2000). Recently, Witt and colleagues have suggested that Notch2 plays a determining role in the 
generation of B1 B cells, as they found selective B1 B cell generation in the presence of 
constitutive Notch2 signals in the spleen, and a reduction of peritoneal B1 B cells upon Notch2 
haploinsufficiency (Witt et al., 2003a; Witt et al., 2003b). Thus, we aimed to analyze the different B 
cell subsets in the peritoneal cavity. Peritoneal cells were isolated from mutant and control mice 
and stained with α-IgM, α-B220, α-CD5, and α-hCD2 antibodies, followed by flow cytometric 
analysis. In the peritoneal cavity of Notch2IC-expressing mice, total B cell numbers were reduced 
to less than 25 % of wild type (Fig. 21A). Whereas the percentage of B1a cells was strongly 
diminished, the percentage of B1b cells was slightly increased in Notch2IC//CD19Cre+/- mice 
compared to controls (Fig. 21B), resulting in strongly reduced B1a cell numbers whereas total 
numbers of B1b cells were less affected. The percentages of B2 cells were normal in 
Notch2IC//CD19Cre+/- mice, but total numbers were reduced to about 20 % of wild type. 
Collectively, these results not only reflect again the strongly diminished pool of circulating Fo B 
cells in Notch2IC//CD19Cre+/- mice, but indicate normal B1b cell differentiation with a 
preferential loss of B1a cells in the peritoneal cavity under constitutive Notch2 signaling. 
 
Figure 21 Notch2IC//CD19Cre+/- mice harbor reduced B cells in the peritoneal cavity and show 
a preferential loss of B1a cells. (A) Absolute numbers of total counted cells, IgM+ B1a (B220lowCD5+), 
B1b (B220lowCD5low), and B2 (B220highCD5-) cells in the peritoneal cavity of Notch2IC//CD19Cre+/- 
(blank circle) and control (filled circle) mice. Points represent data from individual mice and horizontal 
bars mark the mean value, indicated in numbers above each point column. (B) Flow cytometric analysis 
of cells isolated from the peritoneal cavity. Numbers display the mean percentages and SD of lymphocyte-
gated, IgM+ B1a (B220lowCD5+), B1b (B220lowCD5low), and B2 (B220highCD5-) cells. Values were 
calculated from nine independent experiments. ** P<0.01, *** P<0.001, calculated by the two-tailed 
student’s t-test, in comparison to control.  
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3.2.7 Notch2IC-expressing B cells are located in the marginal zone and display a pre-
activated phenotype 
MZ B cells are characterized by their location in the MZ, the expression of characteristic surface 
markers as well as by a pre-activated phenotype, allowing rapid responses particularly to T cell-
independent antigens. To further characterize if Notch2IC-expressing B cells display the 
biological behavior as real MZ B cells, various assays were performed. 
3.2.7.1 Notch2IC-expressing B cells are predominantly located in the marginal zone  
To assess the location of Notch2IC-expressing B cells and to examine whether the overall 
structure of splenic follicles may still be maintained in the presence of an extremely enlarged MZ 
B cell population, we performed immunohistochemical analyses of the spleen. Splenic 
cryosections were prepared and stained with different antibodies, using α-IgM to detect B cells in 
the follicular B cell zone and MZ, α-CD3 to detect T cells in the T cell zone, and α-MOMA-1 to 
detect metallophilic macrophages located at the inner border of the MZ. Immunohistochemistry 
revealed that the overall follicular structure with the respective B and T cell zones as well as the 
MZ was retained in Notch2IC//CD19Cre+/- mice (Fig. 22A). The size of the MZ was strongly 
increased and the follicular B cell zone was significantly diminished, while the T cell zone was 
retained normal in size. Furthermore, we investigated whether Notch2IC-expressing B cells can 
be found exclusively in the MZ. For that purpose, a hCD2-specific antibody was used for 
immunohistochemistry in combination with α-MOMA-1 and α-CD3 antibodies. 
Immunohistochemical analysis showed that transgene-expressing cells are predominantly located 
in the splenic MZ, but can also partially be found at the outer border of the Fo B cell zone (Fig. 
22B, upper panel). Moreover, no clusters of hCD2- B cells were detected within the follicle (Fig. 
22B, lower panel). 
3.2.7.2 Notch2IC//CD19Cre+/- B cells show an enhanced expression of MZ B cell 
markers and display an activated phenotype  
A pre-activated phenotype as well as the expression of characteristic surface markers is a hallmark 
of MZ B cells (Pillai et al., 2005). Therefore, splenic cells were stained with antibodies directed 
against further characteristic markers of MZ B cells (CD1d, CD36, CD9, and CD25) as well as 
against activation and adhesion molecules (CD80, CD86, ICAM-1, and MHCII). The surface 
expression level of these markers was analyzed by FACS. Respective histograms are displayed in 
figure 23. Flow cytometric analysis demonstrated an increased expression of CD1d, CD36, CD9, 
and CD25 on Notch2IC-expressing B cells, confirming the MZ B cell phenotype. Furthermore, 
these cells displayed an enhanced expression of the activation markers CD25, CD80, and CD86, 
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and of the adhesion molecule ICAM-1, suggesting an activated phenotype. Moreover, MHCII 
surface expression was significantly reduced on Notch2IC-expressing B cells compared to 
controls. The analysis of the forward scatter revealed an increased cell size of Notch2IC-
expressing B cells compared to control B cells, being in accordance with the pre-activated status 
as well as the MZ B cell phenotype of these cells and explaining the increase in splenic size and 
weight of Notch2IC//CD19Cre+/- mice compared to wild type mice. 
In summary, these data show that Notch2IC-expressing B cells are MZ B cells not only from 
their immune phenotype and activation status, but also with regard to their localization 
predominantly in the splenic MZ. 
 
 
 
 
 
 
Figure 22 Notch2IC-expressing B cells are predominantly located in the marginal zone. (A) 
Immunohistochemical staining of splenic cryosections from Notch2IC//CD19Cre+/- and control mice 
for MOMA-1+ metallophilic macrophages (α-MOMA-1 – blue), lining the marginal zone at the sinus, 
IgM+ B cells (α-IgM – red), and CD3+ T cells (α-CD3 – blue). The MZ is indicated by arrows. Bar: 250 
µm. (B) Splenic cryosections from mice with indicated genotype were stained for metallophilic 
macrophages (α-MOMA-1 – marine blue) and hCD2 (α-hCD2 – red). In the upper row, the white, 
unstained region within the follicle represents the T cell zone and potential hCD2- B cells. Sections in the 
lower row were additionally stained for CD3+ T cells (α-CD3 – pigeon blue). Arrowheads indicate hCD2+ 
B cells within the follicle. Bar: 250 µm. 
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Figure 23 Notch2IC//CD19Cre+/- B cells show an enhanced expression of marginal zone B cells 
markers and display an activated phenotype. Splenocytes were stained with antibodies specific for 
CD1d, CD36, CD9, CD25, CD80, CD86, ICAM-1, and MHCII and were analyzed by FACS. Histograms 
show overlays of cell size (FSC) or overlays of surface expression of the indicated molecules on 
lymphocyte-gated, B220+, hCD2+ B cells from Notch2IC//CD19Cre+/- mice (grey line) and on 
lymphocyte-gated, B220+ B cells from control mice (blue line). Data are representative for five 
independent experiments; FSC (forward scatter). 
 
3.2.8 Analysis of marginal zone B cell precursors in Notch2IC//CD19Cre+/- mice 
Since we confirmed a MZ B cell phenotype for Notch2IC-expressing B cells in vivo, we aimed to 
investigate the generation of MZ B cells in the mutant mice in detail. Immature B cells, emerging 
from the bone marrow, enter the spleen from the blood stream to undergo further maturation by 
differentiating through the T1 (IgMhighCD23-), T2 (IgMhighCD23+), and T3 (IgMlowCD23+) 
transitional B cell stage. Finally, this differentiation yields Fo or MZ B cells. It is still elusive, at 
which differentiation stage transitional B cells are committed to adopt either a Fo or MZ B cell 
phenotype, and in detail how Notch2 contributes to that lineage decision. Recent studies indicate 
that the Fo versus MZ B cell fate decision is already made at the T1 transitional B cell stage (Tan 
et al., 2009). But also commitment from the T2 transitional B cells stage and even from Fo B cells 
has been postulated (Pillai and Cariappa, 2009). To get further insight into the generation of MZ 
B cells, we analyzed the immature/transitional B cell population in Notch2IC//CD19Cre+/- mice 
in more detail. 
Firstly, we investigated the deletion efficiency of the STOP cassette in the different B cell subsets. 
Deletion efficiencies were determined from the percentages of hCD2+ cells in the respective 
populations and are displayed in table 3. While only poor deletion efficiency in pro- and pre-B 
cells was achieved (< 10 %), more than 40 % of immature B cells in the bone marrow showed 
hCD2 expression. In AA4.1+ transitional B cells, the deletion efficiency peaked with 70 % in T1 
transitional B cells, then decreasing in T2 and T3 transitional B cells to less than 50 %, finally 
reaching > 95 % deletion in MZ and 26 % in Fo B cells. While the T1 transitional B cell 
population was significantly increased in Notch2IC//CD19Cre+/- mice, the T2 and T3 
transitional B cell populations were obviously diminished (Tab. 3). The higher deletion efficiency 
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in T1 as compared to T2 transitional B cells suggests that T1 transitional B cells expressing 
Notch2IC develop to MZ B cells, whereas undeleted cells preferentially proceed to T2 
transitional B cells. The gradual decrease of the deletion efficiency from T2 transitional to Fo B 
cells might indicate that B cells deleting the STOP cassette at the T2 transitional stage might still 
develop to MZ B cells.  
To analyze the MZ B cell precursors in more detail, we examined the splenic B cell compartment 
of Notch2IC//CD19Cre+/- mice in comparison to control mice according to an approach 
previously applied by Allman and colleagues (Srivastava et al., 2005; Calamito et al., 2009). For 
that purpose, splenic B cells were purified and stained with antibodies directed against the 
complement receptors CD21/35 as well as IgM, AA4.1, and CD23. As shown in figure 24A, 
three fractions can be defined (Frs. I to III). These three populations were further subdivided 
based on differential AA4.1 and CD23 levels. Fr. I (IgMhighCD21/35low/int cells) is divided in T1 
(AA4.1+CD23-) and T2 (AA4.1+CD23+) transitional B cells (Fig. 28B, left). Within Fr. II, 
(IgMlow/intCD21/35int cells) T3 transitional (AA4.1+CD23+) and Fo (AA4.1-CD23+) B cells can be 
found (Fig. 24B, middle). Fr. III (IgMhighCD21/35high cells) is divided in MZ B cells (AA4.1- 
CD23-) and MZ B cell precursors (AA4.1lowCD23+) (Fig. 24B, right).  
As expected, the Fr. III harboring MZ B cells and MZ B cell precursors was extremely enlarged, 
while Fr. II, containing mainly Fo B cells, was respectively diminished in Notch2IC//CD19Cre+/- 
mice compared to the control. Fr. I was found in normal percentages, but contained significantly 
more T1 transitional B cells than in the control. Furthermore, Fr. III almost exclusively 
comprised MZ B cells but nearly no MZ B cell precursors, in contrast to the control. The 
increased T1 transitional B cell pool is in line with results described above. However, the absence 
of conventional MZ B cell precursors raised the question whether MZ B cell differentiation in 
Notch2IC//CD19Cre+/- mice does not follow the common way as described previously in the 
literature. In case of intensive MZ B cell commitment already at the T1 transitional B cell stage, 
we suspected another kind of MZ B cell precursor with an IgMint/highCD21/35int/high 
AA4.1lowCD23- phenotype. Indeed, such cells were found in large percentages predominantly in 
Fr. II, but also in Fr. III of Notch2IC//CD19Cre+/- mice but not of control mice. Those cells 
were designated as MZ Pre* in figure 24. In summary, our data suggest that in 
Notch2IC//CD19Cre+/- mice, transitional B cells are committed to the MZ B cell pool 
subsequently after receiving Notch2 signals. Commitment might be preferentially achieved from 
the T1 transitional stage, involving a new IgMint/highCD21/35int/highAA4.1lowCD23- MZ B cell 
intermediate, which has not been described so far. T2 cells might still differentiate into MZ B 
cells via the conventional IgMhighCD21/35highAA4.1lowCD23+ MZ B cell precursor stage, which is 
still present in Notch2IC//CD19Cre+/- mice to some extent.   
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Figure 24 Analysis of marginal zone B cell precursor cells. Flow cytometric analysis of splenic B cells 
isolated from mice with indicated genotypes by depletion of CD43+ cells. B cells were stained with 
antibodies specific for CD21/35, IgM, CD23, and AA4.1 and were analyzed by FACS. (A) Blots are 
lymphocyte-gated and display percentages of cells belonging to fraction I to III (Fr. I, II, III) according to 
Allman and colleagues; IgMhighCD21/35low/int cells (Fr. I); IgMlow/intCD21/35int cells (Fr. II); 
IgMhighCD21/35high cells (Fr. III); (B) Numbers display the frequency of events as function of the 
indicated parent gate, which is stated above. Fr. I harbors T1 and T2 transitional B cells, Fr. II T3 
transitional and Fo B cells as well as potential MZ B cell precursors* (MZ Pre*), and Fr. III MZ B cells 
and conventional MZ B cell precursors as well as further MZ B cell precursors*. Data are representative 
for three independent experiments. 
3.2.9 Notch2IC//CD19Cre+/- B cells are hyper-responsive to LPS and α-CD40 stimulation 
in vitro but do not form germinal centers 
Additionally, we tested whether Notch2IC-expressing B cells are hyper-responsive like real MZ B 
cells in response to certain stimuli. Robust induction of proliferation to lipopolysaccharide (LPS) 
or CD40 ligation is known as hallmark of MZ B cells (Allman et al., 2001b; Oliver et al., 1997). To 
determine the proliferation of Notch2IC-expressing B cells in comparison to control B cells, such 
cells were isolated from the spleen, labeled with carboxyl fluorescein succinimidyl ester (CFSE), 
and were cultured with or without α-CD40 or LPS. CFSE is a fluorescent dye that binds to 
proteins of the inner cell membrane and that can be used to monitor proliferation, due to the 
progressive decline of CFSE fluorescence intensity within daughter cells following each cell 
division. Proliferation profiles were recorded after 72 hours with or without α-CD40 or LPS 
stimulation (Fig. 25A). Notch2IC-expressing B cells showed similar proliferation as control B 
cells without stimulation, but displayed a higher proliferation rate in response to α-CD40 or LPS. 
Besides, cell numbers and percentages of living cells declined similarly to the control over five 
days in culture without stimulation (Fig. 25B and C).  
To test whether the pre-activated status of Notch2IC-expressing B cells also results in enhanced 
class switch recombination upon stimulation, splenic primary B cells were cultured in the 
presence of α-CD40 plus IL4, LPS plus IL4, or without any stimulus, and were stained for 
surface IgG1 before as well as after 48 and 72 hours of culture (Fig. 25D). 
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Figure 25 Notch2IC//CD19Cre+/- B cells are hyper-responsive to LPS and α-CD40 stimulation in 
vitro. Splenic B cells of Notch2IC//CD19Cre+/- and control mice were enriched by depletion of CD43+ 
cells. (A) Cells were labeled with CFSE and cultured with or without the indicated stimuli (LPS 
concentration: 10 µg/ml). After 72 hours, proliferation profiles of propidium iodide negative cells were 
assessed by flow cytometric analysis and are displayed in the histogram overlays as black 
(Notch2IC//CD19Cre+/-) and grey (control) graphs. Notch2IC-expressing B cells were identified by re-
gating histograms additionally on hCD2+ cells. Shown proliferation profiles are representative for four 
independent experiments. (B, C) Cells were cultured up to five days without (w/o) stimulation and their 
viability was analyzed on day 0, 1, 3, and 5 after incubation with propidium iodide. Notch2IC-expressing 
B cells were identified by staining additionally for hCD2. (B) Percentages of viable (propidium iodide 
negative) cells were determined by FACS. Percentages of viable control cells and percentages of viable 
Notch2IC-expressing cells at day 0 were each set to 100 %. (C) Total numbers of viable cells were 
determined using FACS by uptaking all cells of one well and excluding dead (propidium iodide positive) 
cells. The graphs show the mean results with SD of three independent experiments either of living cell 
numbers (C) or of viable cells in relation to the input at day 0. Color coding is indicated beside the 
diagrams. (D) Cells were cultured with α-CD40 and IL4, LPS and IL4, or without stimulation (w/o) (LPS 
concentration: 25 µg/ml). After indicated culture times, cells were stained for IgM, IgG1, and hCD2. 
Numbers indicate mean percentages and SD of IgG1+ control B cells and IgG1+, hCD2+ Notch2IC-
expressing B cells of three independent experiments. Only propidium iodide negative cells were included 
in the analysis. 
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In cultures of Notch2IC-expressing B cells, an enlarged fraction of IgG1 class-switched cells was 
detected compared to control cultures, both upon α-CD40/IL4 and LPS/IL4 stimulation. In 
summary, these data show that Notch2IC-expressing B cells are MZ B cells also with regard to 
their biological behavior, as these cells are hyper-responsive to LPS and α-CD40 stimulation. In 
addition, proliferation and survival in vitro without stimulation were not obviously improved, 
underlining that constitutive Notch2 activity in mature B cells impacts only lineage decision but 
not survival and proliferation properties of mature B cells. 
Next, we tested the responsiveness of Notch2IC-expressing B cells in vivo to different antigens. 
MZ B cells have been reported to secrete more IgM and IgG3 than other immunoglobulins 
isotypes (Oliver et al., 1997). During immune response, MZ B cells rapidly differentiate into 
plasmablasts in response to blood-borne bacteria (Oliver et al., 1999; Phan et al., 2005), and are 
thus considered as major source of IgM upon interaction with T cell-independent (TI) antigens 
(Martin and Kearney, 2000; Martin et al., 2001). Nevertheless, MZ B cells have been also shown 
to respond to T cell-dependent (TD) antigen and to form germinal centers (Attanavanich and 
Kearney, 2004; Song and Cerny, 2003).  
To analyze the responsiveness of Notch2IC-expressing B cells in vivo, we firstly examined total 
titers of the different immunoglobulin isotypes in the sera of non-immunized 
Notch2IC//CD19Cre+/- and control mice by ELISA. As shown in the diagram of figure S3A, 
IgG3 titers of Notch2IC-expressing mice were slightly but statistically significantly decreased 
compared to littermate controls, while IgM, IgG1, IgG2b, IgG2a, and IgA titers were unaltered. 
Thus, Notch2IC-expressing MZ B cells were not observed to secrete more IgG3 as suggested 
previously (Oliver et al., 1997). 
Secondly, we aimed to investigate the immune response of Notch2IC//CD19Cre+/- mice upon 
challenge with TD and TI antigens. For that purpose, we immunized mutant and control mice 
with 4-hydroxy-3-nitrophenylacetyl (NP) conjugated to TD chicken gamma globulin (CGG) or to 
TI type 1 LPS, and determined serum titers of NP-specific antibodies by ELISA 14 days after 
immunization. In case of TD immunization, the presence of splenic germinal centers (GC) was 
revealed 14 days after immunization with flow cytometric and immunohistochemical analyses. 
Following TD immunization, the fraction of CD95highPNAhigh GC B cells was drastically reduced 
in the spleen of Notch2IC//CD19Cre+/- mice in comparison to control mice (Fig. 26A) and GC 
structures were almost not detected by immunohistochemistry (Fig. 26B). As a consequence, only 
low levels of NP-specific IgM and IgG1 antibodies were measured by ELISA in the sera of 
Notch2IC//CD19Cre+/- mice immunized with TD antigen (Fig. S3B). In contrast, immunization 
with the TI type 1 antigen NP-LPS resulted in a similar immune response in 
Notch2IC//CD19Cre+/- mice like in controls. Thus, seven days after immunization, levels of 
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NP-specific immunoglobulin titers were comparable to control levels in the serum of 
Notch2IC//CD19Cre+/- mice (Fig. S3C). Only titers of NP-specific IgG3 were lower.  
In summary, these data indicate that Notch2IC-expressing MZ B are especially impaired in their 
immune response to TD antigen, including GC formation and class switch recombination, but 
are not in general detained in plasma cell differentiation as these cells respond to the TI type 1 
antigen LPS. 
 
 
3.2.10 Signaling pathways active in Notch2IC//CD19Cre+/- B cells 
Since we confirmed that Notch2IC-expressing B cells display a pre-activated phenotype as it is 
described for MZ B cells, we studied whether this phenotype is accompanied with the activation 
of certain signaling pathways like NF-κB, MAP kinase, or PI3K/Akt signaling as well as c-Myc 
expression. Until now, the basal activity of these signaling pathways in MZ B cells has not been 
investigated in detail. Moreover, it is not clear how constitutive Notch2 activity impacts the 
activation of these pathways in B cells in vivo. Recently, enhanced basal phosphorylation of Akt 
kinase as well as higher basal levels of c-Myc has been reported for murine primary MZ B cells in 
comparison to Fo B cells in vitro (Meyer-Bahlburg et al., 2009). Furthermore, it has been described 
that IκBα mRNA levels are diminished in MZ B cells (Zhang et al., 2007). 
3.2.10.1 Notch2IC-expressing B cells display reduced basal non-canonical NF-κB activity 
Several reports have described a cross-talk between Notch and NF-κB signaling, resulting either 
in the stimulation or inhibition of NF-κB activity (Osipo et al., 2008). In addition, Notch2 and 
NF-κB1/p50 have been suggested to synergize during MZ B cell development (Moran et al., 
2007). Therefore, we were interested to analyze the basal activity of the canonical and non-
Figure 26 Notch2IC//CD19Cre+/- B 
cells do not form germinal centers. (A) 
Flow cytometry to identify germinal center 
(GC) B cells (CD95+PNAhigh) in the spleen 
of Notch2IC//CD19Cre+/- and control 
mice 14 days after immunization with 100 
µg NP-CGG. Cells are gated on B220+ 
lymphocytes. Numbers indicate the mean 
percentages of GC B cells with SD. Three 
mice were analyzed per group. (B) 
Immunochemical analysis of GC 
formation in the spleen, 14 days post-
immunization with 100 µg NP-CGG. 
Cryosections were stained for B cells (α-
IgM – red) and for GC B cells (PNA – 
blue). Bar: 250 μm. 
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canonical NF-κB pathways in non-stimulated Notch2IC-expressing B cells. Canonical NF-κB 
signaling requires the phosphorylation and subsequent degradation of IκBα, leading to the 
nuclear translocation of p50/p65 and p50/c-Rel heterodimers. Non-canonical NF-κB signaling 
includes the processing of the precursor protein p100 to p52, resulting in the nuclear 
translocation of p52/RelB heterodimers.  
Western blots of whole-cell extracts showed decreased levels of both phosphorylated and non-
phosphorylated IκBα in mutant B cells compared to control B cells (Fig. 27A). To analyze 
whether the decreased IκBα levels influence the nuclear translocation of canonical NF-κB 
components, we performed nuclear fractionation experiments and analyzed the protein levels of 
p50, p65, and c-Rel in the cytoplasm and the nucleus (Fig. 27B). However, a similar basal 
activation of the canonical NF-κB pathway as in the control was observed in Notch2IC-
expressing B cells. 
 
 
 
Figure 27 Reduced basal non-canonical NF-κB activity in Notch2IC-expressing B cells. (A) 
Splenic B cells were purified from Notch2IC//CD19Cre+/- and control mice and whole-cell extracts from 
non-stimulated B cells were subjected to immunoblot analysis using antibodies specific for p100/p52, 
pIκBα (Ser32/36), and IκBα. Equal protein loading was controlled by an α-Tubulin staining. The result is 
representative for five independent experiments. (B) Cytoplasmic (CP) and nuclear (N) levels of NF-κB 
components of splenic B cells from Notch2IC//CD19Cre+/- and control mice were analyzed by 
immunoblot. The purity of cytoplasmic and nuclear extracts was verified by an α-Tubulin staining and by 
an non-specific (n.s.) signal arising only in the nucleus after staining with an α-Bcl3 antibody. Equal 
protein loading was controlled by Ponceau S staining. The experiment was performed two times. 
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Furthermore, we investigated the basal activity of non-canonical NF-κB signaling. In Western 
blot analyses, we detected decreased p52 and marginally increased p100 protein levels in mutant 
B cells compared to control B cells, indicating a diminished processing of p100 to p52, and thus a 
reduced activation of non-canonical NF-κB signaling (Fig. 27A). To corroborate these findings, 
we analyzed the distribution of RelB and p52 in the cytoplasm and nucleus. In accordance with 
the previous result, levels of RelB and p52 were diminished in nuclear fractions of Notch2IC-
expressing B cells compared to control B cells, pointing to a decreased basal activity of the non-
canonical NF-κB pathway (Fig. 27B). These data suggest that constitutive Notch2 activity in B 
cells reduces rather than activates canonical and non-canonical NF-κB signaling. 
3.2.10.2 Notch2IC//CD19Cre+/- B cells show enhanced PI3K/Akt activity and high c-Myc 
levels 
Furthermore, we wondered whether the pre-activated status of Notch2IC-expressing B cells is 
reflected in an enhanced basal phosphorylation of Akt and the MAP kinases Erk and Jnk as well 
as in increased levels of c-Myc. The transcription factor c-Myc is a prominent target of Notch 
signaling and is associated with proliferation, cell growth, and apoptosis. MAP kinases are known 
to mediate proliferation and survival in immune cells, including B cells. Akt kinase promotes cell 
survival and its basal phosphorylation reflects the activity of PI3K, which acts upstream of Akt. 
Thus, we investigated the basal phosphorylation and the total protein amount of these kinases as 
well as protein levels of c-Myc by subjecting whole-cell extracts from Notch2IC-expressing and 
control B cells to Western blot analyses (Fig. 28).  
 
 
Figure 28 Notch2IC//CD19Cre+/- B 
cells show high c-Myc levels as well 
as an enhanced activation of Akt and 
the MAP kinases Erk and Jnk. Splenic 
B cells were purified from 
Notch2IC//CD19Cre+/- and control 
mice and whole-cell extracts from non-
stimulated cells were subjected to 
Western blot analyses using antibodies 
specific for pAkt (pS473) and the 
corresponding non-phosphorylated 
form as well as for c-Myc (A), pJnk1/2 
(Thr183/Tyr185), pErk1/2 (Thr202/ 
Tyr204), and the corresponding non-
phosphorylated forms (B). Equal 
protein loading was controlled by an α-
Tubulin staining. The result is 
representative for four (A) and seven (B) 
independent experiments. 
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We found that the phosphorylated forms of Akt and of the MAP kinases Erk and Jnk were 
strongly increased in non-stimulated Notch2IC-expressing B cells compared to control cells, 
pointing to a constitutive activity of these kinases. Additionally, increased Akt phosphorylation 
indicates enhanced PI3K activity in the mutant cells. Furthermore, Western blot analyses showed 
that c-Myc levels were strongly increased in Notch2IC-expressing B cells in comparison to the 
control (Fig. 28A). In summary, we observed that the pre-activated state of Notch2IC-expressing 
B cells is reflected in an enhanced activation of the PI3K/Akt and MAPK signaling cascades as 
well as in high basal levels of c-Myc protein.  
3.2.11 Constitutive Notch2 signaling overcomes CD19 deficiency during marginal zone B 
cell differentiation  
CD19 functions as a co-receptor of the BCR and was shown to be required for the generation of 
MZ B cells, as these cells are absent in CD19-deficient mice (Pezzutto et al., 1987; Carter et al., 
1991; Engel et al., 1995; Rickert et al., 1995). Since CD19 signals most prominently via PI3K 
(Buhl et al., 1997), diminished PI3K signaling might be responsible for the lack of MZ B cells in 
CD19-deficient mice. This is in accordance with further observations that also the lack of the 
PI3K isoform p110δ has been described to result in defective MZ B cell generation (Clayton et 
al., 2002). The capacity of constitutive Notch2 signaling to induce constitutive phosphorylation 
of Akt, the main downstream target of PI3K signaling, prompted us to investigate whether 
constitutive Notch2 signaling can restore MZ B cell development in the absence of CD19. In 
CD19Cre+/- mice, Cre is placed into and disrupts one CD19 locus, thereby resulting in the knock-
out of one endogenous CD19 allele. Thus, CD19 deficiency was achieved by generating CD19-
Cre homozygous mice (CD19Cre+/+). These mice were crossed to Notch2IC-transgenic mice to 
obtain Notch2IC-expressing, CD19-deficient mice (Notch2IC//CD19Cre+/+). Flow cytometric 
analyses of the B cell compartment of Notch2IC//CD19Cre+/+ mice demonstrated by a 
CD21/CD23 staining that also in the absence of CD19 the MZ B cell population is enlarged 
comparable to Notch2IC//CD19+/- mice up to 70 %, while the Fo B cell fraction is even 
stronger reduced to less than 10 % (Fig. 29A, upper panel). This was confirmed by an additional 
IgM/IgD staining, showing an increased percentage of IgM+IgDlow MZ and immature B cells, 
while the IgM+IgD+ Fo B cell population was dramatically diminished (Fig. 29A, lower panel). 
Immunohistochemistry of splenic sections from Notch2IC//CD19Cre+/+ mice revealed a similar 
follicular organization as found in the spleen of Notch2IC//CD19Cre+/- mice (cp. Fig. 22A), 
including an enlarged MZ. In contrast to Notch2IC-expressing, CD19-proficient mice, B cells 
were not detected inside the follicle, most likely due to the lower numbers of Fo B cells. Sections 
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are illustrated in comparison to sections of CD19Cre+/+ mice, which harbor no MZ but only Fo 
B cells (Fig. 29B). 
 
 
 
Figure 29 Notch2IC induces marginal zone B development despite the absence of CD19. (A) 
Splenic lymphocytes from mice of the indicated genotypes were analyzed by flow cytometry for the 
expression of CD21 and CD23 (upper panel) or IgM and IgD (lower panel); Fo B cells (CD21intCD23+) 
and MZ B cells (CD21highCD23-) (upper panel); Fo B cells (IgM+IgD+), MZ and transitional B cells 
(IgM+IgDlow) (lower panel); Numbers indicate mean percentages and SD of lymphocyte-gated populations 
of B220+ B cells displaying the respective phenotype. The calculation is based on four independent 
experiments. (B) Immunohistochemical staining of splenic cryosections from mice of the indicated 
genotypes for MOMA-1+ metallophilic macrophages (α-MOMA-1 – blue), lining the marginal zone at the 
sinus, IgM+ B cells (α-IgM – red), and CD3+ T cells (α-CD3 – blue). The MZ B cell zone is indicated by 
arrows. Bar: 250 µm. 
Total splenic B cell numbers of Notch2IC//CD19Cre+/+ mice were reduced to about the half of 
CD19Cre+/+ mice, which already suffer from a strongly reduced B cell compartment (Fig. S2A). 
The reduction of mature B cells was traced back to a slightly defective early B cell development 
that was observed in Notch2IC//CD19Cre+/+ mice, mirrored in lower percentages of pre-B cells 
in the bone marrow and less transitional B cells (Tab. 4). This defect can be due to the doubled 
amount of Cre in Notch2IC//CD19Cre+/+ mice because of the CD19-Cre homozygosity, what 
was reflected in a higher deletion efficiency already in the bone marrow compared to 
Notch2IC//CD19Cre+/- mice, yielding 70 % of hCD2+ immature B cells in 
Notch2IC//CD19Cre+/+ mice in comparison to 42 % in Notch2IC//CD19Cre+/- mice. In 
addition, higher percentages of Thy1.2+ cells within the hCD2+ lymphocyte population of the 
bone marrow were observed in Notch2IC//CD19Cre+/+ mice compared to 
Notch2IC//CD19Cre+/- mice (Fig. S2B). Since CD19-Cre expression is known as highly B cell-
specific (Rickert et al., 1997), this may suggest a trans-differentiation of already committed pro-B 
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cells to the T cell lineage as a consequence of an earlier or more intense onset of Notch2IC 
expression due to the CD19-Cre homozygosity. 
Investigating the transitional B cell compartment, an increased T1, but decreased T2 and T3 
transitional B cell populations were found in Notch2IC//CD19Cre+/+ mice in comparison to  
CD19Cre+/+ mice, similarly as observed in Notch2IC//CD19Cre+/- mice. T1 transitional B cells 
displayed again the highest deletion efficiency, suggesting again MZ B cell commitment at that 
stage. Off note, hCD2 expression was found in almost 95 % of T1 transitional B cells, indicating 
that at that stage roughly no B cells are left to escape Notch2-induced MZ B cell commitment. 
All cell numbers and deletion efficiencies of the respective sub-populations are stated in table 4. 
To test whether these CD19-deficient MZ B cells show also a pre-activated phenotype and are 
hyper-responsive to stimulation in vitro, surface expression of activation molecules and MZ B cell 
markers as well as proliferation in response to α-CD40 stimulation were examined. B cells 
isolated from Notch2IC//CD19Cre+/+ mice showed an even larger size than 
Notch2IC//CD19Cre+/- B cells and displayed an increased expression of the markers CD86 and 
CD36 compared to the control (Fig. 30A). In response to stimulation with α-CD40, Notch2IC-
expressing, CD19-deficient B cells showed a higher proliferation rate than control cells, 
comparable to Notch2IC-expressing B cells proficient for CD19 (Fig. 30B). Consequently, a pre-
activated and hyper-responsive phenotype of Notch2IC-expressing B cells was also observed in 
the absence of CD19. Ultimately, Western blot analyses evidenced an increased activation of the 
MAP kinases Erk and Jnk as well as elevated levels of c-Myc protein in Notch2IC-expressing B 
cells also in the absence of CD19 (Fig. 30C). However, preliminary results of first analyses 
indicated only normal activation of Akt in Notch2IC//CD19Cre+/+ B cells (data not shown).  
In summary, constitutive Notch2 signaling was shown to overcome CD19 deficiency, 
demonstrating that constitutive Notch2 signaling acts independently of CD19 in the generation 
of MZ B cells. Increased activation of PI3K/Akt due to constitutive Notch2 signals could form 
the basis to compensate for CD19 ablation.  
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Figure 30 CD19-deficient, Notch2IC-expressing B cells are pre-activated and hyper-responsive 
and show increased MAPK activation as well as c-Myc levels. (A) To examine the immune 
phenotype of Notch2IC//CD19Cre+/+ B cells, splenocytes were stained with antibodies specific for the 
indicated surface markers. Histograms show overlays of cell size (FSC) or overlays of the surface 
expression of the indicated molecules on lymphocyte-gated, B220+ B cells from the indicated genotypes. 
Data are representative for three independent experiments; FSC (forward scatter). (B) To test whether 
Notch2IC//CD19Cre+/+ B cells are hyper-responsive, splenic B cells from mice of the indicated 
genotypes were enriched by depletion of CD43+ cells and were labeled with CFSE before cells were 
cultured with α-CD40 antibody. After 48 hours, the proliferation profiles were assessed by flow 
cytometric analysis and are displayed in the histograms. Numbers indicate percentages of lymphocyte-
gated, propidium iodide-negative cells of one representative analysis. Notch2IC-expressing B cells were 
identified by gating on hCD2+ cells. The experiment was performed twice. (C) To investigate whether the 
pre-activation of Notch2IC//CD19Cre+/+ B cells is also reflected in the activation of certain signaling 
pathways, splenic B cells were purified from mice of indicated genotypes and whole-cell extracts from 
non-stimulated cells were subjected to Western blot analysis using antibodies specific for pErk1/2 
(Thr202/Tyr204), pJnk1/2 (Thr183/Tyr185), and the corresponding non-phosphorylated forms (left 
panel) as well as c-Myc (right panel). Equal protein loading was controlled by an α-Tubulin staining. The 
result is representative for three independent experiments. 
Results 
 58
3.3 The role of B cell receptor signaling in LMP1/CD40-activated B cells 
In a second project of this work, we were interested in the role of B cell receptor (BCR) signaling 
in pre-malignant B cells in vivo. Survival of resting, peripheral B cells critically depends on the 
expression of a functional BCR. It is believed that BCR-mediated survival signals occur ligand-
independently and are thus of “tonic” nature. Recently, these signals were shown to be mediated 
by PI3K (Srinivasan et al., 2009). Until now, it is in question whether aberrantly activated or 
malignant B cells also depend on this tonic BCR signal. This brought us to the question whether 
constitutive CD40 signaling can overcome the need for a functional BCR. To investigate this 
hypothesis, we have genetically abrogated Igβ, one signaling molecule of the BCR complex, in 
pre-malignant B cells in vivo that underlie constitutive CD40 signaling. 
3.3.1 Genetic ablation of Igβ in LMP1/CD40-transgenic mice 
A former member of our laboratory, C. Hömig-Hölzel, established a conditional transgenic 
mouse strain, in which a LMP1/CD40 chimeric protein is B cell-specifically expressed based on 
the Cre/loxP system and mediates constitutive CD40 signaling. This resulted in B cell activation, 
leading to B cell expansion as well as to enhanced proliferation and survival properties in vitro, 
ultimately followed by the development of B cell lymphomas at high incidence with a latency of 
12 to 19 months (Homig-Holzel et al., 2008) (see 1.5.2 for details). In this mouse strain, BCR 
signaling was to be impaired in mature B cells by deleting the ITAM-containing domain of Igβ in 
a Cre/loxP-dependent manner. For that purpose, we made use of a conditional Igβ-deficient 
mouse strain, which was established by N. Uyttersprot, a former member of our department. In 
the conditional Igβ-deficient mouse strain (fl(GFP)), deletion of Igβ can be traced by GFP 
expression (ΔGFP) (see 1.5.3 for details). Since the ablation of Igβ during early B cell 
differentiation in the bone marrow leads to a block of B cell development, Igβ deletion was 
achieved by using CD21-Cre mice (Kraus et al., 2004), expressing Cre recombinase under the 
control of the CD21 promoter and thus deleting the floxed alleles efficiently only from the T2 
transitional B cell stage on. Igβfl(GFP)/Δc//CD21Cre mice carry one deleted Igβ allele in all body 
cells (IgβΔc), while the second Igβ allele (Igβfl(GFP)) can be Cre-mediated and GFP-traced deleted, 
to receive homozygous Igβ deficiency. Whether the deletion of BCR-associated signaling 
components like Igα or Igβ only severely impairs or entirely abrogates tonic BCR signaling is not 
clear. However, as the deletion of Igα (Kraus et al., 2004), ablation of Igβ resulted in a strongly 
diminished Fo B cell compartment and the disappearance of the MZ B cell population in 
Igβfl(GFP)/Δc//CD21Cre mice (N. Uyttersprot, personal communication), indicating that both 
signaling molecules are essential for tonic BCR signaling and thus for the survival of peripheral B 
cells. By mouse crossings, the Igβfl(GFP)/Δc, the CD21-Cre, and the LMP1/CD40 alleles were 
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combined. Upon CD21-Cre-mediated deletion of the floxed allele and concomitant GFP 
expression, the fl(GFP) allele is referred to as ΔGFP. Thus, LMP1/CD40//Igβfl(GFP)/Δc// 
CD21Cre (referred to as LMP1/CD40//IgβΔGFP/Δ) mice were established and were analyzed in 
comparison to Igβfl(GFP)/wt//CD21Cre (referred to as IgβΔGFP/wt), Igβfl(GFP)/Δc//CD21Cre (referred 
to as IgβΔGFP/Δ), and LMP1/CD40//Igβfl(GFP)/wt//CD21Cre (referred to as 
LMP1/CD40//IgβΔGFP/wt) mice. As the heterozygous deletion of Igβ does not negatively impact 
B cell development and activation, controls were also maintained to a heterozygous background, 
in order to monitor the deletion efficiency from the respective GFP expression.  
3.3.2 Constitutive CD40 signaling rescues Igβ-deficient B cells to a certain extent 
C. Hojer has shown that the deletion of Igβ in LMP1/CD40 B cells leads to the ablation of B cell 
expansion. However, LMP1/CD40 expression can rescue Igβ-deficient B cells to a certain extent 
as LMP1/CD40//IgβΔGFP/Δ mice harbor about the same numbers of B cells in the peripheral 
lymphatic organs like IgβΔGFP/wt control mice (Fig. 31A). In addition, the deletion efficiency in 
LMP1/CD40//IgβΔGFP/Δ B cells is roughly as high as in IgβΔGFP/wt B cells, indicating that 
LMP1/CD40//IgβΔGFP/Δ B cells are almost not counter-selected, in contrast to Igβ-deficient B 
cells that do not express LMP1/CD40 (IgβΔGFP/Δ) (Tab. 5). 
 
 
Figure 31 Constitutive CD40 signaling rescues Igβ-deficient B cells to a certain extent (adapted 
from C. Hojer). (A) Absolute numbers of B220+ B cells in spleen (SP) and inguinal lymph node (iLN) of 
mice with genotypes as indicated besides the diagrams; * P<0.05, *** P<0.001, calculated by the two-
tailed student’s t-test compared to IgβΔGFP/wt control mice. (B) Splenic lymphocytes were analyzed for the 
expression of IgM/IgD by flow cytometry. The upper panel is only gated on living, B220+ lymphocytes, 
whereas the lower panel is additionally gated on GFP, thus depicting only Igβ-deleted cells. Numbers 
represent mean percentages and SD of gated populations from three independent experiments. Data were 
collected by C. Hojer as content of her PhD thesis and were confirmed by myself in further analyses. 
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Furthermore, the analysis of Ig surface expression revealed that the deletion of Igβ results in the 
downregulation of the BCR molecules IgM and IgD (Fig. 31B) (Hojer et al., in preparation).  
In this work, LMP1/CD40-expressing, Igβ-deficient B cells were further characterized according 
to their activation status as well as their proliferation and survival properties in comparison to 
Igβ-deficient B cells that do not express LMP1/CD40 (IgβΔGFP/Δ). 
 
 
3.3.3 LMP1/CD40//IgβΔGFP/Δ B cells display an activated phenotype 
An activated phenotype, displayed by high expression of CD95 or CD80 on the cell surface, is a 
hallmark of LMP1/CD40-transgenic B cells. Thus, we were interested whether constitutive 
CD40 signaling may also lead to an activation of Igβ-deficient B cells. Therefore, splenic B cells 
were isolated from all four genotypes, and cells were stained with respective antibodies before 
surface expression levels of respective activation molecules and the forward scatter was analyzed 
by FACS (Fig. 32). Flow cytometry revealed an increased expression of CD95 and CD80 on 
LMP1/CD40//IgβΔGFP/Δ B cells compared to IgβΔGFP/Δ and IgβΔGFP/wt B cells, similar as detected 
on LMP1/CD40-expressing B cells proficient for Igβ. In addition, a significant larger size than 
control B cells was detected in the forward scatter analysis. These results show that constitutive 
CD40 signaling leads to an activated B cell phenotype also in the absence of Igβ. 
 
Figure 32 LMP1/CD40//IgβΔGFP/Δ B cells display an activated phenotype. Splenocytes were stained 
with antibodies specific for CD95 and CD80 and were subjected to flow cytometric analysis. Histograms 
show overlays of cells size (FSC) or overlays of surface expression of the indicated molecules on 
lymphocyte-gated, B220+, GFP+ B cells from mice with genotypes as indicated besides the histograms. 
Data are representative for three independent experiments; FSC (forward scatter). 
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3.3.4 LMP1/CD40 expression prolongs the survival of Igβ-deficient B cells in vitro and in 
vivo 
Constitutive CD40 signaling in B cells via LMP1/CD40 expression leads to prolonged survival 
and spontaneous cell division ex vivo (Homig-Holzel et al., 2008). In Igβ-deficient mice, 
constitutive CD40 signaling restores the peripheral B cell compartment to comparable B cell 
numbers as found in wild type mice (Hojer et al., in preparation). Consequently, we aimed to 
characterize the survival properties of LMP1/CD40//IgβΔGFP/Δ B cells in vitro and in vivo.  
3.3.4.1 LMP1/CD40//IgβΔGFP/Δ B cells show a prolonged survival in vitro 
To test whether constitutive CD40 signaling prolongs the survival of Igβ-deficient B cells in vitro, 
splenic B cells from all four genotypes were isolated and cultured for five days without additional 
stimulation. At day 1, 2, 3, and 5 of the culture, cells were stained with the vital dye TOPRO-3 
and were subjected to flow cytometric analysis. From beginning of the culture, the survival of 
LMP1/CD40//IgβΔGFP/Δ B cells declined much slower than of the rapidly dropping IgβΔGFP/Δ B 
cells, and thus similarly to IgβΔGFP/wt control B cells (Fig. 33A). While monitoring the percentage 
of GFP+ cells over five days in culture, the percentages of GFP+ cells in the IgβΔGFP/Δ culture 
dropped rapidly, indicating a negative selection of Igβ-deficient B cells (Fig. 33B). LMP1/CD40 
expression was observed to counteract that negative selection, as the percentages of GFP+ cells in 
the LMP1/CD40//IgβΔGFP/Δ culture remained rather constant, similarly as in the culture of 
IgβΔGFP/wt control B cells. All together these results show that LMP1/CD40 expression prolongs 
the survival of Igβ-deficient B cells in vitro, and indicate that constitutive CD40 signaling is able to 
rescue Igβ-deficient B cells from cell death to a certain extent.  
3.3.4.2 Constitutive CD40 signaling enlarges the life-span of Igβ-deficient B cells in vivo 
To confirm a prolonged life-span of LMP1/CD40//IgβΔGFP/Δ B cells also in vivo, we performed 
bromodeoxyuridine (BrdU) pulse chase experiments. BrdU is a thymidine analog that is 
incorporated into replicating cells during the S-phase of the cell cycle by substituting for 
thymidine in all newly synthesized DNA strands. By applying BrdU to cell cultures or 
experimental animals (pulse), and subsequently detecting BrdU in the DNA with a specific 
antibody, cells that have entered the S-phase can be identified. After the pulse, the life-span of 
labeled cells can be monitored over a period of time without further labeling (chase). Since 
peripheral B cells are resting and barely proliferate, BrdU+ B cells in the periphery are derived 
from transitional B cells emerging from the bone marrow, where they underwent several cycles of 
cell division during early B cell development (Forster and Rajewsky, 1990). For the in vivo assay, 
mice were fed with BrdU in the drinking water for 14 days (pulse) and were further observed 
Results 
 62
over a period of 56 days until day 70 (chase). Mice were analyzed on day 14 at the end of the 
pulse, and on day 42 and 70 during the chase. The percentages of BrdU+ splenic B cells were 
determined by flow cytometry. The respective values are displayed with the graphs in figure 33C. 
 
 
 
Figure 33 Constitutive CD40 signaling prolongs the life-span of Igβ-deficient B cells. (A, B) 
Splenic B cells of the indicated genotypes were enriched by depletion of CD43+ cells. Cells were cultured 
up to five days without stimulation and were analyzed for viability with TOPRO-3 incubation on day 0, 1, 
2, 3, and 5 by flow cytometry. Percentages of viable (TOPRO-3-) cells were determined and mutant cells 
were identified by re-gating on GFP+. The graphs show (A) mean percentages of viable GFP-expressing 
cells with SD of three independent experiments in relation to the input at day 0, which were set as 100 % 
or (B) mean percentages of viable GFP+ cells of the respective genotypes over the time of the culture. (C) 
Mice were fed with 0.8 mg/ml BrdU in their drinking water for 14 days during the pulse period and 
BrdU+ B cells were tracked until day 70 during the chase period. Splenic samples were taken at day 14, 42, 
and 70. Percentages of BrdU+, B220+ B cells were determined by flow cytometry. The graphs show the 
mean results (symbols) with SD of three different BrdU pulse chase experiments. The four different 
genotypes are indicated besides.  
 
At day 14 of the pulse period, IgβΔGFP/Δ mice showed high percentages of BrdU+ B cells (57 %). 
In contrast, percentages of BrdU+ B cells in LMP1/CD40//IgβΔGFP/Δ mice were much lower (37 
%) and similar to IgβΔGFP/wt control mice (32 %). During the chase period, Igβ-deficient B cells 
showed a rapid decline of BrdU-labeled cells (5 % at day 70), whereas LMP1/CD40//IgβΔGFP/Δ 
mice cells showed a similar decline of BrdU+ B cells (5 % at day 70) as IgβΔGFP/wt control mice (7 
% at day 70). The similar kinetics of BrdU labeling and decline in B cells of 
LMP1/CD40//IgβΔGFP/Δ mice like in B cells of IgβΔGFP/wt control mice indicates a similar survival 
of LMP1/CD40//IgβΔGFP/Δ B cells as control IgβΔGFP/wt B cells. LMP1/CD40//IgβΔGFP/wt mice 
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showed not only the lowest percentage of BrdU+ B cells after the pulse (23 %), but also the 
slowest decline of labeled cells during the chase (12 % at day 70), evidencing a prolonged survival 
of peripheral LMP1/CD40-expressing B cells in vivo. 
The increased percentage of BrdU+ B cells in Igβ-deficient mice at day 14 as well as the fast 
decline during the chase period is most likely caused by a high influx of immature B cells from 
the bone marrow to the periphery, due to the diminished life-span of peripheral B cells deficient 
for Igβ (N. Uyttersprot, personal communication). By constitutive CD40 signaling, the survival 
of Igβ-deficient B cells was approximated to the survival of wild type B cells in vivo. Therefore, 
these results strengthen again the observations we made in vitro, namely that constitutive CD40 
signaling is able to rescue Igβ-deficient B cells from cell death to a certain degree. However, this 
data also show that the ablation of Igβ results in the drop of survival of LMP1/CD40-expressing 
B cells to wild type level, evidencing that though constitutive CD40 signaling, pre-malignant B 
cells are still susceptible to the impairment of tonic BCR signals.  
3.3.5 Analysis of signaling pathways in LMP1/CD40//IgβΔGFP/Δ B cells 
LMP1/CD40-transgenic B cells show a selective activation of the non-canonical NF-κB pathway 
and the MAP kinases Erk and Jnk (Homig-Holzel et al., 2008). Since these signaling pathways are 
associated with survival and proliferation in B cells, we were interested whether the improved 
survival of Igβ-deficient B cells due to constitutive CD40 signaling is somehow reflected in the 
activation of these signaling pathways in LMP1/CD40//IgβΔGFP/Δ B cells. Since IgβΔGFP/Δ mice 
have strongly reduced peripheral B cell numbers, showing less than 30 % deletion efficiency in 
the spleen, the analysis of signaling pathways was technically not feasible in IgβΔGFP/Δ B cells. 
Thus, only B cells from LMP1/CD40//IgβΔGFP/Δ, IgβΔGFP/wt, and LMP1/CD40//IgβΔGFP/wt mice 
were subjected to further analyses. 
3.3.5.1 LMP1/CD40 expression leads to increased non-canonical NF-κB activity despite 
Igβ deficiency  
Firstly, we examined the basal activity of the canonical and non-canonical NF-κB pathways in 
non-stimulated B cells by Western blot with or without nuclear fractionation experiments. 
Canonical NF-κB signaling includes the phosphorylation and subsequent degradation of IκBα, 
resulting in the nuclear translocation of p50/p65 and p50/c-Rel heterodimers. Non-canonical 
NF-κB signaling requires the processing of the precursor protein p100 to p52, leading to the 
nuclear translocation of p52/RelB heterodimers. In Western blots of whole-cell extracts, an 
increased level of p52 protein was detected in LMP1/CD40//IgβΔGFP/Δ B cells, similar as found 
in LMP1/CD40//IgβΔGFP/wt, but not in IgβΔGFP/wt control B cells (Fig. 34A). Besides, less 
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phosphorylated IκBα was detected in LMP1/CD40//IgβΔGFP/Δ B cells compared to IgβΔGFP/wt 
control B cells, reminiscent of LMP1/CD40 B cells proficient for Igβ, indicating that 
LMP1/CD40 leads to the selective activation of the non-canonical NF-κB pathway also in the 
absence of Igβ. To corroborate these findings, we performed nuclear fractionation experiments 
and analyzed the protein levels of NF-κB components in the cytoplasm and the nucleus (Fig. 
34B). In accordance with the previous results, the levels of RelB, p52, and p50 were increased in 
the nuclear fraction of LMP1/CD40//IgβΔGFP/Δ B cells compared to IgβΔGFP/wt control B cells, to 
a similar extent as seen in LMP1/CD40//IgβΔGFP/wt B cells. An increased level of p105 like in 
LMP1/CD40 B cells was not observed after the deletion of Igβ (cp. Homig-Holzel et al., 2008). 
These data show that constitutive CD40 signaling still activates the non-canonical NF-κB 
pathway, despite the Igβ deficiency. 
 
 
 
 
Figure 34 Enhanced non-canonical NF-κB activity is maintained in LMP1/CD40//IgβΔGFP/Δ B 
cells. (A) Splenic B cells were purified from the indicated genotypes and whole-cell extracts from non-
stimulated cells were subjected to immunoblot analysis using antibodies specific for p100/p52, pIκBα 
(Ser32/36), and IκBα. Equal protein loading was controlled by an α-Tubulin staining. The result is 
representative for three independent experiments. (B) Cytoplasmic (CP) and nuclear (N) levels of NF-κB 
components in non-stimulated splenic B cells from the indicated genotypes were analyzed by 
immunoblot. The purity of cytoplasmic and nuclear extracts was verified by α-Tubulin and α-Bcl3 
stainings, respectively. Equal protein loading was controlled by a Ponceau S staining.  The experiment was 
performed three times. 
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3.3.5.2 Enhanced activation of the MAPK Erk and Jnk is maintained in 
LMP1/CD40//IgβΔGFP/Δ B cells  
Secondly, we investigated the activation status of the MAP kinases Erk and Jnk. For that 
purpose, whole-cell extracts from splenic B cells were prepared and the phosphorylation state of 
these proteins as well as the total protein amounts were analyzed by Western blotting (Fig. 35). In 
LMP1/CD40//IgβΔGFP/Δ B cells, we observed an increased phosphorylation of Erk and Jnk 
compared to IgβΔGFP/wt control B cells. The phosphorylation was similarly enhanced as in 
LMP1/CD40-expressing B cells proficient for Igβ. Therefore, we concluded that constitutive 
CD40 signaling activates Erk and Jnk irrespective of Igβ deficiency.  
This result is moreover important for another study of our laboratory showing that the 
phosphorylation of Erk is mediated through CD19 in LMP1/CD40-expressing B cells and is 
critically involved in the survival of these cells. Since phosphorylation of Erk is not abrogated in 
LMP1/CD40//IgβΔGFP/Δ B cells, but in LMP1/CD40-expressing B cells deficient for CD19, this 
result indicates that the requirement of CD19 for Erk activation by constitutive CD40 signaling is 
independent of the BCR (Hojer et al., in preparation). 
 
 
 
 
3.3.5.3 LMP1/CD40//IgβΔGFP/Δ B cells maintain basal phosphorylation of Akt 
PI3K is most prominently activated upon BCR engagement but has also been shown to be 
essential for prolonged survival of LMP1/CD40 B cells in vitro (Hojer et al., in preparation). PI3K 
activity is reflected in the phosphorylation of Akt kinase. However, LMP1/CD40 B cells show 
normal basal phosphorylation of Akt (Hojer et al., in preparation). Thus, we were interested 
Figure 35 Enhanced activation of the MAPK Erk and Jnk is 
maintained LMP1/CD40//IgβΔGFP/Δ B cells. Whole-cell extracts 
were isolated from non-stimulated splenic B cells of mice with 
indicated genotypes and were subjected to immunoblot analysis 
using antibodies specific for pJnk1/2 (Thr183/Tyr185) and 
pErk1/2 (Thr202/Tyr204), as well as for the corresponding non-
phosphorylated forms. Equal protein loading was controlled by an 
α-Tubulin staining. The result is representative for three 
independent experiments. 
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whether basal phosphorylation of Akt is maintained in non-stimulated LMP1/CD40//IgβΔGFP/Δ 
B cells. In Western blot analyses, comparable phosphorylation of Akt like in IgβΔGFP/wt and 
LMP1/CD40//IgβΔGFP/wt B cells was detected in LMP1/CD40//IgβΔGFP/Δ B cells (Fig. 36A), 
evidencing that Igβ deficiency does not abrogate basal Akt activation in LMP1/CD40-expressing 
B cells. 
3.3.5.4 Ablation of Igβ reduces c-Myc levels in LMP1/CD40 B cells 
c-Myc is a major target of the Erk pathway and is both phosphorylated and transcriptionally 
regulated by the Erk cascade (McCubrey et al., 2007; Z. Hao, personal communication). 
Furthermore, c-Myc is highly expressed in LMP1/CD40-expressing B cells and may partially 
account for the phenotype of these cells (Hojer et al., in preparation). As basal phosphorylation of 
Erk is maintained in LMP1/CD40//IgβΔGFP/Δ B cells, we were interested whether high c-Myc 
expression would still be found in these cells. Western blot analyses showed that c-Myc levels are 
significantly reduced in LMP1/CD40//IgβΔGFP/Δ B cells in comparison to 
LMP1/CD40//IgβΔGFP/wt B cells (Fig. 36B). Thus, a diminished c-Myc level might explain that 
LMP1/CD40 is only partially able to rescue Igβ-deficient B cells, but cannot maintain B cell 
expansion and survival as found in LMP1/CD40-expressing B cells proficient for Igβ. 
 
 
Figure 36 LMP1/CD40//IgβΔGFP/Δ B cells maintain basal phosphorylation of Akt kinase, but 
show reduced levels of c-Myc. Whole-cell extracts were isolated from non-stimulated splenic B cells of 
mice with indicated genotypes and were subjected to immunoblot analysis using antibodies specific for 
(A) pAkt (pS473) and its corresponding non-phosphorylated form, (B) c-Myc. Equal protein loading was 
controlled by an α-Tubulin staining. The result is representative for three independent experiments. 
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4 Discussion 
Notch signaling influences cell fate decisions during differentiation processes of a wide range of 
tissues, including lymphocyte development. In the hematopoietic system, Notch1 signals are 
required for T cell development and T effector class decisions (Han et al., 2002; Radtke et al., 
1999; Pui et al., 1999; Schmitt et al., 2004). In mature B cells, Notch2 is the Notch family member 
that is mainly expressed and is essential for MZ B cell differentiation (Saito et al., 2003). 
Constitutive activation of Notch is clearly transforming for T cells and induces T cell leukemia 
(Ellisen et al., 1991; Pear et al., 1996; Bellavia et al., 2000; Rohn et al., 1996). However, the effect of 
deregulated Notch signaling in B lymphocytes in regard to the development of B cell 
malignancies is still controversial. In this work, we provide deeper insights into the role of 
Notch2 signaling in B cell differentiation, activation, and B cell lymphomagenesis.  
4.1 Notch1/2IC activate proliferation-associated as well as pro-apoptotic 
genes in human B cells in vitro 
Through the interaction with RBP-Jκ, Notch and the Epstein-Barr-viral protein EBNA2 use the 
same signaling cascade to activate their target genes. Therefore, it is in discussion whether 
EBNA2 makes use of the Notch signaling pathway to contribute to B cell immortalization. 
However, previous work has shown that neither constitutive active Notch1 nor Notch2 
(Notch1/2IC) can replace EBNA2 in its function to maintain B cell immortalization. Although 
Notch1/2IC expression drove some B cells into the S-phase of the cell cycle, cell numbers did 
not increase, presumably due to an increased apoptosis rate in Notch1/2IC-expressing cells 
(Kohlhof et al., 2009). Based on mRNA expression analyses, we investigated whether the 
biological differences between Notch1/2IC and EBNA2 can be traced back to differences in the 
regulation of genes associated with proliferation or survival.  
We show that both Notch1/2IC and EBNA2 induce the expression of cell cycle- and 
proliferation-associated genes, but only EBNA2 leads to the strong induction of anti-apoptotic 
genes in parallel. Like EBNA2, Notch1/2IC induced the expression of cyclins and CDKs, 
although most of them were less intensely upregulated as by EBNA2. Exceptionally, a small 
group of genes containing CCND2, CCND1, and CDK2 was comparably induced by 
Notch1/2IC and EBNA2. This observation corroborates previous studies, reporting that 
Notch1IC can upregulate CCND1 and CDK2, leading to S-phase entry (Ronchini and 
Capobianco, 2001; Stahl et al., 2006). The profound differences between Notch1/2 and EBNA2 
in maintaining B cell proliferation might be partially attributed to the diverse regulation of PI3K 
and c-MYC expression by EBNA2 and Notch1/2IC. PI3KR1 and c-MYC are both direct target 
genes of EBNA2 and were rapidly and intensively upregulated solely by EBNA2. These genes 
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play an essential role in the proliferation of immortalized cell lines in concert with the Epstein- 
Barr-viral genes LMP1 and LMP2A (Dirmeier et al., 2005; Kilger et al., 1998). Whereas Notch1/2 
did not induce the expression of PI3K, c-MYC expression levels were upregulated to a certain 
degree. This is in line with previous observations showing that c-MYC is a direct target gene of 
Notch1IC in T cell acute lymphoblastic leukemia (T-ALL) (Weng et al., 2006; Palomero et al., 
2006; Sharma et al., 2006), as well as with our own observations that constitutive Notch2 
signaling elevates c-Myc levels in B cells in vivo. However, Notch1/2IC were not able to induce 
the high peak of c-MYC levels in EREB2.5 cells as observed early after EBNA2 induction. High 
c-MYC expression itself can induce hyperphosphorylation of Rb, activation of CDK2, and entry 
into the cell cycle (Schuhmacher et al., 1999). Thus, high c-MYC levels as induced by EBNA2 
might be essential to drive EBV-infected cells into the cell cycle. As soon as EBV-infected cells 
express all viral latency genes, which drive B cell proliferation and activation, c-MYC expression 
may significantly decrease to an even lower level than in Notch1/2IC-expressing cells. One 
reason for a different nature of gene regulation by EBNA2 and Notch1/2IC may be attributed to 
differences in their structures. This might lead to different binding affinities of EBNA2- and 
NotchIC-containing complexes to certain RBP-Jκ binding sites, or to qualitative differences in 
the interactions with other transcription factors that bind additionally within EBNA2- or Notch-
responsive promoters. Moreover, EBNA2 and NotchIC cooperate very exclusively with viral and 
cellular proteins that modulate their transcriptional activity (Zimber-Strobl and Strobl, 2001).  
Furthermore, we concluded that the increased percentages of apoptotic cells in cultures of 
Notch1/2IC/EREB cells may be traced back to the predominant induction of pro-apoptotic 
genes by Notch1/2IC in comparison to EBNA2. Strikingly, both Notch1/2IC and EBNA2 
upregulated the expression of several pro-apoptotic genes, whereas only EBNA2 led to the 
intensive induction of anti-apoptotic genes. Since most of these anti-apoptotic genes are known 
as target genes of LMP1 (Dirmeier et al., 2005), their high expression in EBNA2-expressing cells 
is most likely due to the high amount of LMP1 in EBNA2/EREB compared to 
Notch1/2IC/EREB cells. As this observation implied the presence of anti-apoptotic signals as a 
prerequisite that Notch1/2IC may induce proliferation in B cells, we aimed to analyze whether a 
similar interplay of Notch with such signaling pathways can be found also in human B cell 
tumors. Using the recently established human transcriptome data base “GeneSapiens” (Kilpinen 
et al., 2008), an expression analysis across a wide range of tumor samples revealed a very high 
DTX1 expression in certain B cell lymphomas, suggesting that Notch signaling is active in these 
tumors. Interestingly, high DTX1 expression was in most cases correlated with high expression 
of anti-apoptotic genes like BCL2A1 and BIRC5, indicating that active Notch signaling is present 
in certain B cell lymphomas, in which anti-apoptotic signals are provided by other stimuli 
Discussion 
 69
(Kohlhof et al., 2009). These data underline the hypothesis that deregulated Notch signaling 
induces proliferation of B cells only in the presence of anti-apoptotic stimuli. Thus, this 
implication contributes to the understanding of the role of Notch in B cell lymphomas, as further 
discussed in section 4.3.  
4.2 Constitutive Notch2 signaling is instructive for marginal zone B cell 
differentiation in vivo   
To further investigate the importance of Notch2 during normal and malignant B lymphopoiesis 
in vivo, we have established a transgenic mouse strain, allowing the conditional expression of a 
constitutive active form of Notch2 (Notch2IC) in a Cre/loxP-dependent manner. The 
concomitant expression of a truncated human CD2 molecule enables the tracing of Notch2IC-
expressing cells. To study the function of Notch2 in early and late B cell development, Notch2IC 
expression was activated in B cells in vivo either dependent on mb1-Cre (Hobeika et al., 2006) or 
on CD19-Cre (Rickert et al., 1997). 
4.2.1 Notch2IC expression dependent on mb1-Cre blocks early B cell differentiation and 
leads to ectopic T cell development in the bone marrow 
Constitutive Notch2 activity dependent on mb1-Cre completely blocked B cell development 
beyond the pro-B cell stage and led to the formation of an aberrant T cell population in the bone 
marrow, reminiscent of the T cell population detected after the transplantation of Notch1IC-
transduced bone marrow progenitors into irradiated mice (Pui et al., 1999). Unlike normal T cells, 
only low CD3 and no T cell receptor (TCR) expression were detected on these Notch2IC-
expressing T cells, which is in contrast to the abovementioned study of Pui et al. (1999), reporting 
intermediate αβ TCR levels on bone marrow-derived, Notch1IC-expressing T cells. Successful 
transition through the β-selection as a prerequisite for differentiation to the CD4+CD8+ double 
positive (DP) stage requires the cooperative action of both Notch and pre-TCR signaling (Starr et 
al., 2003; Wolfer et al., 2002; Ciofani et al., 2006; Maillard et al., 2006; Allman et al., 2001a). Thus, 
the DP phenotype of Notch2IC-expressing T cells despite the absence of TCR β expression is 
somehow surprising. Either constitutive Notch2 signaling mimics pre-TCR-derived signals as it 
has been recently suggested for Notch1IC (Michie et al., 2007), or the aberrant T cell phenotype 
is induced by the ectopic expression of T cell-specific genes such as gata3, which encodes an 
important T cell transcription factor, and has been recently identified as target gene of Notch in 
T cells in vivo (Amsen et al., 2007; Fang et al., 2007). The bone marrow-derived Notch2IC-
expressing T cells failed to further mature to CD4 or CD8 single positive T cells, what might be 
due to the lack of thymus-specific factors in the bone marrow (Carlyle and Zuniga-Pflucker, 
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1998) and/or to a Notch-induced block of terminal T cell differentiation. Thus, after successful 
β-selection during thymic T cell development, pre-TCR signaling mediates the downregulation of 
Notch1 expression (Taghon et al., 2006; Yashiro-Ohtani et al., 2009). This mechanism is 
presumed to be essential to avoid oncogenic effects of Notch (Weng et al., 2006) and may explain 
the block of further T cell differentiation when high levels of Notch signaling are maintained 
beyond the DN4 stage.  
In Notch2IC//mb1Cre+/- mice, B cell maturation was arrested at Hardy fractions A and B and 
no peripheral, mature B cells were found. This is in contrast to a former study performed by Witt 
and colleagues, reporting that retroviral high-level expression of Notch2IC blocked B cell 
development at the large pre-B cell stage (Hardy fraction C/C´), whereas lower-level expression 
of Notch2IC selectively promoted B1 B cell differentiation in the spleen (Witt et al., 2003a). In 
our case, the very few B cells found in the spleen of Notch2IC//mb1Cre+/- mice did not display 
a B1 cell but rather an immature phenotype. The differences of these two experimental settings 
might be due to a different expression level of Notch2IC.  
In contrast to previous studies, expressing NotchIC retrovirally in all hematopoietic stem cells 
(HSC), Notch2IC expression should be restricted to the B cell lineage in our approach. The mb1-
Cre-mediated recombination was described as primarily B cell-specific (Hobeika et al., 2006). 
Therefore, it was surprising to observe a very similar phenotype concerning the build-up of bone 
marrow-derived T cells also upon mb1-Cre-dependent Notch2IC expression. The reason might 
be that Cre-mediated recombination already occurs occasionally in single CLPs. Using transgenic 
reporter mice, mb1-Cre was reported to lead to a low frequency (< 1 %) of T cells having deleted 
the STOP cassette (Hobeika et al., 2006). These T cells may arise from CLPs, which have already 
deleted the STOP cassette and have further developed into normal T cells, as the expression of 
the reporter transgene had not interfered with T cell development. However, strong and 
constitutive Notch2 signaling in CLPs might enforce T cell commitment at the expense of B 
cells, prompting ectopic T cell development in the bone marrow environment as it has been 
previously described for retrovirally expressed Notch1/2IC (Pui et al., 1999; Witt et al., 2003a). 
Alternatively, the aberrant T cell-like population in Notch2IC//mb1Cre+/- mice may arise from 
already committed pro-B cells starting to express Notch2IC and therefore trans-differentiating to 
the T cell lineage. Constitutive Notch2 signaling might suppress the induction of B cell-specific 
transcription factors like Pax5, EBF, and E2A and may simultaneously upregulate the expression 
of T cell-specific factors, thus leading to the trans-differentiation of early B cell progenitors. Our 
assumption is corroborated by findings of F. Jundt and colleagues, showing that in Hodgkin 
lymphoma cells Notch1 signaling antagonizes the key transcription factors EBF and E2A, leading 
to the suppression of B cell lineage genes and induction of lineage-inappropriate genes (Jundt et 
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al., 2008). Moreover, our own, unpublished data demonstrated that in a human B cell line, 
Notch1/2IC negatively regulate the expression of B cell-specific genes as Igα, Igβ, E2A, and Igμ, 
whereas T cell-specific factors like CD3 and GATA3 are positively regulated (H. Kohlhof, 
personal communication).  
In contrast to former investigations, our data do not point to an established T cell leukemic 
disease at the time point of analyses, which was six to 12 weeks of age. It has been previously 
shown that weak gain-of-function Notch1 alleles, which induce relatively weak Notch signaling 
activity, were only able to induce ectopic T cell development, but failed to initiate T cell leukemia 
(Chiang et al., 2008). Assuming that transgenic expression of Notch2IC might result in a lower 
Notch2 protein level or activity as in previous retroviral approaches, this might explain the 
induction of only ectopic, but not malignant T cells in our experimental system. 
Notch2IC//mb1Cre+/- mice died with nine to 12 weeks of age for unknown reasons. Therefore, 
we cannot exclude that these mice would have developed T cell leukemia at an age beyond.  
4.2.2 Notch2IC expression dependent on CD19-Cre induces marginal zone B cell 
differentiation at the expense of follicular B cells 
Negative selection of early Notch2IC-expressing B cells was counteracted by delayed activation 
of Notch2IC dependent on CD19-Cre, resulting in normal percentages and numbers of 
developing B cells in the bone marrow. Mature B cells of Notch2IC//CD19Cre+/- mice exhibited 
a strong shift to the MZ B cell compartment at the expense of Fo B cells. However, also the 
remaining B cells at the outer border of the follicular B cell zone were observed to express 
Notch2IC and high levels of IgM. Recently, Cariappa and colleagues have described two distinct 
Fo B cell populations, namely IgMlow Fo-I and IgMhigh Fo-II B cells (Cariappa et al., 2007). Thus, 
the remaining Fo B cell population of Notch2IC//CD19Cre+/- mice is reminiscent of the Fo-II 
B cells, which have been postulated to serve as a reservoir for replenishing the MZ B cell 
compartment (Pillai and Cariappa, 2009). Based on the current data, we can only hypothesize 
about the nature of the Notch2IC-expressing B cells within the follicle. In theory, those cells 
could be (i) MZ B cells that have migrated into the follicle potentially as a consequence of an 
overcrowded MZ, (ii) transitional or Fo B cells that have just initiated Notch2IC expression and 
thus start to migrate towards the MZ, or (iii) MZ B cell precursors. While MZ B cells can 
exclusively be found in the spleen in wild type mice, Notch2IC//CD19Cre+/- mice harbored 
significant amounts of MZ-like B cells also in the inguinal lymph nodes. These cells may originate 
either from (i) splenic MZ B cells that have migrated to the lymph nodes, (ii) transitional B cells 
that have started to express Notch2IC in the blood stream and migrated to the lymph nodes 
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rather than to the spleen, or (iii) Fo B cells that were already located in the lymph nodes before 
starting to express Notch2IC and to differentiate into MZ B cells. 
It is still unclear, at which developmental stage immature B cells are committed to adopt either a 
Fo or MZ B cell phenotype, and in detail how Notch2 contributes to that lineage decision. 
Previous reports suggest that MZ B cell commitment occurs at the T1 transitional B cell stage 
upon the interaction of Notch2, expressed on these cells, with the ligand Dll1, expressed on 
endothelial cells located in the splenic red pulp and MZ (Tan et al., 2009). However, other studies 
in the rat suggest an origin of MZ B cells also from the Fo B cell pool (Dammers et al., 1999), 
indicating that each B cell, including T2 and Fo B cells, receiving a Notch2 signal may adopt a 
MZ B cell phenotype. In Notch2IC//CD19Cre+/- mice, we observed a higher deletion efficiency 
in T1 as in T2 transitional B cells as well as diminished T2 and T3 transitional B cell populations, 
suggesting that in Notch2IC//CD19Cre+/- mice, MZ B cells mainly develop from the T1 
transitional B cell stage. This differentiation step might most likely involve a so far non-
characterized MZ B cell precursor displaying a CD21/35int/highIgMint/highAA4.1lowCD23- 
phenotype. Cells undeleted at the T1 transitional stage may preferentially mature to T2 
transitional B cells, which might still differentiate into MZ B cells upon Notch2IC expression via 
the conventional MZ B cell precursor stage displaying a CD21/35highIgMhighAA4.1low CD23+ 
phenotype. A sequential model for MZ B cell development involving those kinds of MZ B cell 
precursors is illustrated in figure 37.  
 
 
 
 
Figure 37 A sequential model 
for marginal zone B cell 
development (modified from 
Pillai and Cariappa, 2009). 
Transitional (T1 or T2) B cells 
can develop either into follicular 
(Fo) I B cells forming the major 
mature B cell population, or 
into Fo II B cells, potentially 
serving as reservoir for marginal 
zone (MZ) B cells. Transitional 
(T1 or T2) B cells that are 
committed to the MZ B cell 
compartment develop into MZ 
B cell precursors (MZ P) before 
maturing to MZ B cells. Upon 
constitutive Notch2 signals, MZ 
B cell commitment is enforced 
in transitional B cells, but 
appears to predominantly 
involve another variant of MZ 
B cell precursor (MZ P*) when 
commitment is achieved from 
the T1 B cell stage (shown in 
bright grey arrows).  
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Our data clearly evidence that Notch2 mediates differentiation of MZ B cells. Whether it is also 
required for MZ B cell survival and whether Notch2IC can also induce MZ B cell differentiation 
in Fo B cells may be studied particularly with a conditional and inducible Notch2IC-transgenic 
mouse strain that will allow switching off Notch2IC expression in an established MZ B cell 
compartment or activating Notch2IC expression in an existing Fo B cell population. 
B cells of Notch2IC//CD19Cre+/- mice were hyper-responsive to LPS and α-CD40 stimulation 
in vitro. Robust proliferation to LPS or CD40 ligation is known as hallmark of MZ B cells (Allman 
et al., 2001b; Oliver et al., 1997). Moreover, α-IgM stimulation resulted in increased cell death of 
Notch2IC-expressing B cells (data not shown), consistent with previous reports showing that α-
IgM treatment induces apoptosis in MZ B cells (Oliver et al., 1997; Meyer-Bahlburg et al., 2009). 
Hence, the localization in the MZ, the surface marker expression, and the biological behavior of 
Notch2IC//CD19Cre+/- B cells is perfectly reminiscent of MZ B cells. Thus, entire lineage 
characteristics of MZ B cells are maintained in Notch2IC-expressing B cells, confirming these 
cells as real MZ B cells. Despite their pre-activated phenotype, Notch2IC-expressing B cells were 
impaired in germinal center (GC) formation and class switch recombination after challenging 
mice with the TD antigen NP-CGG. Not only NP-specific IgG1 but also IgM antibodies were 
diminished, suggesting a general defect of these cells to respond to TD antigens. However, 
Notch2IC-expressing B cells were not generally detained in plasma cell differentiation, indicated 
by their normal response to the TI type 1 antigen LPS. The impaired TD immune response of 
Notch2IC-expressing B cells might either be due to their MZ B cell phenotype or to the 
influence of constitutive Notch2 signaling. Previously, MZ B cells have been suggested to 
participate also in TD immune response, since they were fully capable to initiate GC formation 
and to undergo somatic hypermutation following activation by TD antigens in cell transfer 
studies (Song and Cerny, 2003). Most likely, constitutive Notch2 expression in MZ B cells 
inhibits the migration of these cells towards the follicular T cell zone upon antigen contact, where 
B cells receive costimulatory signals provided by TH cells. Members of our laboratory have 
recently shown in human B cells in vitro that Notch1/2IC represses the expression of various 
genes encoding for chemokines their selves or their receptors (H. Kohlhof, personal 
communication). Signals mediated via such components influence cellular migration properties 
profoundly. Thus, a migration defect of Notch2IC-expressing MZ B cells may explain the 
impaired immune response to TD antigen. Future studies, allowing Notch2IC expression 
specifically in activated B cells dependent on γ1-Cre or using a conditional and inducible 
Notch2IC-expressing mouse strain, have been initiated to investigate the role of Notch2 in B cell 
activation and immune response in vivo in more detail. 
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4.2.3 The basal activity of the non-canonical NF-κB pathway is reduced in Notch2IC-
expressing B cells 
An interplay of NF-κB and Notch signaling has been described in various cellular systems. These 
interactions are partially based on the identification of NF-κB components as Notch1 target 
genes, as well as on physical interactions between Notch and NF-κB components (Osipo et al., 
2008). Previously, it has been reported that soluble Notch ligand triggers IκBα phosphorylation 
(Jang et al., 2004) and that IκBα is a Notch1 target gene (Oakley et al., 2003). However, in 
Notch2IC-expressing B cells, both the levels of phosphorylated and non-phosphorylated IκBα 
were significantly reduced. Since p50, p65, and c-Rel levels were not increased in the nucleus of 
Notch2IC-expressing B cells, we suggest that the reduced levels of IκBα do not reflect an 
enhanced activity of the canonical NF-κB pathway. However, it might be possible that other IκB 
members are able to partially replace IκBα in its function in Notch2IC-expressing B cells. 
Compared to wild type cells, both nuclear p52 and RelB levels were reduced in Notch2IC-
expressing B cells, whereas p100 levels were increased, indicating a selective reduction of basal 
non-canonical NF-κB signaling. This could indicate that constitutive Notch2 signaling might 
render the cell generally less dependent on signaling cascades that activate the non-canonical NF-
κB pathway, such as signaling upon engagement of the BAFF receptor.  
In this regard, we cannot differentiate whether the NF-κB status in Notch2IC-expressing B cells 
reflects the common NF-κB status of MZ B cells or is due to an interplay between NF-κB and 
constitutive Notch2 signaling in B cells. Indeed, diminished IκBα expression in MZ B cells has 
been already reported (Zhang et al., 2007), suggesting that reduced IκBα levels as observed in 
Notch2IC-expressing B cells could be assigned to their MZ B cell phenotype. In general, MZ B 
cell maintenance, and potentially MZ B cell commitment may be less dependent on NF-κB 
signaling in the presence of constitutive active Notch2. This might indicate that Notch2 has to be 
regarded downstream of NF-κB signaling during MZ B cell differentiation under normal 
circumstances. Since the Notch2 gene harbors a NF-κB binding site in its promoter region 
appearing to be conserved over different organisms (L.J. Strobl, personal communication), the 
NF-κB signaling strength may determine the surface expression level of Notch2 on transitional B 
cells. Already haploinsufficiency of Notch2 results in the absence of MZ B cells (Witt et al., 
2003b, U. Zimber-Strobl, personal communication), indicating that NF-κB signaling may 
critically influence the MZ B cell lineage decision by modulating the Notch2 surface expression 
level. To further investigate this hypothesis, we will cross conditional Notch2IC-transgenic mice 
with conditional MALT1-deficient mice, which are defective in their MZ B cell generation due to 
an impaired canonical NF-κB activity (Ruland et al., 2003). This will shed light on the hierarchy of 
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these signaling pathways and will clarify whether constitutive Notch2 signaling may act 
independently of canonical NF-κB signaling during MZ B cell differentiation. 
4.2.4 Notch2IC//CD19Cre+/- B cells display high c-Myc levels as well as enhanced 
MAPK and PI3K/Akt activity 
The pre-activated state of Notch2IC-expressing B cells is mirrored in an increased activation of 
PI3K/Akt and the MAP kinases Erk and Jnk as well as in higher basal levels of c-Myc protein. 
Akt is broadly known to promote cell survival by a variety of mechanisms including the direct 
inhibition of pro-apoptotic proteins like Bad, caspase-9, or Bax as well as the indirect inhibition 
of the tumor suppressor gene p53 (Khwaja, 1999; Tsuruta et al., 2002; Brazil et al., 2002). 
Phosphorylation of Akt is thought to directly reflect PI3K activity. In Notch2IC-expressing B 
cells, enhanced PI3K/Akt activity is most likely the result of an increased expression of Hes1. In 
T-ALL and other Notch-regulated malignancies, Hes1 as target of Notch1 has been shown to 
mediate transcriptional downregulation of Pten, which negatively regulates PI3K activity by 
inactivating PIP3 (Palomero et al., 2007; Katso et al., 2001; Sulis and Parsons, 2003; Cully et al., 
2006; Samuels and Ericson, 2006; Hay, 2005; Sarbassov et al., 2005). Besides, increased levels of 
TCL1 gene product are suggested to be involved in the activation of Akt in many B cell 
malignancies (Gold, 2003). In human B cells in vitro, TCL1 mRNA expression has been shown to 
be particularly induced by Notch2IC (H. Kohlhof, personal communication). Therefore, it 
remains to be further investigated whether a reduced expression of Pten or an enhanced 
expression of TCL1 can also be found in Notch2IC-expressing B cells in vivo, contributing to 
enhanced Akt activity. 
Additionally, Erk was found to be strongly phosphorylated in Notch2IC-expressing B cells. Erk 
is commonly activated via the Ras-Raf-MEK-Erk cascade. Also PI3K is involved in Erk 
activation in association with PLCγ2 (Jacob and Kelsoe, 1992), acting upstream of that cascade. 
Activated Raf kinases phosphorylate MEK1/2, ultimately resulting in the activation of Erk1/2. 
Erk in turn modulates the activity of a wide range of substrates that are critically involved in the 
regulation of cell proliferation and survival. However, neither Raf (B-Raf or Raf-1) nor MEK1/2 
showed an increased activation in Notch2IC-expressing B cells. Moreover, Raf-1 protein levels 
were of unknown reasons consistently reduced in Notch2IC//CD19Cre+/- B cells (data not 
shown). Probably, the enhanced activation of Erk and Akt depends on PI3K. Analysis of the 
basal activation of these kinases in the presence of chemical inhibitors that target PI3K activity 
might shed light on the signaling cascade leading to the activation of Erk and Akt. 
In Notch2IC//CD19Cre+/- B cells, we found moreover significantly elevated c-Myc levels. Both 
active Akt and Erk were reported to lead to the upregulation of c-Myc protein levels (Grumont et 
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al., 2002, Z. Hao, personal communication). Additionally, c-Myc is a known target gene of 
Notch1 not only in T-ALL (Palomero et al., 2006; Weng et al., 2006; Sharma et al., 2006), but also 
in other cells including B lymphocytes (Gordadze et al., 2001; Kohlhof et al., 2009). Enhanced 
basal phosphorylation of Akt kinase as well as higher basal levels of c-Myc have been recently 
reported for MZ B cells in vitro in comparison to Fo B cells (Meyer-Bahlburg et al., 2009). Thus, it 
can not be discriminated whether the activation state/protein level of these signaling molecules in 
Notch2IC-expressing B cells is due to the MZ B cell phenotype itself or to constitutive Notch2 
signaling. 
In this context, it is still in question whether the phenotype of MZ and Fo B cells is mainly 
regulated by the presence and absence of Notch2 signaling. Comparing the gene expression 
profiles and activity of signaling pathways in Notch2IC-expressing vs. wild type MZ B cells as 
well as in Notch2-deficient vs. wild type Fo B cells might clarify this issue. Furthermore, it is 
from a special interest to reveal target gene regulation by Notch2 in B cells ex vivo, as Notch 
target genes in B cells have so far only been studied in vitro. Since the IgMhighCD23- phenotype of 
Notch2IC//CD19Cre+/- B cells did not reflect the repression of Igμ and the induction of CD23 
expression, which has been described after in vitro induction of NotchIC in mature B cells (Strobl 
et al., 2000; Hubmann et al., 2002), this already indicates that the ex vivo analysis will reveal 
differences in the gene regulation by Notch2 in B cells compared to data collected in vitro. 
4.2.5 Constitutive Notch2 signaling acts independently of CD19 during marginal zone B 
cell development 
Current data suggest that BCR signaling is involved in the cell fate decision between MZ and Fo 
B cells. Thereby, PI3K signaling seems to play a crucial role. Like the deficiency for the BCR co-
receptor CD19, mutations in the PI3K isoform p110δ result in defective MZ B cell development 
(Rickert et al., 1997; Clayton et al., 2002), whereas in mice deficient for Pten, a negative regulator 
of PI3K signaling, enhanced MZ B cell formation is observed (Suzuki et al., 2003). In this work, 
we show that Notch2IC expression in CD19-deficient B cells (Notch2IC//CD19Cre+/+) can 
overcome the defect in MZ B cell differentiation. Enhanced PI3K/Akt signaling upon 
constitutive Notch2 activity as it has been discussed in 4.3.4 is likely to compensate for the 
deficiency for CD19, which signals most prominently via PI3K (Buhl et al., 1997). Thus, our 
results are reminiscent of studies of Anzelon and colleagues, showing that Pten deficiency, what 
results in constitutive activation of PI3K activity, can rescue CD19 deficiency in vivo (Anzelon et 
al., 2003). Notch2IC//CD19Cre+/+ B cells showed again elevated levels of c-Myc protein as well 
as enhanced activation of the MAP kinases Erk and Jnk, indicating that constitutive Notch2 
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signaling acts independently of CD19 in the activation of these signaling cascades and in the 
generation of MZ B cells.  
Our data also shed a critical light on the hypothesis that the BCR signaling strength is an 
important determinant for MZ B cell lineage commitment. Based on the results of a variety of 
gain- or loss-of-function studies in vivo, particularly S. Pillai and A. Cariappa have been 
postulating over the last years that a strong BCR signal in transitional B cells induces 
commitment to the Fo B cell pool, while weak BCR signals render the cell sensitive for Notch2 
signals and allow MZ B cell commitment (Pillai and Cariappa, 2009). Since the probability of a 
maturing B cell to receive a strong or a weak BCR signal can be assumed to be the same in a wild 
type or a Notch2IC-expressing mouse, we think that any dependency on this signaling strength is 
overcome in case of constitutive Notch2 activity as demonstrated by the extensive MZ B cell 
formation in Notch2IC//CD19cre+/- mice. Our data indicate that constitutive Notch2 signaling 
acts independently of BCR signaling during the induction of MZ B cell differentiation. 
Furthermore, we demonstrate that Notch2 signals are sufficient for MZ B cell differentiation, 
also in the absence of CD19, similarly as Notch1 signals are instructive for T cell lineage 
commitment. 
4.3 Activation of Notch signaling itself is not sufficient to induce B cell 
lymphomagenesis 
The role of Notch in the development of B cell lymphomas is still controversially discussed. 
Notch2 is highly expressed in B-CLL and both Notch1 and Notch2 are overexpressed in 
Hodgkin lymphoma (HL) cells. Engagement of Notch receptors resulted in an increased 
proliferation of HL and multiple myeloma cell lines and prolonged the survival of B-CLL cell 
lines (Hubmann et al., 2002; Jundt et al., 2002b; Jundt et al., 2004; Rosati et al., 2009). However, 
our results as discussed above in 4.1 indicate that Notch itself may induce apoptosis in B cells as 
long as anti-apoptotic stimuli, for instance LMP1 or CD40 signals, are missing (Kohlhof et al., 
2009). This corroborates other studies, reporting the inhibition of cell growth and the induction 
of apoptosis by NotchIC in avian, murine, and human B cell lines (Morimura et al., 2000; Romer 
et al., 2003; Zweidler-McKay et al., 2005). Moreover, this is in line with recently published data 
showing a proliferative effect of Notch signaling in murine primary B cells in cooperation with 
BCR and CD40 stimulation and with the observation of our own laboratory that Notch1IC 
induces proliferation only in combination with LMP1 in B cells (Thomas et al., 2007; Hofelmayr 
et al., 2001).  
The conditional Notch2IC-expressing mouse line allowed analyzing whether constitutive Notch2 
signaling itself promotes rather B cell differentiation and expansion or the induction of apoptosis 
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in B cells in vivo. In Notch2IC//mb1Cre+/- mice, B cell development was blocked at the pro-B 
cell stage. The block in B cell development was accompanied by the development of ectopic T 
cells in the bone marrow, indicating that Notch2IC interferes with further B cell differentiation 
beyond the pro-B cell stage, forcing T cell development instead. In HLs, which derive from 
germinal center (GC) B cells and have lost their B cell phenotype, Notch1 has been recently 
suspected to contribute to the suppression of B lineage-specific genes and to the induction of B 
lineage-inappropriate genes by antagonizing the key B cell transcription factors E2A and EBF 
(Jundt et al., 2008). This suggests that Notch signaling may be able to interfere with the B cell 
phenotype when it is activated at certain differentiation stages as in pro-B cells or GC B cells.  
Activation of Notch2IC in immature B cells dependent on CD19-Cre did not result in a loss of 
the B cell phenotype but strongly induced MZ B differentiation. B cell numbers were normal in 
comparison to wild type mice and neither prolonged survival, increased proliferation, nor 
enhanced apoptosis of Notch2IC//CD19Cre+/- B cells was observed during in vitro cultures in 
comparison to control B cells. Since MZ B cells are described as very long-lived (Hao and 
Rajewsky, 2001), Notch2IC-expressing B cells may be suspected to exhibit a similar longevity in 
vivo. Therefore, it will be interesting to study the survival of Notch2IC//CD19Cre+/- B cells also 
in vivo. Strikingly, the increased levels of c-Myc as well as the enhanced activation of Akt and Erk 
were not reflected in an increased proliferation of Notch2IC//CD19Cre+/- B cells in vitro. In T-
ALL, c-MYC is a direct transcriptional target downstream of oncogenic Notch1 (Palomero et al., 
2006; Weng et al., 2006; Sharma et al., 2006) and the Notch1/c-Myc transcriptional regulatory 
loop is regarded as the core mechanism mediating T cell transformation by oncogenic Notch1. 
Besides, PI3K/Akt signaling is known as further mechanism how Notch1 regulates cell growth in 
immature T cells (Gutierrez and Look, 2007). Also in B cells, the c-Myc and PI3K/Akt cascade 
are associated with cell growth and proliferation (Wade and Wahl, 2006; Harnett et al., 2005). 
Thus, constitutive activation of c-Myc in B cells in vivo causes B cell transformation (Adams et al., 
1985). Moreover, Erk signaling is associated with proliferation of mature B cells and constitutive 
active Erk is found in HL cells (Kuppers, 2009). Therefore, it is tempting to speculate whether B 
cell lymphomas will develop in Notch2IC//CD19Cre+/- mice with an increased incidence over 
time when other mutations are acquired during the life-time of these animals, ultimately leading – 
in concert with already activated signaling cascades – to the transformation of these cells. 
To finally address the question whether constitutive activity of Notch2 and CD40 cooperate in 
terms of B cell lymphomagenesis, Notch2IC-transgenic mice will be crossed to LMP1/CD40-
transgenic mice, expressing a constitutive active CD40 receptor. 
The differences received based on the activation of Notch2IC expression at various stages of B 
cell development by using different Cre strains underline that the biological outcome of Notch 
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signaling highly depends on the cellular background, the developmental stage, and the present co-
stimulatory signals. Longevity of MZ B cells and the intense activation of growth- and survival-
associated signaling pathways in Notch2IC-expressing B cells make it conceivable that B cell 
lymphomas will develop with a longer latency. Thus, further studies will be necessary to explore 
whether Notch2 signaling contributes in fact mechanistically to B cell lymphomagenesis. This will 
shed light on the question whether Notch2 may serve as a potential target for the treatment of 
certain B cell malignancies.  
4.4 Ablation of BCR signaling abrogates LMP1/CD40-mediated B cell 
expansion in vivo  
B cells are permanently selected for the expression of a functional BCR during all stages of their 
development. Also resting, peripheral B cells critically require signals delivered by the BCR for 
their survival (Lam et al., 1997; Kraus et al., 2004). However, it is still unclear whether aberrantly 
activated or malignant B cells also depend on this tonic BCR signal. To address this question, we 
genetically abolished the BCR-associated signaling component Igβ in pre-malignant B cells in vivo 
that express a constitutive active CD40 receptor. Members of our laboratory have recently shown 
that deregulated CD40 signaling in B cells provided by a LMP1/CD40 fusion protein prolongs 
survival as well as induces spontaneous cell division ex vivo and ultimately leads to the 
development of B cell lymphomas (Homig-Holzel et al., 2008). Furthermore, it has been 
previously demonstrated in normal B cells that ablating of BCR-associated signaling molecules 
like Igα or Igβ results in strongly diminished peripheral B cell numbers, indicating that both 
signaling subunits are essential for the maintenance signal delivered through the BCR (Kraus et 
al., 2004, N. Uyttersprot, personal communication). 
By deleting Igβ in mature LMP1/CD40-expressing B cells, LMP1/CD40-mediated B cell 
expansion was abrogated, demonstrating that also pre-malignant B cells displaying constitutive 
CD40 signaling are not independent of tonic BCR signals. However, B cell numbers of 
LMP1/CD40//IgβΔGFP/Δ mice were elevated to wild type level, indicating that LMP1/CD40 
expression can rescue Igβ-deficient B cells to some degree (Hojer et al., in preparation). This was 
confirmed by analyzing the survival and proliferation of these cells in vitro and in vivo revealing 
that the survival and proliferation properties of LMP1/CD40//IgβΔGFP/Δ B cells are similar to 
those of wild type B cells, in contrast to rapidly dying Igβ-deficient B cells. Moreover, 
constitutive CD40 signaling induced an activated B cell phenotype despite the Igβ deficiency. 
Both the non-canonical NF-κB pathway and the MAP kinases Erk and Jnk, which are highly 
activated in LMP1/CD40 B cells, were still active in LMP1/CD40-expressing B cells deficient for 
Igβ. The activity of these signaling pathways might enhance the survival and proliferation of 
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LMP1/CD40//IgβΔGFP/Δ B cells, in contrast to Igβ-deficient B cells without LMP1/CD40 
expression.  
However, constitutive CD40 signaling could not entirely overcome the need of a functional BCR, 
as the ablation of Igβ resulted in a drop of the survival of LMP1/CD40-expressing B cells to wild 
type level. Therefore, we suspected that the Igβ deficiency must be reflected at least partially in 
changes of activated signaling cascades compared to LMP1/CD40 B cells proficient for Igβ. 
Tonic BCR signals are considered to occur ligand-independently, and were recently shown to be 
mediated by PI3K (Srinivasan et al., 2009), though their entire nature is not known so far. 
Although PI3K/Akt signaling is most prominently activated upon BCR signaling, it can also be 
triggered by CD40 engagement (Harnett, 2004). PI3K-dependent Erk activation has been shown 
to be crucial for the survival of LMP1/CD40 B cells (Hojer et al., in preparation). Surprisingly, 
basal phosphorylation of Akt was completely maintained in LMP1/CD40 B cells also in the 
absence of Igβ. Based on the crucial role of PI3K in mediating tonic BCR signaling (Srinivasan et 
al., 2009), retained PI3K activation in LMP1/CD40//IgβΔGFP/Δ B cells may be regarded as one 
potential mechanism how constitutive CD40 partially compensates the impairment of tonic BCR 
signals. c-Myc is highly expressed in LMP1/CD40 B cells and elevated c-Myc levels are suggested 
to be at least partially responsible for the LMP1/CD40-induced phenotype of B cell expansion 
(Hojer et al., in preparation). High c-Myc levels in LMP1/CD40 B cells are thought to depend on 
the Erk pathway as the latter is able to control c-Myc levels both transcriptionally and 
posttranslationally. Although basal activation of Erk is still maintained in 
LMP1/CD40//IgβΔGFP/Δ B cells, c-Myc expression was reduced to wild type levels. Thus, 
diminished c-Myc levels may at least partially account for the fact that LMP1/CD40 can only 
rescue Igβ-deficient B cells to a certain extent, but cannot maintain B cell expansion and 
prolonged survival as found in LMP1/CD40-expressing B cells proficient for Igβ. 
However, we still aim to characterize Igβ-deficient cells with or without LMP1/CD40 expression 
in more detail. To analyze how the impairment of BCR signaling affects B cell functionality, we 
will test whether these cells are still sensitive to α-IgM treatment or CD40 ligation in vitro. As 
increased Erk phosphorylation was inconsistently detected also in Igβ-deficient cells without 
LMP1/CD40 expression, we have moreover to absolutely rule out that maintained Erk 
phosphorylation in LMP1/CD40//IgβΔGFP/Δ B cells is triggered by stress-induced activation 
during preparation. Therefore, further attempts to characterize activated signaling pathways in 
Igβ-deficient cells without LMP1/CD40 expression by intracellular flow cytometric analysis will 
be done. To further approve the survival properties of B cells from LMP1/CD40 B cells 
proficient or deficient for Igβ, survival of these cells will be monitored in vivo. For that purpose, 
the percentages of peripheral, GFP+ B cells will be followed while blocking the influx of newly 
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generated B cells from the bone marrow to the periphery by administering an α-IL7R antibody 
that blocks early B cell development in the bone marrow (Sudo et al., 1993). 
In summary, the observation that the ablation of Igβ results in a drop of survival of 
LMP1/CD40-expressing B cells to wild type level evidences that pre-malignant B cells are still 
susceptible to the impairment of tonic BCR signals. Unfortunately, the development of 
lymphomas could not be investigated over a longer period of time since CD21-Cre mediates 
ectopic recombination also in other tissues than mature B cells as in the forehead (Schmidt-
Supprian and Rajewsky, 2007). This might lead to unspecific LMP1/CD40 expression and did 
not allow keeping mice longer than six months. Any lymphoma development in 
LMP1/CD40//IgβΔGFP/Δ mice was not observed up to that age and is also not expected based on 
both in vitro and in vivo survival studies. Although deregulated BCR expression has not been 
described in B cell lymphomas so far, the tonic survival signals that are constantly delivered by 
the BCR are suspected to contribute to tumor initiation or maintenance. This is corroborated by 
the observation that most B cell lymphoma cells still express the BCR and seem to be positively 
selected for BCR expression (Kuppers et al., 2005). Therefore, targeting tonic BCR signaling, for 
instance by inhibiting Syk, is regarded as promising new treatment of Non-Hodgkin lymphomas 
(Gururajan et al., 2006; Young et al., 2009; Chen et al., 2008). Our data even more encourage such 
approaches, as we provide evidence that tonic BCR signaling is crucial for the survival of pre-
malignant B cells in vivo and most likely a prerequisite to allow their malignant transformation. 
 transformation. 
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5 Summary  
Notch2 is known to be essential for the development of marginal zone (MZ) B cells. However, 
the precise mechanism leading to the generation of these cells is still elusive. In divers B cell 
lymphomas, enhanced Notch expression is moreover found, but the role of deregulated Notch 
signaling in the development of B cell malignancies is still unclear. In this work, we aimed to 
investigate the role of Notch signaling in B cell development, activation, and lymphomagenesis in 
more detail.  
Using a human B cell line, we observed that the expression of constitutive active Notch1 or 
Notch2 (Notch1/2IC) initiates cell cycle entry, but also appears to actively induce apoptosis, 
potentially due to the absence of appropriate survival signals. In the current study, these 
biological effects were assigned to the induction of several cell cycle- and proliferation-associated 
genes as well as to the predominant upregulation of pro- but not anti-apoptotic genes by 
Notch1/2IC. Thus, we conclude that a sudden, constitutive Notch signal in B cells rather induces 
apoptosis than proliferation, as long as anti-apoptotic stimuli are missing (Kohlhof et al., 2009).  
In order to analyze the influence of constitutive Notch2 signaling on B cell development and 
lymphomagenesis in vivo, a conditional transgenic mouse strain that expresses a constitutive active 
Notch2 receptor (Notch2IC) based on the Cre/loxP system was generated and characterized. 
Notch2IC expression from the pro-B cell stage on mediated by mb1-Cre blocked early B cell 
development, and led to ectopic T cell development in the bone marrow. In contrast, delayed 
activation of Notch2IC in B cells dependent on CD19-Cre did not interfere with early B cell 
development. However, mature B2 cells were strongly shifted to the MZ B cell compartment at 
the expense of follicular B cells. Thereby, most MZ B cells appeared to branch from the T1 
transitional B cell stage. Compared to wild type B cells, Notch2IC-expressing B cells displayed 
enhanced PI3K/Akt and MAPK signaling as well as increased c-Myc protein levels, while the 
basal activity of non-canonical NF-κB signaling was reduced. Of note, exclusive generation of 
MZ B cells was achieved even in the absence of CD19, which has been shown to be essential for 
MZ B cell development. However, B cell expansion or lymphoma development has been not 
observed until the current age of mice (six month). Our findings not only underline the 
differences in the outcome of Notch2 signaling depending on the B cellular developmental stage, 
but point to an instructive role of Notch2 signals during MZ B cell lineage decision.  
Previously, our group was able to demonstrate that the expression of a constitutive active CD40 
receptor, LMP1/CD40, in B cells in vivo results in B cell expansion and lymphomagenesis 
(Homig-Holzel et al., 2008). To determine whether such pre-malignant B cells still require tonic 
BCR signals for their survival as normal, resting B cells do, tonic BCR signaling was impaired in 
mature LMP1/CD40-expressing B cells by deleting Igβ. Constitutive CD40 signaling prolonged 
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the survival of Igβ-deficient B cells, most likely due to a maintained activation of the MAP 
kinases Erk and Jnk as well as of the non-canonical NF-κB pathway by LMP1/CD40. However, 
in comparison to expanded LMP1/CD40-expressing B cells, the ablation of Igβ was 
accompanied by a drop of survival to a similar level as of wild type B cells, which was at least 
partially assigned to severely reduced basal c-Myc levels. Thus, these data indicate that pre-
malignant B cells are still sensitive to the impairment of tonic BCR signaling.  
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6 Zusammenfassung  
Notch2-Signale spielen bei der Bildung von Marginalzonen (MZ) B-Zellen eine essentielle Rolle. 
Allerdings ist der Mechanismus wie Notch2 zur MZ B-Zellgenerierung beiträgt noch weitgehend 
unbekannt. Des Weiteren findet man in verschiedenen B-Zelllymphomen eine verstärkte Notch-
Expression, wobei die Bedeutung der deregulierten Notch-Signale bei der Entstehung dieser 
Tumore noch unklar ist. Deshalb wurde in dieser Arbeit die Rolle des Notch-Signalweges 
während der B-Zellentwicklung, -aktivierung und -lymphomentstehung genauer untersucht.  
Vorausgegangene Arbeiten zeigten, dass die Expression eines konstitutiv-aktiven Notch1- oder 
Notch2-Rezeptors (Notch1/2IC) in einer humanen B-Zelllinie zwar den Eintritt in den 
Zellzyklus initiiert, aber vermutlich mangels entsprechender Überlebenssignale auch zur aktiven 
Apoptoseinduktion führt. Diese Arbeit zeigte, dass jene biologischen Befunde auf der Induktion 
verschiedener zellzyklus- und proliferations-assoziierter Gene, sowie vor allem pro- aber nicht 
anti-apoptotischer Gene basieren. Daraus schließen wir, dass ein dereguliertes, konstitutives 
Notch-Signal in B-Zellen eher Apoptose als Proliferation induziert, sofern es an anti-
apoptotischen Stimuli mangelt (Kohlhof et al., 2009).  
Um den Einfluss von konstitutiven Notch2-Signalen auf die B-Zellentwicklung und                      
-lymphomentstehung in vivo zu untersuchen, wurde des Weiteren auf Basis des Cre/loxP-Systems 
ein transgener Mausstamm generiert und charakterisiert, in dem ein konstitutiv-aktiver Notch2-
Rezeptor (Notch2IC) konditional exprimiert wird. Notch2IC-Expression ab dem pro-B-
Zellstadium durch mb1-Cre blockierte die frühe B-Zellentwicklung und induzierte ektopische T-
Zellentwicklung im Knochenmark. Im Gegensatz dazu beeinträchtigte eine im Verlauf der B-
Zellentwicklung etwas spätere Aktivierung von Notch2IC mittels CD19-Cre die frühe B-
Zellentwicklung nicht, führte aber im reifen B2-Zellkompartiment zu einer stark vermehrten 
Generierung von MZ B-Zellen, zu Lasten der sehr verringerten follikulären B-Zellpopulation. 
Dabei schienen sich die meisten MZ B-Zellen aus T1 transitionellen B-Zellen zu entwickeln. Im 
Vergleich zur Wildtypkontrolle zeigten die Notch2IC-exprimierenden B-Zellen eine verstärkte 
Aktivierung des PI3K/Akt- und des MAPK-Signalwegs sowie ein erhöhtes Proteinlevel von c-
Myc, während die basale Aktivität des nicht-kanonischen NF-κB Signalweges vermindert war. 
Interessanterweise konnte zudem in Abwesenheit von CD19, welches für die MZ B-
Zellentwicklung unter normalen Umständen essentiell ist, eine ausschließliche Generierung von 
MZ B-Zellen bewirkt werden. Eine Expansion der B-Zellen oder gar die Entstehung von B-
Zelllymphomen wurde bis zum jetzigen Alter der Tiere von sechs Monaten nicht beobachtet. Die 
Ergebnisse verdeutlichen zum einen die unterschiedlichen Effekte von Notch2-Signalen in 
Abhängigkeit des Differenzierungsstadiums der B-Zellen, und unterstreichen zum anderen, dass 
Notch2-Signale bei der MZ B-Zellentwicklung instruktiv wirken. 
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In Vorarbeiten zu einem weiteren Projekt konnte unsere Gruppe zeigen, dass die Expression 
eines konstitutiv-aktiven CD40-Rezeptors, LMP1/CD40, in B-Zellen in vivo zur B-Zellexpansion 
und Lymphomentstehung führt (Homig-Holzel et al., 2008). Um zu untersuchen, ob das 
Überleben solch prämaligner B-Zellen immer noch von tonischen B-Zellrezeptor-(BCR)-Signalen 
abhängig ist, so wie es für normale, ruhende B-Zellen der Fall ist, wurde in reifen LMP1/CD40-
exprimierenden B-Zellen Igβ deletiert, was zu einer starken Beeinträchtigung der tonischen BCR-
Signale führt. Konstitutive CD40-Signale verbesserten die Überlebensfähigkeit von Igβ-
defizienten B-Zellen, was auf eine aufrechterhaltene Aktivierung der MAP-Kinasen Erk und Jnk 
sowie der nicht-kanonischen NF-κB-Aktivität durch LMP1/CD40 zurückgeführt wurde. Im 
Gegensatz zu den expandierten LMP1/CD40-exprimierenden B-Zellen führte die Igβ-Deletion 
allerdings zu einer verminderten Überlebensfähigkeit ähnlich dem Überleben von Wildtyp-B-
Zellen, was zumindest zum Teil einem stark verringertem c-Myc-Level durch die Igβ-Defizienz 
zugeschrieben wurde. Diese Befunde zeigen deutlich, dass das Überleben von prämalignen B-
Zellen durch die Abschwächung von tonischen BCR-Signalen beeinträchtigt werden kann.  
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7 Material  
7.1 Plasmids  
I) DCR26CAGp-IRESCD2 (provided by M. Schmidt-Supprian)  
Modified pROSA26-1 vector (Zambrowicz et al., 1997), allowing homologous recombination 
with the murine rosa26 locus via a short (1 kb) and a long (4 kb) homologous arm. Between the 
two homologous arms, a constitutive active CAGGS (CMV early enhancer/chicken β-
actin/rabbit globin) promoter is located, followed by a loxP sites-flanked STOP cassette, 
containing a transcription and translation termination site and a neomycin-geneticin resistance 
gene, mediating resistance against G418 (Geneticin). Using the AscI site downstream of this 
region, a gene of interest may be inserted that will be followed by a frt sites-flanked IRES-hCD2 
coding sequence, allowing the concomitant expression of a truncated human CD2 molecule. 
II) pHprt_Notch2IC (provided by C. Hojer) 
Plasmid containing notch2IC cDNA, initially isolated from the pTracer-CMV-Notch2cDNA 
vector (Shimizu et al., 2000), harboring the sequence of full length murine notch2 cDNA. 
III) DCR26CAGp-IRESCD2-Notch2IC 
DCR26CAGp-IRESCD2 plasmid, containing notch2IC cDNA within the AscI restriction site. The 
notch2IC cDNA corresponds to cDNA 5253 to 7583 of NCBI NM_010928 and was isolated 
from pHprt_Notch2IC. The vector was cloned as described in 8.3.4 and was used to target the 
abovementioned expression cassette containing notch2IC cDNA into the rosa26 locus of murine 
IDG2.3 embryonic stem cells, in order to establish the Notch2ICflSTOPP-transgenic mouse strain. 
IV) puc18 (provided by G. Laux) 
High copy number plasmid, used to subclone notch2IC cDNA. 
V) pGK-Cre-bpA (provided by K. Fellenberg) 
Plasmid encoding for Cre recombinase, controlled by the pGK promoter. This plasmid was used 
for transient transfection of recombinant ES cell clones to delete the loxP sites-flanked STOP 
cassette, in order to test clones for transgene expression. 
VI) pRTS-1-N1, pRTS-1-N2, pRTS-1-CAT (Kohlhof et al., 2009) 
pRTS-1 vectors (Bornkamm et al., 2005), containing coding sequences for the full length 
intracellular part of the human Notch1 receptor from position 5278 to 7668 of NM_0176173 
(Notch1IC) and of the human Notch2 receptor from position 5362 to 7672 of NM_024408.2 
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(Notch2IC), respectively, including the PEST domain, but excluding the 3´ untranslated regions. 
Notch1IC and Notch2IC (Notch1/2IC) are under the control of a doxycycline-inducible 
bidirectional Tet-O7 promoter, which also controls the expression of a truncated nerve growth 
factor receptor (ΔNGFR). pRTS-1 also encodes for EBV nuclear antigen 1 (EBNA1). 
Chloramphenicol acetyl transferase (CAT) was inserted instead of Notch1/2IC to generate the 
control vector. Vectors are referred to as pRTS-1-N1, pRTS-1-N2, and pRTS-1-CAT, 
respectively. The plasmids were stably transfected into EREB2.5 cells, in order to identify Notch-
regulated genes in B cells. Cloning and stable transfection were performed by H. Kohlhof. 
7.2 Bacteria 
DH5α (E. coli) 
Genotype: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80d lacZ ΔM15 Δ(lacZYA-
argF) U169 hsdR17 (rK- mK+), λ- . 
7.3 Cell lines 
I) IDG2.3 embryonic stem cells (ES) (Hitz et al., 2007) 
Murine ES cell line, derived from a male C57BL/6Jx129/SV (F1) blastocyst. Cells were used for 
gene targeting to generate the Notch2ICflSTOPP-transgenic mouse strain. 
II) Embryonic feeder (EF) cells  
EF cells were prepared from pSV2neo, PEP-IL4 C57BL/6 embryos at day 13.5 as described in 
8.1.2 and were used until the third passage for ES cell culture. 
III) Notch1/2IC/EREB and CAT/EREB cells (Kohlhof et al., 2009) 
EREB2.5 is a conditionally EBV-immortalized, lymphoblastoid cell line that encodes an EBNA2 
estrogen receptor (ER) fusion protein (ER-EBNA2). Thus, the function of EBNA2 depends on 
the presence of estrogen in EREB2.5 cells (Kempkes et al., 1995a). In the absence of functional 
EBNA2, cells exhibit a resting phenotype, similar to mature, naive B cells, before having 
encountered antigen. In the presence of estrogen, EBNA2 is functional and able to transactivate 
not only the viral LMP1 and LMP2A promoters, but also cellular target genes (Kempkes et al., 
1995a; Kempkes et al., 1995b).  This results in cell activation and proliferation, reminiscent of 
mature B cells after antigen-dependent activation. The cell lines Notch1IC/EREB, 
Notch2IC/EREB, and CAT/EREB were established by stably transfecting the pRTS-1-N1, 
pRTS-1-N2, and pRTS-CAT vectors, respectively (Kohlhof et al., 2009). These cell lines were 
used to compare Notch- and EBNA2-regulated genes in B cells.  
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7.4 Mouse strains 
I) C57BL/6 (Charles River Laboratories) 
This mouse strain was used for blastocyst injection and for crossings to obtain germline 
transmission of the notch2IC transgene. 
II) CD19-Cre (Rickert et al., 1997) 
C57BL/6 mouse strain with the Cre recombinase gene placed into the CD19 locus, thereby 
destructing the CD19 gene. The expression of the Cre gene is regulated by the CD19 promoter. 
III) IgβΔc (Reichlin et al., 2001) 
C57BL/6 mouse strain with deleted exons 5 and 6 of the Igß gene. 
IV) Igβfl(GFP) (Casola et al., 2006) 
C57BL/6 mouse strain with loxP sites-flanked exons 5 and 6 of the Igß gene and a downstream 
IRES-GFP sequence. Only in the presence of Cre, the flanked region is excised and GFP is 
concomitantly expressed (ΔGFP). 
V) LMP1/CD40flSTOPP (Homig-Holzel et al., 2008) 
Balb/C mouse strain that is conditional transgenic for the chimeric LMP1/CD40 gene placed 
into the rosa26 locus. A loxP sites-flanked STOP cassette upstream of the LMP1/CD40 gene 
prevents transgene expression. Only in the presence of Cre, the STOP cassette is excised and 
LMP1/CD40 is expressed under the control of the endogenous rosa26 promoter. 
VI) CD21-Cre (Kraus et al., 2004) 
C57BL/6 mouse strain with a randomly integrated BAC clone encoding Cre under the control of 
the CD21 promoter. 
7.5 DNA probes for Southern blotting 
I) Rosa26 
698 bp DNA fragment that was isolated from pRosa26-5-pBS-KS (kindly provided by P. 
Soriano) using the restriction enzymes EcoRI and Pac1. 
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II) hCD2  
424 bp DNA fragment that was isolated from pBS_hCD2 using the restriction enzymes BmgBI 
and BsaI. 
III) Notch2IC 
319 bp DNA fragment that was isolated from pSG5_N2IC using the restriction enzymes XmaI 
and StuI. 
7.6 Oligonucleotides 
I) Primers for PCR and sequencing reactions 
 
Primer name Primer sequence  (5´ to 3´) 
B29-9R CTTGTCAAGTAGCAGGAAGA 
B29-18F GTGGCACGGAACTTCTAGTC 
CD19c AACCAGTCAACACCCTTCC 
CD19d CCAGACTAGATACAGACCAG 
CD21 Cre rev GAACCTCATCACTCGTCGTTGCAT C 
CD21 NDE TCTGGC ATACTTATTCCCTGAAG 
CD40 PCR3 CTGAGATGCGACTCTCTTTGCCAT 
Cre 7 TCAGCTACACCAGAGACGG 
Ex1Fw1 LMP1 AGGAGCCCTCCTTGTCCTCTA 
Notch2IC 18 seq ATCTACCTGCAGGGGTCATC 
Notch2IC 21 seq GGGATGTGATCATGGGAGAG 
Notch2IC 22 seq TCTTGACTTCTGCGCTCTCA 
Notch2IC 25 rev (T) ATCCCGGTCTCCGTATAGTG 
Notch2IC 33 fw (T) CCCTTGCCCTCTATGTACCA 
Mb1-Cre P54 GGAGATGTCCTTCACTCTGATTCT 
Mb1-Cre P55 ACCTCTGATGAAGTCAGGAAG AAC 
Rosa fw1 (60) CTCTCCCAAAGTCGCTCTG 
Rosa rev2 (62) TACTCCGAGGCGGATCACAAGC 
TV fw 3 GTCCAGGGTTTCCTTGATGA 
TV fw 4 TGACGTCAATGGGTGGAGTA 
TV fw 5 GCTAACCATGTTCATGCCTTC 
TV fw 6 ATGCGATGTTTCGCTTGGT 
TV fw 7 TAAAGTCGACTCGGGGACAC 
TV fw 8 TGCCATCTAGTGATGATGAGG 
TV fw 9 CGCCATCATGCCTACATTCT 
TV fw 10 ACTCCTGGAGGTGGTGGAG 
TV fw 11 GGACGTGGTTTTCCTTTGAA 
TV fw 12 GAGGAGTCGGAGAAATGATGA 
 
II) Primers for qPCR  
Transcript Primer sequence (5´ to 3´) 
Bcl2l1 seq GTAAACTGGGGTCGCATTGT 
Bcl2l1 rev TGTCTGGTCATTTCCGACTG 
Bfl-1 seq CCGTAGACACTGCCAGAACA 
Bfl-1 rev AAAATTAGGCCGGTTTCACA 
Birc5 seq GGACCACCGCATCTCTACAT 
Birc5 rev TCTCCGCAGTTTCCTCAAAT 
Casp1 seq TTTGAAGGACAAACCGAAGG 
Casp1 rev CATCTGGCTGCTCAAATGAA 
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CD21 seq AGATCCTAAGAGGCCGAATGG 
CD21 rev CACATAGCCAGGGTTACAGC 
Cdk2 seq TCCTCCACCGAGACCTTAAA 
Cdk2 rev CATCCTGGAAGAAAGGGTGA 
Cdk4 seq CCGAAGTTCTTCTGCAGTCC 
Cdk4 rev AGGCAGAGATTCGCTTGTGT 
Cdk6 seq TGTTTCAGCTTCTCCGAGGT 
Cdk6 rev TCTCCTGGGAGTCCAATCAC 
c-Myc seq CTTGTACCTGCAGGATCTGA 
c-Myc rev AGTTGTGCTGATGTGTGGAG 
CyclinA2 seq CCTGCAAACTGCAAAGTTGA 
CyclinA2 rev CTCTGGTGGGTTGAGGAGAG 
CyclinE1 seq CAGATTGCAGAGCTGTTGGA 
CyclinE1 rev GGGGAGAGGAGAAGCCCTAT 
CyclinE2 seq TACTGACTGCTGCTGCCTTG 
CyclinE2 rev CCTGGTGGTTTTTCAGTGCT 
CyclinD1 seq CTTCAAATGTGTGCAGAAGG 
CyclinD1 rev GCATTTTGGAGAGGAAGTGT 
CyclinD2 seq CATTTACACCGACAACTCCA 
CyclinD2 rev CACGTCTGTGTTGGTGATC 
CyclinD3 seq TGACCATCGAAAAACTGTGC 
CyclinD3 rev AGCTTCGATCTGCTCCTGAC 
Deltex1 seq GCCATCTACGGGGAGAAGA 
Deltex1 rev AGCCAGCACGTTGTCTAGGT 
G1toS seq CCCAGGTGAAAACCTCAAAA 
G1toS rev AAGGTGAAACGACCCATCTG 
Hes1 seq GAAAAGACGAAGAGCAAGAATAA 
Hes1 rev ATTGATCTGGGTCATGCAGT 
Hey1 seq GCTAGAAAAAGCCGAGATCC 
Hey1 rev CGGGTGATGTCCGAAGAC 
Ig seq GAGGACACAGCCGTGTATTACTG 
Ig rev CCGAATTCAGACGAGGGGGAAAAGGGTT 
LMP1 seq TGTTCATCACTGTGTCGTTGTCC 
LMP1 rev AGAAGAGACCTTCTCTGTCCACT 
LMP2A seq ATGACTCATCTCAACACATA 
LMP2A rev CATGTTAGGCAAATTGCAAA 
PIK3R1 seq TTGTGGCACAGACTTGATGTT 
PIK3R1 rev AAGCCATATTTCCCATCTCG 
ribosomal protein L23a seq CTCCTAAAGCTGAAGCCAAA 
ribosomal protein L23a rev GCCTGTTTAATCTGGTGCTT 
 
 
III) Oligonucleotide used for cloning 
Name Oligonucleotide sequence (5´ to 3´) 
Oligo 1 (puc18) GGAAGCGGAAGAGCGGCGCGCCGTTTAAACTTGGCTCATTCTGATCTACCTGCAGGGGGCGCGCCAAGCTTAAG 
 
Oligonucleotides were synthesized by Metabion, Martinsried. 
7.7 Enzymes 
Restriction endonucleases were purchased from New England BioLabs and MBI Fermentas. Taq 
DNA polymerase was purchased from Invitrogen Life Technologies. 
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7.8 Antibodies 
I) Antibodies for immunoblotting 
Antigen Manufacturer Source kDa Dilution Diluent 
Akt Cell Signaling rabbit 60 1:1000 TBST, 5 % (w/v) BSA 
pAkt (Ser) Cell Signaling rabbit 60 1:1000 TBST, 5 % (w/v) BSA 
Bcl3 Santa Cruz rabbit 60 1:500 TBST, 5 % (w/v) BSA 
c-Rel Santa Cruz mouse 75 1:500 TBST, 5 % (w/v) BSA 
Deltex1 Santa Cruz rabbit 67 1:1000 TBST, 5 % (w/v) BSA 
Erk Cell Signaling rabbit 42, 44 1:1000 TBST, 5 % (w/v) BSA 
pErk Cell Signaling rabbit 42, 44 1:1000 TBST, 5 % (w/v) BSA 
Hes1 Santa Cruz rabbit 34 1:1000 TBST, 5 % (w/v) BSA 
IκBα Santa Cruz rabbit 40 1:1000 TBST, 5 % (w/v) BSA 
pIκBα Cell Signaling mouse 40 1:1000 TBST, 5 % (w/v) milk powder 
Jnk Cell Signaling rabbit 46, 54 1:1000 TBST, 5 % (w/v) BSA 
pJnk Cell Signaling rabbit 46, 54 1:1000 TBST, 5 % (w/v) BSA 
c-Myc Cell Signaling rabbit 64 1:1000 TBST, 5 % (w/v) BSA 
c-Myc (h) Santa Cruz rabbit 64, 67 1:2000 TBS, 5 % (w/v) milk powder 
p50p105 Santa Cruz goat 50, 100 1:500 TBST, 5 % (w/v) BSA 
p52p100 Cell Signaling rabbit 52, 100 1:1000 TBST, 5 % (w/v) BSA 
p65 Santa Cruz rabbit 65 1:1000 TBST, 5 % (w/v) BSA 
PI3K p55 Upstate rabbit 55 1:2000 PBS, 3 % (w/v) milk powder 
RelB Cell Signaling rabbit 70 1:1000 TBST, 5 % (w/v) BSA 
Tubulin Cell Signaling mouse 55 1:1000 TBST, 5 % (w/v) BSA 
The hybridoma for the Notch2 antibody (C651.6DbHN), developed by Dr. Artavanis-Tsakonas, 
was obtained from the Developmental Studies Hybridoma Bank (University of Iowa) and was 
diluted in TBS, containing 5 % (w/v) milk powder.  
II) Antibodies for immunohistochemistry 
Antigen Source Coupled to Dilution Manufacturer 
Human CD2 Rat Biotin 1:50 BD Bioscience 
Mouse CD3 Dog  1:2 By courtesy of E. Kremmer 
Mouse IgM Goat Peroxidase 1:100 Sigma 
Mouse MOMA-1 Rat  1:100 Biomedicals 
PNA Rat Biotin 1:2000 Vector 
Rat IgG2 Mouse Biotin 1:250 Jackson Laboratories 
 
7.9 Software 
Adobe Illustrator CS3 Epson Scanner program 
Adobe Photoshop CS3 Microsoft Excel 
Basic Local Alignment Search Tool (BLAST) Microsoft Word 
Clone Manager 9 OpenLab Improvision 
CELLQuest Becton Dickinson Primer3 
Endnote 9 Roche LightCycler Software 3 
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8 Methods 
8.1 Cell culture methods 
8.1.1 Culture of EREB2.5 cells 
Notch1IC/EREB, Notch2IC/EREB, and CAT/EREB cells (Kohlhof et al., 2009) were grown in 
1x RPMI (Gibco), supplemented with 10 % (v/v) heat-inactivated FCS (Biochrom KG), 1 % 
(v/v) L-glutamine, 1 % (v/v) sodium pyruvate, 1 % (v/v) penicillin-streptomycin (all purchased 
from Gibco), 75 µg/ml hygromycin (Invitrogen), and 1 µM 1.2-estrogen (Sigma). In general, 
EREB2.5 cells were centrifuged at 300 x g for 10 minutes. In order to deprive estrogen, cells 
were washed three times in cold 1x RPMI, 10 % (v/v) FCS. Between the second and the third 
washing step, cells were incubated in 1x RPMI, 10 % (v/v) FCS for 20 minutes at RT, to increase 
the efficiency of the estrogen removal. 4x105 cells per ml were plated again in 1x RPMI, 
supplemented as described before, but not containing estrogen. In order to activate EBNA2 
function, 1.2-estrogen was added to the culture medium in a concentration of 1 µM. Expression 
of Notch1/2IC and CAT was induced by adding 100 ng doxycycline per ml medium. 
8.1.2 Preparation of embryonic fibroblasts 
IDG2.3 ES cells (Hitz et al., 2007) have to be cultured on a layer of embryonic fibroblasts (EF 
cells) to prevent differentiation. EF cells were dissected from pSV2neo, PEP-IL4 C57BL/6 
embryos at day 13.5. Pregnant mice were killed by neck breaking and the belly was moistened 
with 70 % (v/v) ethanol before uteri were dissected. For washing, uteri were transferred twice to 
a new falcon tube containing sterile PBS. Uteri were subsequently placed on a Petri dish 
underneath a laminar front flow bench to dissect the embryos and to remove all membranes. 
Embryos were collected in a Petri dish containing PBS (Gibco) and heads were removed from 
the embryos by cutting straight above the arms. Each embryonic body was laid on its back in a 
new Petri dish placed under a stereomicroscope (Nikon) to remove all internal organs. Carcasses 
were collected in a 50 ml falcon tube containing PBS while continuing with the other embryos. 
Around 25 carcasses were washed in 35 ml PBS three times to remove the blood as efficient as 
possible. After sucking off the PBS, carcasses were transferred to a Petri dish placed on ice and 
were minced with a scalpel not longer than five minutes. Minced bodies were collected in 10 ml 
trypsin (Gibco) containing 0.2 mg/ml DNAse I (Invitrogen) and were incubated for 15 minutes 
at 37 °C. Meanwhile, a sterile mesh was washed once with trypsin and placed on an Erlenmeyer 
flask. Embryos were subsequently placed on the mesh and pressed through using a syringe 
plunger. To flush remaining clumps from the mesh, trypsin was continuously added during the 
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procedure (50 ml in total). In case the solution had become too viscous due to released DNA, 
more DNAse I in a concentration of 10 mg/ml was added (200 to 600 μl). Off note, total trypsin 
treatment should not exceed 30 minutes. The suspension was carefully decanted in four falcon 
tubes each containing 25 ml DMEM (Gibco) and was spun down at 250 x g at RT for five 
minutes. The cell pellet was washed twice in medium. If the pellet was too viscous, another 500 
μl DNAse I were added and the pellet was incubated for 30 minutes at RT. Finally, cells were 
resuspended in 10 ml EF cell medium (see 8.1.3) and were counted using Trypan blue. 3x107 cells 
can be expected per 10 embryos. 5x106 cells were plated per 15 cm dish and were cultured over 
night. The next day, the medium was changed to remove all cell debris. When cells had grown to 
80 % confluence after two to three days, cells were brought in suspension by trypsin treatment 
and 5x106 cells were frozen per vial. At that point, cells are referred to as “F0”. 
8.1.3 Culture of embryonic fibroblasts 
EF cells were cultured until the third passage (“FIII”) in DMEM containing 10 % (v/v) heat-
inactivated FCS (Biochrom KG), 1 % (v/v) L-glutamine, and 1 % (v/v) non-essential amino 
acids (both purchased from Gibco). One vial EF cells was plated on five 10 cm dishes after 
thawing and EF cells were split in a ratio of 1:5 every three to four days. For culture with ES 
cells, EF cells were mitotically inactivated by incubation with Mitomycin C (Sigma), a Streptomyces 
caespitosus-derived cell toxin. Adherently grown EF cells were washed once with PBS, incubated 
with 10 μg/ml Mitomycin C for three hours at 37 °C, and washed again three times with PBS. EF 
cells were subsequently brought in suspension by incubation with 1x trypsin (Gibco) at 37 °C for 
five minutes before the reaction was stopped by adding two volumes of FCS-containing medium. 
A single cell suspension was obtained by cautiously pipetting the cells up and down. Cells were 
subsequently centrifuged, counted, and plated on freshly gelatinized plates (15 minutes incubation 
with 0.1 % (v/v) gelatin PBS solution) in an average density of 1.5x106 cells per 10 cm dish. ES 
cells were seeded on the EF cell layer after 12 hours.  
8.1.4 Culture of embryonic stem cells (ES cells) 
IDG2.3 ES cells were cultured on a layer of Mitomycin C treated EF cells in DMEM (Gibco) 
containing 15 % (v/v) ES cell-tested FCS (PAN Biotech), 2 % HEPES, 1.5 % (v/v) L-glutamine, 
1 % (v/v) sodium pyruvate, 1 % (v/v) non-essential amino acids, and 50 mM β-mercaptoethanol 
(all purchased from Gibco). 0.1 % (v/v) LIF (Leukemia inhibitory factor, Chemicon 
International) was added freshly to prevent ES cell differentiation. Medium was changed every 
day and the culture was split every other day. In general, ES cells were centrifuged at 250 x g for 
five minutes. As ES cells grow in adherent colonies on the EF cell layer, trypsinization was 
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required for passaging. For that purpose, cells were rinsed once with PBS and subsequently 
incubated with half the volume of culture medium of 1x trypsin, supplemented with 1 % (v/v) 
chicken serum (Gibco) for 10 minutes at 37 °C before the reaction was stopped by adding two 
volumes of serum-containing culture medium. Single cells were obtained by pipetting the 
suspension up and down 10 times. Cells were subsequently centrifuged, counted, and plated on 
an EF cell layer in the appropriate density (in general 7.5x105 cells per 10 cm dish). 
8.1.5 Freezing and thawing of cells 
For freezing, 500 μl cell suspension containing 1x106 ES or EF cells and 5x106 EREB2.5 cells, 
respectively were pipetted to a cryovial tube (Nunc) before adding 500 μl 2x freezing medium, 
containing 50 % (v/v) respective FCS, 30 % respective culture medium, and 20 % (v/v) DMSO 
(Sigma). Vials were immediately placed in a pre-chilled freezing box (Nalgene), filled with 
isopropyl alcohol to allow slow freezing of the cells in a rate of -1 °C per minute in a -80 °C 
freezer. After two days, vials were transferred to liquid nitrogen (-196 °C) for long-term storage. 
In order to thaw frozen cells quickly, cryovial tubes were placed at 37 °C until the still frozen, 
major part of cells could be mixed with 1 ml pre-warmed medium. After washing cells in 10 
volumes of culture medium to remove DMSO, cells were plated immediately in fresh culture 
medium. 
8.1.6 Transfection of ES cells 
ES cells were either stably transfected to establish ES cell clones carrying the notch2IC transgene 
within their genome or were transiently transfected for transgene expression analysis. In both 
cases, ES cells were grown to a density of 5x106 to 1x107 cells per 10 cm dish and the culture 
medium was changed three hours before transfection to obtain highly proliferating cells. ES cells 
were then trypsin-treated as described above, washed once with PBS, and resuspended in 
transfection medium (RPMI w/o phenol red, PAA). 7x106 ES cells in 700 µl transfection medium 
were transfected with 20 µg of linearized plasmid DNA in case of stable transfection or of 
circular plasmid DNA in case of transient transfection. DNA resolved in 100 µl transfection 
medium was pipetted to a transfection cuvette (Gene Pulser cuvette, 0.4 cm electrode, Bio-Rad), 
and subsequently cells were added. Cells and DNA were incubated for 10 to 20 minutes on ice 
before transfection was performed with an electroporator (Gene Pulser, Bio-Rad) at 230 V, 500 
µF. After the pulse, cells were left at RT for 10 minutes. 7x106 transfected ES cells were diluted in 
40 ml culture medium and then plated on four 10 cm dishes. Cells were plated on an EF cell layer 
in case of stable transfection and on gelatin in case of transient transfection. 
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In case of stable transfection, 1x105 non-transfected cells were plated as control on a 10 cm dish 
on an EF cell layer to be treated later with G418 (Gibco) containing medium, in order to monitor 
cell death due to the G418 treatment. As further controls, 1x103 transfected and non-transfected 
cells were plated each on gelatinized 6 cm plates with normal medium to determine the cell loss 
due to the transfection.  
8.1.7 Selection and expansion of stably transfected ES cell clones 
After stable transfection with the targeting vector DCR26CAGp-IRESCD2-Notch2IC, ES cells 
were grown in normal culture medium for 24 hours. Subsequently, the medium was replaced by 
G418 selection medium (culture medium with 140 μg active G418 per ml medium). The used 
targeting construct contains a neomycin-geneticin-resistance gene, mediating resistance against 
G418. The amino-glycoside antibiotics G418 is toxic for eukaryotic cells besides other, since it 
blocks protein biosynthesis. Therefore, only cells that have successfully integrated parts of the 
construct and have thus acquired geneticin-resistance can grow in G418 selection medium. The 
selection medium was renewed every day and the G418 concentration was increased in the 
beginning every day by 10 µg/ml up to 170 µg/ml medium. After seven days, non-recombined 
cells had died as controlled by the non-transfected cells treated with G418, and thus selection had 
occurred. At that day, colonies appeared to be nicely formed as well as appropriate for picking 
and transferring to 96-well plates. The medium was exchanged by PBS and colonies were picked 
with a 200 µl tip in a laminar front flow under a stereomicroscope (Nikon) and were transferred 
in 25 µl PBS to a 96-well plate (round bottom). To each well containing a colony, 50 µl trypsin 
were added and the plate was incubated at 37 °C for 10 minutes. 50 µl G418 selection medium 
were added to stop the reaction and single cells were obtained by pipetting up and down 10 
times. The cell suspensions were then transferred to a 96-well plate (flat bottom) containing a 
Mitomycin C-treated EF cell layer and 100 µl G418 selection medium. Cells were cultured for 
two or three days, with medium change each day, before splitting to three 96-well plates. Two of 
these plates contained EF cells to expand the ES cell clones for freezing and later injection into 
blastocysts, whereas the other one was only gelatinized to expand the ES cell clones for DNA 
preparation and subsequent Southern blot analysis. The two 96-well plates containing ES cell 
clones on the EF cell layer were frozen one and two days, respectively after the splitting to obtain 
the optimal proliferation state of each clone. Plates were frozen after trypsinization, the addition 
of 50 µl ES cell freezing medium (20 % (v/v) DMSO, 80 % (v/v) FCS), and covering with 50 µl 
mineral oil (Sigma). The plates were wrapped into several layers of cellulose towels to allow slow 
freezing in a -80 °C freezer, where frozen ES cells can be stored up to two months. Two days 
after first passaging, cells on the 96-well plate for DNA preparation were split onto two 
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gelatinized plates, to have one backup. Cells were grown to full density for four to five days to 
receive enough cells for DNA extraction for Southern blot analysis.  
8.1.8 Thawing and expansion of homologous recombined ES cell clones 
ES cell clones showing homologous instead of random recombination were identified by 
Southern blot. To preserve these clones for long-term, the cells have to be thawed from the 96-
well plate, expanded in culture, and frozen in cryovial tubes in liquid nitrogen at -196 °C. For that 
purpose, 96-well plates were thawed in a semi-sterile water bath of 37 °C and each positive clone 
was transferred without the covering oil to a 24-well, containing a mitotically inactive EF cell 
layer and 1 ml G418 selection medium. The medium was exchanged after eight hours to remove 
DMSO. After three days, cells were trypsin-treated and transferred to 6-well plates without 
centrifugation, and from there after two days to a 10 cm plate by the same procedure. When cells 
had been properly growing on a 10 cm dish, cells from one plate were frozen in four cryovial 
tubes for long-term storage. G418 selection medium was used until one passage before blastocyst 
injection. 
8.1.9 Induction of transgene expression in transiently transfected ES cell clones 
Correctly targeted ES cell clones were chosen for testing transgene expression. For this purpose, 
cells were transfected with the Cre expression plasmid pGK-Cre-bpA, encoding Cre recombinase 
to delete the loxP sites-flanked STOP cassette upstream of the notch2IC-IRES-hCD2 transgene 
and to allow its expression. Cells were cultivated in medium containing 1 % (v/v) penicillin-
streptomycin. As control, non-transfected ES cells were grown to monitor leaky expression. The 
next day, the medium was changed. After 48 hours, cells were brought in suspension by the same 
procedure as trypsinization, but using versene (Gibco) instead, to protect surface expression of 
the hCD2 molecule. hCD2 expression was analyzed by flow cytometry after staining cells with a 
hCD2-specific antibody. 
8.1.10 Preparation of stably transfected ES cell clones for blastocyst injection 
After verification of correctly integrated notch2IC cDNA by Southern blot and testing for 
transgene expression, three clones were chosen for injection into blastocysts. For this purpose, 
cells were thawed and cultured on Mitomycin C-treated EF cells. From now on, normal culture 
medium without G418 was used. Medium was renewed every day and cells were trypsinized for 
passaging two or three days after thawing. After 36 hours, cells displayed a highly proliferative 
state. Thus, cells were trypsin-treated again, resuspended in culture medium, and subsequently 
injected into blastocysts (in cooperation with the Institute of Developmental Genetics at the 
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Helmholtz Center Munich). Blastocysts were derived from pregnant C57BL/6 mice to obtain 
visible chimerism in the offspring. IDG2.3 ES cells are F1 chimeras out of black C57BL/6 and 
brown 129/SV mice, and thus give rise to mice with a coat color mixed out of black and brown. 
Therefore, chimeras can be identified by the occurrence of brown coat on the black C57BL/6 
background.  
8.2 Mice-associated methods 
8.2.1 Mouse breeding 
Mice carrying the notch2ICflSTOP allele were crossed to the CD19-Cre mouse strain (on a C57BL/6 
background) to generate mice expressing the transgene from the pro-B cell stage with a gradual 
increase in Cre-mediated recombination during proceeding B cell differentiation (Rickert et al., 
1997) (Notch2IC//CD19Cre+/-). Notch2IC//CD19Cre+/+ mice were generated by crossing 
Notch2IC//CD19Cre+/- and CD19-Cre (C57BL/6) mice. Notch2ICflSTOP mice were crossed to 
the mb1-Cre mouse strain (on a C57BL/6 background) to generate mice expressing Notch2IC 
from the early pro-B cell stage in the bone marrow (Notch2IC//mb1Cre+/-). 
LMP1/CD40//Igβfl(GFP)/Δc//CD21Cre (referred to as LMP1/CD40//IgβΔGFP/Δ) mice were 
generated by crossing LMP1/CD40flSTOP (Balb/C), Igβfl(GFP)/Δc (C57BL/6), and CD21-Cre 
(C57BL/6) mice (Kraus et al., 2004).  
Consequently, analyses were performed on a mixed background. Mice were analyzed at eight to 
16 weeks of age, unless otherwise stated. Mice that were monitored for the development of 
lymphomas or leukemic disease were kept under special observation. All mice were bred and 
maintained in specific pathogen-free conditions. All experiments were performed in compliance 
with the German animal welfare law and have been approved by the Institutional Committee on 
Animal Experimentation and the government of Upper Bavaria. 
8.2.2 Isolation of primary lymphocytes 
Mice were euthanized by CO2 gassing for five minutes and were subsequently dissected. 
Peritoneal cells were harvested by rinsing the peritoneal cavity with B cell medium (1x RPMI 
1640 (Gibco), containing 5 % (v/v) heat-inactivated FCS (Biochrom KG), 1 % (v/v) penicillin-
streptomycin, 1 % (v/v) sodium pyruvate, 1 % (v/v) L-glutamine, and 50 mM β-mercaptoethanol 
(all purchased from Gibco)) and draining it with a syringe. Spleen, thymus, and lymph nodes were 
taken out as whole organs and were maintained in medium until further procedures. To isolate 
cells from the bone marrow, tibia bones were dissected and cut and the cavity was rinsed with 
medium. To receive single cell suspensions, tissues were passed through a capillary cell strainer 
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(Becton Dickinson). Single cell suspensions from spleen and bone marrow were depleted from 
erythrocytes by lysis with a hypotonic buffer (1 part of 170 mM Tris/HCl, pH 7.65, 9 parts of 
155 mM NH4Cl) for three minutes. Cells were kept on ice during the entire procedures and were 
generally centrifuged for 10 minutes at 300 x g at 4 °C.  
Isolation of splenic B cells was performed by depletion of CD43+ non-B cells by magnetic cell 
separation (MACS), using α-CD43 beads and LS columns according to the manufacturer’s 
specifications (Miltenyi Biotec). This resulted in a purity of 85 to 95 % B cells.  
For Western blot analyses, splenic cells were maintained from the beginning in B cell medium 
containing only 1 % (v/v) FCS. 
8.2.3 Flow Cytometry (FACS) 
Single cell suspension prepared from various lymphoid organs were surface-stained with a 
combination of FITC-, PE-, PerCP- and APC-conjugated monoclonal antibodies, diluted in 
FACS buffer. Antibodies specific for AA4.1, B220, CD1d, CD2 (human), CD3, CD5, CD9, 
CD19, CD21, CD23, CD25, CD36, CD43, CD80, CD86, CD95, ICAM-1, IgD, IgM, and 
MHCII were purchased from BD Biosciences. The monoclonal antibody to Thy1.2 was kindly 
provided by J. Mysliwietz. Data were analyzed from 3x104 viable, lymphocyte-gated cells as 
determined from forward and side scatter as well as TOPRO-3 or propidium iodide (PI) staining 
(both Molecular Probes). TOPRO-3 and PI are intercalating fluorescent dyes that bind DNA and 
thus only stain dead cells that are permeable for the dye to diffuse into the nucleus. All analyses 
were performed with a FACSCaliburTM flow cytometer (BD Biosciences) and results were 
analyzed using CELLQuest software. 
8.2.4 In vitro culture of primary lymphocytes 
Splenic, MACS-purified B cells were cultured in B cell medium with 10 % (v/v) FCS with or 
without stimuli up to five days in 96-well plates (5x105 cells/well). Stimuli included 
lipopolysaccharide (10 to 25 µg/ml; E. coli 055:B5; Sigma), IL4 (10 ng/ml; mouse recombinant; 
Sigma), α-CD40 antibody (2.5 µg/ml; eBioscience (HM40-3)), and anti-IgM F(ab’)2 (5 µg/ml, 
AffiniPure F(ab’)2 goat α-mouse IgM, µ-chain, Dianova). At different time points, cells were 
surface-stained with various antibodies and were analyzed or counted with a FACSCaliburTM. The 
percentage of living cells was determined by staining and excluding dead cells by TOPRO-3 or PI 
that binds to DNA. For proliferation assays, splenic B cells (5x106 cells/ml) were labeled for five 
minutes by incubation in serum-free B cell medium containing 5-(and 6)-carboxyfluorescein 
diacetate N-succinimidyl ester (CFSE, Molecular Probes, final concentration 5 µM) at 37 °C. 
CFSE binds to proteins on the inner cell membrane and is consequently transferred equally to 
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each daughter cell upon cell division, leading to declining fluorescence intensity. CFSE-labeled 
cells were cultured for up to five days in 96-well plates (5x105 cells/well) in 200 μl B cell medium 
per well with 10 % (v/v) FCS and were analyzed by flow cytometry every day.  
For Western blot analyses, MACS-purified B cells were left untreated for one hour in B cell 
medium with 1 % (v/v) FCS at 37 °C before proteins were isolated.  
8.2.5 In vivo 5-bromo-2´-deoxyuridine (BrdU) assay 
Mice were fed with 0.8 mg/ml BrdU (Sigma) in the drinking water for 14 days, while the water 
was exchanged every three to four days. Mice were maintained up to day 70 after the start of the 
BrdU feeding. Mice were analyzed at day 14, 42, and 70 during the assay. Thereby, the spleen was 
dissected and splenocytes were isolated as described above. BrdU incorporation into the DNA of 
splenic B cells was analyzed by using the APC BrdU Flow Kit (BD Biosciences) according to 
manufacturer’s instructions. 
8.2.6 Immunization of mice 
Mice at the age of eight to 12 weeks were immunized with 50 μg NP-Lipopolysaccharide (LPS), 
50 μg NP-Ficoll, or 100 μg NP-chicken gamma globulin (CGG) (4-hydroxy-3-nitrophenylacetyl 
hapten, all Biosearch Technologies). The latter was precipitated by potassium aluminum sulfate to 
enhance the immune response in mice. For precipitation, one volume of antigen was mixed with 
one volume of 10 % (w/v) KAl(SO4)2 and the pH was adjusted to pH 6.5 with 1 N NaOH. After 
30 minutes incubation on ice, the antigen was centrifuged for 10 minutes at 2.300 x g and washed 
three times in sterile PBS. NP-LPS and NP-Ficoll antigen stocks were quickly centrifuged before 
usage and the supernatant was transferred to a new tube to remove any precipitation. Finally, 50 
μg of each antigen were resuspended in 200 μl sterile PBS for intraperitoneal injection. 
8.2.7 Enzyme-linked immunosorbent assay (ELISA) 
To determine the serum concentration of secreted antibodies that offer a certain antigen 
specificity and/or are from a certain immunoglobulin isotype, the serum was collected and an 
ELISA was performed. 
8.2.7.1 Preparation of serum from murine blood 
Before and seven days after immunization, blood was collected from mice from the caudal vein 
using a glass capillary. Dissecting the mice seven or 14 days after immunization or in a regular 
analysis without immunization, blood was collected directly from the heart. Afterwards, the 
blood was incubated on ice for at least three hours and was subsequently centrifuged at 9.000 x g 
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and 4 °C for 10 minutes. The supernatant was transferred to a new tube and the procedure was 
repeated once to guarantee pure serum.  
8.2.7.2 Detection of specific standard immunoglobulin titers 
Maxisorb 96-well plates (Nunc) were coated over night at 4 °C with 5 µg/ml of immunoglobulin 
isotype-specific rat α-mouse antibodies (depending on the isotype: IgM, II/41; IgG1, A85-3; 
IgG2a, R11-8; IgG2b, R9-91; IgG3, R2-38; IgA, C11-3, all from BD Bioscience), diluted in 0.1 M 
NaHCO3 (pH 9.2). All the following procedures were performed at RT. Wells were blocked with 
PBS, 1 % (w/v) milk powder solution for 30 minutes. Subsequently, different dilutions of serum 
were applied to the wells and were incubated for one hour, then incubated one hour with biotin-
conjugated secondary antibodies specific for the different antibody isotypes (depending on the 
isotype: IgM-Bio, R6-60.2; IgG1-Bio, A85-1; IgG2a-Bio, R19-15; IgG2b-Bio, R12-3; IgG3-Bio, 
R40-82; IgA-Bio, C10-1, all from BD Bioscience), followed by a 30 minutes incubation with 
streptavidin-coupled alkaline phosphatase (SA-AP), diluted in 0.1 M NaHCO3 (pH 9.2) (1:2000). 
The amount of bound SA-AP was detected by incubation with O-phenyldimine (Sigma) in 0.1 M 
citric acid buffer containing 0.015 % (v/v) H2O2 that serves as substrate for the reaction. 
Following each incubation step, plates were washed three times with PBS. The absorbance was 
determined at 405 nm, using a microplate reader (Photometer Sunrise RC, Tecan) and antibody 
concentrations were determined by comparing with isotype-specific standards (IgM, G155-228; 
IgG1, MOPC-31-C; IgG2a, G155-178; IgG2b, MPC-11; IgG3, A112-3; IgA, M18-254). 
8.2.7.3 Detection of NP-specific immunoglobulin titers 
α-NP immunoglobulin titers of the different isotypes were determined by ELISA with the same 
procedure as described above, but using NP-BSA as capture antigen. Plates were coated with 5 
µg/ml NP17-BSA or NP3-BSA (both Biosearch Technologies) to detect low and high affinity NP-
specific IgG1 antibodies, respectively. After serum incubation, plates were subsequently 
incubated with the IgG1-specific rat α-mouse antibody A85-3 (BD Bioscience). To detect NP-
specific antibodies of the different isotypes, plates were coated with 5 µg/ml NP17-BSA and were 
incubated with the different immunoglobulin isotype-specific rat α-mouse antibodies (see above) 
after serum incubation. 
8.2.8 Immunohistochemistry 
Spleens were embedded in O.C.T. Tissue Tek (Sakura) and were frozen in liquid nitrogen for 
some seconds. Embedded organs were stored at -20 °C, wrapped in aluminum foil to avoid air 
contact. Sections of 4 to 8 µm in thickness were cut, using a cryostat (Leica Microsystems) and 
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were air-dried over night. Sections were fixed for five minutes in 100 % (v/v) acetone. 
Subsequently, sections were dried again at RT and stored at -20 °C wrapped in aluminum foil 
until analysis. For immunohistochemistry, sections were thawed 30 minutes at RT, washed with 
PBS, and incubated for 20 minutes in quenching buffer (PBS containing 10 % (v/v) goat serum, 
0.1 % (v/v) H2O2, 1 % (w/v) BSA) to block non-specific binding sites. Afterwards, sections were 
incubated for each 15 minutes in two different blocking buffers (Avidin/Biotin Blocking Kit; 
Vector Laboratories). Between procedures for blocking, sections were washed for five minutes in 
PBS, whereas before and after labeling procedures, sections were washed with PBS each three 
times for five minutes. Subsequently, labeling was performed by incubating sections with 
different antibodies and streptavidin-conjugated Phosphatase (Sigma), diluted 1:400 in PBS, each 
for one hour. 
Antibodies conjugated to streptavidin were detected in blue using Blue Alkaline Phosphatase 
Substrate Kit III (Vector laboratories). Antibodies conjugated to peroxidase were stained in red 
due to a reaction with 3-amino-9-ethylcarbazole (AEC) after treatment with Peroxidase Substrate 
Kit AEC (Vector laboratories). Staining reactions were stopped by washing with PBS. All 
incubation steps were performed at 22 °C in a wet chamber. 
Sections were air-dried and subsequently embedded in gelatin before a coverslip was put on top. 
Slides were inspected using a fluorescent microscope (Zeiss). Pictures were obtained with a digital 
camera (RS Photometrics) and edited using Adobe Photoshop software. 
8.3 Standard methods of molecular biology  
8.3.1 DNA isolation 
8.3.1.1 Plasmid isolation from bacteria and preparation for ES cell transfection 
Plasmids were isolated from bacteria with the Jetstar Kit (Genomed) for cloning or with the 
endotoxin-free Qiagen Maxi Kit (Qiagen) for transfection into ES cells. The targeting plasmid 
was linearized with SgfI according to the manufacturer’s protocol overnight at 37 °C and was 
purified by phenol-chloroform extraction. One volume of phenol-chloroform-isoamyl alcohol 
(ratio of components: 25:24:1, Roth) was added to the restriction mix and the tube was inverted. 
After centrifugation at 20.000 x g for five minutes, the upper phase containing genomic DNA 
was saved, one volume of chloroform-isoamyl alcohol (24:1) was added, and the tube was 
inverted. After the same centrifugation procedure, 1/10 volume 3 M NaAc and 2.5 volumes 100 
% ethanol (v/v) were added to the upper phase and the tube was inverted each time. To 
precipitate DNA efficiently, the tube was kept at -20 °C for 30 minutes. DNA was then spun 
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down by high speed centrifugation for 20 minutes. The pellet was washed and at the same time, 
the tube was sterilized by filling it completely with 70 % (v/v) ethanol. DNA was stored in this 
way until the day of transfection. For usage, the tube was centrifuged as described before and the 
DNA pellet was air-dried underneath the ES cell laminar flow bench. The dried pellet was 
resolved in 100 µl transfection medium (RPMI w/o phenol red, PAA) by incubation at RT for 
one hour and its density was subsequently measured to determine DNA concentration.  
8.3.1.2 Isolation of genomic DNA from ES cells 
To isolate DNA from ES cells growing on a 96-well plate, cells were grown to 90 % confluence 
in medium without LIF, and were washed twice with PBS before cells were incubated with lysis 
buffer (10 mM Tris pH 7.5, 10 mM EDTA, 10 mM NaCl, 0.5 % (w/v) sarcosyl, 0.4 mg/ml 
proteinase K) at 56 °C overnight. During this procedure, the 96-well plate was wrapped into 
plastic foil and put into a wet chamber (Tupperware®) to prevent drying out. Following, the 
Tupper box was cooled down at RT for one hour. After eight minutes centrifugation at 400 x g, 
100 µl 100 % (v/v) ethanol were added to each well to precipitate DNA. After incubation for one 
hour at RT and centrifugation as described above, the liquid was decanted and the DNA was 
washed with 150 µl of 70 % (v/v) ethanol three times before drying at RT up to one hour. 35 µl 
of the restriction buffer mix was directly added. 
To isolate DNA from ES cells growing on a 10 cm dish, cells were brought in suspension when 
grown to approximately 90 % of confluence. Cells were portioned in three 2 ml Eppendorf 
tubes, pelletized, and stored at -20 °C until DNA extraction. Cells of one tube were lysed over 
night in 750 µl of abovementioned cell lysis buffer. 305 µl of a saturated (> 5 M) NaCl solution 
were added and the sample was centrifuged at 9.000 x g. The supernatant was transferred to a 
new reaction tube and the DNA was purified by phenol-chloroform extraction as described in 
8.3.1.1. The DNA pellet was air-dried and resolved in TE buffer (10 mM Tris, pH 7.9, 1 mM 
EDTA) by shaking the tube for four hours at 37 °C.  
8.3.1.3 Isolation of genomic DNA from murine tails  
DNA from murine tails was isolated according to a slightly modified procedure derived from 
Laird (Laird et al., 1991). A small piece of murine tail was incubated shaking over night at 56 °C in 
500 µl lysis buffer (100 mM Tris/HCl pH 8, 5 mM EDTA, 0.2 % (w/v) SDS, 200 mM NaCl, 100 
µg/ml proteinase K). 170 µl of a saturated (> 5 M) NaCl were added to precipitate proteins and 
the sample was centrifuged at 10.000 x g. The supernatant was transferred into a new tube and 
the DNA was precipitated by adding 600 μl 100 % (v/v) isopropyl alcohol and inverting the tube. 
Samples were centrifuged as described above. The DNA was washed once by adding 1 ml 70 % 
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(v/v) ethanol, air-dried afterwards, and ultimately dissolved in 100 µl TE by shaking for several 
hours at 37 °C. 
8.3.2 DNA analysis 
8.3.2.1 Polymerase Chain Reaction (PCR) 
PCR (Saiki et al., 1985; Saiki et al., 1988) was applied to amplify notch2IC cDNA from the genomic 
DNA of targeted ES cells for sequencing or to detect specific regions in the DNA of transgenic 
mice for genotyping by analyzing their tail DNA. The following reaction mixture was used in 
different variations: 
 
Reaction batch 1x Reaction cycle   
Taq (10x)/Phusion (5x) buffer 2.5/5 μl Starting temperature 94 °C 5’  
MgCl2 (50 mM)/MgSO4 (25 mM) 1-2 μl Cyclic denaturation 94 °C  45’’ 
dNTP mixture (10 mM) 0.5 μl Cyclic annealing 55-63 °C 45’’ 
Primer sense 0.1-0.25 μl Cyclic elongation 72 °C 1-3’ 
Primer antisense 0.1-0.25 μl Final elongation 72 °C 10’ 
TaqPol (5 U/μl), Phusion (2 U/μl) 0.15-0.75 μl # cycles 30-35  
DNA (about 5 ng) 1.5 μl    
DMSO (100 %) 0.25 μl    
H2O To 25 μl    
8.3.2.2 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was performed according to Sambrook (2001), to determine the yield 
of a DNA isolation or PCR reaction, and to size-fractionate restriction-digested DNA molecules, 
which were then eluted from the gel. Gels contained 1x TAE (40 mM Tris/HCl, 20 mM acetic 
acid, 1 mM EDTA pH 8.5), 5 μg/ml ethidium bromide, and 0.8 to 2 % (w/v) agarose. 
Electrophoresis was performed in a gel electrophoresis chamber (Peqlab) with 1x TAE buffer at 
80 to 100 V for one to two hours. Specific DNA fragments of interest were excised from the gel 
with a clean scalpel and DNA was isolated using QIAquick Gel Extraction Kit (Qiagen) 
according to manufacturer’s suggestions. 
8.3.2.3 Sequencing 
DNA fragments were sequenced by Sequiserve, Vaterstetten, Germany, utilizing the chain 
termination method according to Sanger (Sanger et al., 1977) slightly modified.  
8.3.2.4 Restriction digest of DNA 
Restriction digest of plasmid DNA was accomplished using specific restriction enzymes 
according to manufacturer’s recommendations for reaction conditions and buffers. 
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Genomic DNA from ES cells was restricted by specific enzymes for the subsequent performance 
of Southern blotting. An efficient restriction buffer mix, containing 1 mM Spermidin, 1 mM 
DTT, 100 μg/ml BSA, 50 μg/ml RNase, respective 1x buffer, and 100 to 150 U of the respective 
enzyme, was either added directly to undissolved ES cell DNA (96-well) or to DNA from ES 
cells dissolved in TE buffer. DNA was digested for 16 hour at 37 °C.  
8.3.3 Southern blotting (Southern et al., 1997) 
This method was used for the identification of homologous recombined ES cell clones. Thereby, 
electrophoretically separated DNA is transferred from the agarose gel to a nitrocellulose 
membrane, and the hybridization of a radioactively labeled DNA probe to the denatured DNA 
on the membrane allows the detection of specific DNA fragments as definite bands on the 
membrane.  
After digestion as described in 8.3.2.4, the samples were electrophoretically separated on a 0.8 % 
(w/v) agarose gel together with a standard 1 kb DNA ladder (Invitrogen) and a λ DNA-Mono 
Cut Mix ladder (1.5 to 48.5 kb fragments, New England Biolabs) overnight. Having recorded the 
separated DNA in the gel on a UV luminescent screen together with a ruler, the gel was 
incubated in 0.25 N HCl for 25 minutes to denature and fragment the DNA. To equilibrate the 
gel for the following DNA transfer, the gel was shortly rinsed in water and subsequently 
incubated for 40 minutes in alkaline transfer buffer (0.4 M NaOH, 0.6 M NaCl). Afterwards, the 
DNA was blotted from the gel to a nylon membrane (ImmobilonTM Ny+ membrane, Millipore) 
over night from top to bottom by capillary pressure of the transfer buffer. After transfer, the 
slots of the gel were marked on the membrane and the membrane was rinsed shortly in 2x SSC 
(0.3 M NaCl, 0.03 M NaCitrate, pH 6.5) for neutralization. Then, DNA was cross-linked to the 
membrane by baking for one hour at 80 °C. In order to prevent unspecific binding, the 
membrane was pre-hybridized in pre-heated hybridization solution (1 M NaCl, 50 mM Tris, pH 
7.5, 10 % (w/v) dextran sulfate, 1 % (w/v) SDS, 250 μg salmon sperm DNA/ml) for at least six 
hours at 65 °C, before incubation with the radioactively labeled probe. 
Applying Random Prime Labeling Kit (GE Healthcare) according to manufacturer’s instructions, 
100 ng DNA probe were labeled with 50 μCi α32-dCTP (Hartmann Analytic). Subsequently, the 
labeled probe fraction was purified using a G50 sephadex column (GE Healthcare) according to 
manufacturer’s specifications. For denaturation, the probe was incubated for five minutes at 100 
°C and was quenched for two minutes on ice. The membrane was incubated for another 16 
hours at 65 °C in the hybridization solution, containing pre-hybridization buffer with labeled 
probe. 
Methods 
 105
Afterwards, the membrane was rinsed three times each for 10 minutes in pre-heated washing 
buffer (0.2x SSC, 0.5 % (w/v) SDS) at 58 °C to wash off unbound probe. Washing was stopped 
when radioactivity reached 30 counts. Radioactivity was visualized by autoradiography, using 
radiosensitive films (Biomax MS PE Applied Biosystems 35x43 cm, KODAK), exposed for one 
day at -80 °C in a Biomax cassette.  
8.3.4 Cloning 
Cloning of the DCR26CAGp-IRESCD2-Notch2IC vector was performed as follows: To obtain 
suitable restriction sites, the multiple cloning site of the puc18 vector was exchanged with a 
fragment containing SapI – AscI – SbfI – AscI – HindIII restriction sites (puc18_Oligo1). The 
notch2IC cDNA, corresponding to cDNA 5253 to 7583 (NCBI NM_010928) and thus encoding 
the full length murine notch2IC cDNA, was isolated from vector pHprt_Notch2IC by SbfI 
restriction and was then sub-cloned into the puc18 vector (puc18_Oligo1_Notch2IC). The 
notch2IC cDNA was then inserted into the DCR26CAGp-IRESCD2 targeting vector by AscI 
restriction of puc18_Oligo1_Notch2IC and DCR26CAGp-IRESCD2 (DCR26CAGp-IRESCD2-
Notch2IC). After plasmid propagation and isolation, the sequence integrity of important 
elements of this vector, including the CAGGS promoter, the loxP sites, the STOP cassette with 
neomycin-resistance gene, and the sequence encoding notch2IC-IRES-hCD2 was verified by 
sequencing. The targeting vector was linearized by SgfI digest for transfection into ES cells. 
8.3.5 RNA analysis 
8.3.5.1 Resolving of RNA  
Total RNA that had been isolated before using TRIzol reagent according to manufacturer’s 
specifications (Invitrogen), and had been stored precipitated in 100 % (v/v) isopropyl alcohol at -
80 °C was pelletized by centrifugation at 12.000 x g for eight minutes at 4 °C. Having washed the 
RNA pellet with 75 % (v/v) ethanol, it was briefly air-dried and the RNA was dissolved in 15 μl 
DEPC-H2O by passing the solution a few times through a pipette tip and incubating for 15 
minutes at 55 to 60 °C.  
To employ a definite amount of total RNA for cDNA synthesis, 2 μl RNA were diluted in 198 μl 
DEPC-H2O in a mini-cuvette (UVette, Eppendorf) and its absorbance at 260 nm was 
determined, using a Bio-Photometer (Eppendorf) to calculate RNA concentration. Additionally, 
the ratio of the readings at 260 nm and 280 nm (OD260/ OD280) provides an estimation of the 
purity of the RNA preparation, with respect to contaminants that absorb UV, such as proteins. 
Pure RNA has an OD260/OD280 ratio of > 1.95. 
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8.3.5.2 cDNA synthesis 
RNA can be reversely transcribed into a single-stranded DNA intermediate, called copy or 
complementary DNA (cDNA). Using oligo-dT primers, reverse transcriptase synthesizes the new 
cDNA strand starting at the 3´-end of the poly(A)-mRNA. 1 μg total RNA was reversely 
transcribed with > 10 U of viral AMV Reverse Transkriptase, using 1st Strand cDNA Synthesis 
Kit for RT-PCR [AMV] (Roche Diagnostics) with 0.02 A260 units (0.8 μg) Oligo-p(dT)15 primers 
according to manufacturer’s instructions, whereas each reaction was performed in a final volume 
of 10 µl. The resulting first strand cDNA was stored at -20 °C and was used as a template for 
qPCR. 
8.3.5.3 Quantitative real-time PCR (qPCR) 
Principle 
The technique of quantitative real-time PCR (qPCR) allows studying mRNA expression in a 
comparative manner and can be performed using the LightCycler system (Roche Diagnostics). 
Within the LightCycler instrument, a fluorescence-coupled PCR, working with FastStart Taq 
polymerase and SYBR green fluorescent dye, occurs in special glass capillaries and is monitored 
on-line by the instrument by means of fluorescence detection. SYBR green intercalates 
specifically into the minor groove of double-stranded DNA (Morrison et al., 1998). Whereas the 
unbound dye exhibits very little fluorescence, fluorescence is dramatically increased upon DNA 
binding. Therefore, the intensity of the fluorescence signal is directly proportional to the amount 
of double-stranded DNA generated by PCR. The fluorescence is measured at the end of each 
elongation phase, what allows monitoring the increase in the amount of amplified DNA in real 
time. In turn, the amount of amplified DNA provides an estimate of the amount of cDNA 
present in the sample that is specifically recognized by the used primers.  
Performance 
qPCR was performed using LightCycler FastStart DNA Master SYBER Green. cDNA was 
diluted in a ratio of 1:10 before use. For LightCycler reaction, a mastermix  was prepared as listed 
below and the mixture was filled in the LightCycler glass capillaries after adding the cDNA. 
Capillaries were centrifuged before qPCR was carried out with the LightCycler instrument (all 
purchased from Roche Diagnostics), using the protocol as stated below. Dilution series (10-3, 10-5, 
10-7, and 10-9) of former LightCycler amplification products were prepared to generate calibration 
curves, needed to determine PCR efficiencies later on. As negative control, template DNA was 
replaced by PCR-grade water. To document the specificity of the desired PCR products, samples 
were electrophoretically separated on a 2 % (w/v) agarose gel and analyzed on a UV luminescent 
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screen. As the specificity of a particular DNA product can also be assessed by monitoring the 
melting temperature of the amplified PCR products, LightCycler melting curve analysis was 
performed in addition according to manufacturer’s instructions.  
Mastermix  1x LightCycler run protocol 
Roche SYBER green mix 1 µl Starting temperature 95 °C 10’ 
MgCl2 (25 µM) ) 0.8 µl Cyclic denaturation 95 °C  1’’ 
Primer 1 (10 µM) 0.5 µl   Cyclic annealing 54-65 °C 10’’ 
Primer 2 (10 µM) 0.5 µl  Cyclic elongation 72 °C 16’’ 
H2O 6.2 µl Melting 70-97 °C 10’ 
cDNA 1 µl Cooling 40 °C 15’ 
  Transitionrate 0.1 °C/sec.  
Volume per Capillary 10 µl # cycles 40  
Primers 
Using Primer3 software, primers were designed to produce amplification products with the 
length of 300 to 400 bp. In addition, primers spanned always two flanked exons, to eliminate the 
possibility that contaminating genomic DNA would be amplified. Primers are listed in 7.6.  
Data normalization and processing 
In order to correlate the initial number of template molecules with real-time fluorescent curves, a 
certain quantity that is referred to as the crossing point (CP) needs to be determined for each 
transcript. The CP is defined as the point at which the fluorescence signal appreciably exceeds the 
background fluorescence (Higuchi et al., 1992). Thereby, the CP indicates the fractional cycle 
number at which the fluorescence signal reaches this fixed threshold. At the CP, the number of 
formed amplification products is supposed to be the same in all samples that are being compared. 
This number is assumed to be about 1010 copies. Furthermore, the PCR efficiency of each run 
has to be determined for the correlation. Therefore, serial dilutions of LightCycler products were 
carried out for each run. By plotting the CP cycles versus the logarithm of the dilution factor of 
product input, a standard curve is obtained. The corresponding PCR efficiency (E) of one run 
was calculated from the given slope of the standard curve according to the equation  
(1/slope)10E     (Rasmussen, 2001) (1) 
In order to quantify the amount of a target transcript present in one sample, the relative 
quantification method was applied, which is based on the relative mRNA expression of a target 
gene versus a reference gene. Therefore, a stable and securely unregulated gene, such as a 
housekeeping gene, is applicable. The gene encoding human ribosomal protein L23a, which is a 
component of the 60S subunit of the ribosome, was employed as reference gene, since its mRNA 
expression is considered to be stable, even under experimental treatment. 
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Based on the following mathematical assumptions, the amount of a target transcript that is 
initially present can be quantified. Assuming that X(target)CP is the number of target molecules 
present at the crossing point CPtarget, X(target)0 is the initial number of target molecules, and Etarget is 
the PCR efficiency of target amplification, an equation can be set up as follows: 
targetCP
target0CP )(EX(target)X(target)    (2) 
A similar equation for the reference reaction is 
refCP
ref0CP )(EX(ref)X(ref)     (3) 
where X(ref)CP is the number of reference molecules present at the crossing point CPref, X(ref)0 is 
the number of reference molecules initially present, and Eref is the PCR efficiency of reference 
amplification. Presuming that the number of molecules present at the crossing point is the same 
both in the target and the reference amplification reaction, the following equation can be 
arranged: 
reftarget CP
ref0
CP
target0 )(EX(ref))(EX(target)   (4) 
Setting X(ref)0 equal to 1, the initial number of target molecules can be calculated as follows: 
target
ref
CP
target
CP
ref
0
)(E
)(E
X(target)     (5) 
This is referred to as the relative concentration of target molecules compared to the number of 
reference molecules, initially present in the sample. In the majority of cases, the comparison of 
the relative concentration in one sample with the relative concentration in a corresponding 
control, for instance in respect of a special kind of treatment, the time, or the genotype, is 
especially necessary. Therefore, the relative expression ratio of target mRNA compared to the 
reference mRNA is calculated from the PCR efficiencies and the crossing point of the sample 
versus a control. 
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target
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
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This can be simplified to the equation as follows: 
   
   samplecontrolΔCPref
samplecontrolΔCP
target
ref
target
E
E
atio 

r   (Pfaffl, 2001b) (6) 
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with ΔCPtarget is the CP derivation of (control – sample) of the target gene transcript and ΔCPref  is 
the CP derivation of (control – sample) of the reference gene transcript. Having generated three 
biological replicates, one experimental run was performed from each cDNA and the ECP mean 
value was determined to calculate the relative expression ratio (R) according to equation 6. 
EREB2.5 cells were sampled at different time points (t = 0, 8, 24, 72 hours) to monitor the mRNA 
expression of target genes over a period of time. In order to calculate Rtime, values obtained at the 
time point t = 0 hours were set as control, and thus all residuals values are normalized to t = 0 
hours. Rtime of each biological repeat was determined separately before averaging the results. Data 
analyses were carried out using Excel software (Microsoft). 
8.3.6 Protein detection 
8.3.6.1 Protein isolation  
Following MACS purification, B cells were subsequently rested for one hour in B cell medium 
containing 1 % (v/v) FCS at 37 °C before proteins were isolated. Cells were washed twice with 
ice-cold PBS before protein extraction. To prepare whole-cell extracts, 20 µl of 2x NP40 lysis 
buffer (100 mM Tris pH 7.4, 300 mM NaCl, 4 mM EDTA, 2 % (v/v) NP40) containing freshly 
added phosphatase inhibitors (Halt phosphatase inhibitor cocktail, Pierce) and protease inhibitors 
(Mini Complete, Roche Diagnostics) were added to a pellet of 5x106 B cells without resuspension 
and the tube was shaken on a vortexer at 4 °C for 20 minutes. Cell debris and DNA was 
separated from the protein supernatant by centrifugation at maximum speed for 15 minutes at 4 
°C. For B cell fractionation, 2x107 B cells were incubated in 100 µl buffer A (10 mM HEPES pH 
7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1x protease inhibitors) for 15 
minutes on ice. After the addition of 6.75 µl 10 % (v/v) NP40 and shaking for five minutes at 4 
°C, nuclei were spun down at maximum speed for 15 minutes, and the supernatant containing 
the cytoplasmic fraction was saved. Nuclei were washed once with buffer A before lysis in 40 µl 
buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1x 
protease inhibitors). After shaking at 4 °C for 30 minutes and centrifugation at maximum speed 
for 15 minutes, the supernatant containing the nuclear fraction was saved. Protein samples were 
subsequently frozen at -80 °C. 
8.3.6.2 SDS polyacrylamide gel electrophoresis (PAGE) 
The protein concentration of each sample was quantified using a Bradford reagent (DC protein 
assay, Bio-Rad) according to manufacturer’s instructions and a bovine serum albumin standard 
slope. Protein mixtures were separated by discontinuous SDS PAGE (Laemmli, 1970). In 
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discontinuous PAGE, the acrylamide gel is composed of a stacking gel (5 % (v/v) acrylamide, 
0.625 mM Tris pH 6.8, 0.1 % (w/v) SDS, 0.1 % (w/v) APS, 0.006 % (w/v) TEMED), in which 
negatively charged proteins are focused at the separation line, and a resolving gel (10 to 12 % 
(v/v) acrylamide, 3.75 mM Tris pH 6.8, 0.1 % (w/v) SDS, 0.1 % (w/v) APS, 0.004 % (w/v) 
TEMED), in which proteins are separated according to molecular weight. 5x Laemmli buffer 
(300 mM Tris pH 6.8, 7.5 % (w/v) SDS, 50 % (v/v) glycerin, 0.01 % (v/v) bromphenol blue, 1 
% (v/v) β-mercaptoethanol) was added to the samples to a concentration of 1x before heating 
the samples at 70 °C for 10 minutes and loading denatured proteins onto a SDS polyacrylamide 
gel together with a protein standard (BenchmarkTM, Invitrogen). Electrophoresis was 
accomplished in Laemmli running buffer (25 mM Tris base, 0.2 M glycine, 0.1 % (v/v) SDS) at 
20 to 40 mA per gel, using a Bio-Rad electrophoresis chamber. 
8.3.6.3 Western blotting 
After having separated proteins by SDS PAGE, proteins were transferred onto a polyvinyliden 
fluoride (PVDF) membrane by using electrical current (Western blotting, Towbin et al., 1979). 
Proteins were blotted to the PVDF membrane (ImmobilonTM P membrane, Millipore) by wet 
transfer for three hours at 250 mA in transfer buffer (25 mM Tris base, 0.2 M glycine, 20 % (v/v) 
methanol), utilizing a Bio-Rad mini tank blotting chamber on a magnetic stirrer in the cold room. 
To verify protein transfer and equal loading, the membrane was incubated for five minutes in 
Ponceau S solution (Sigma) to stain proteins non-specifically.  
8.3.6.4 Immunostaining 
To block non-specific binding sites, membranes were incubated for one hour in TBST (0.1 M 
Tris/HCl pH 7.5, 0.1 M NaCl, 0.02 % (v/v) tween), containing 5 % (w/v) milk powder, with 
slight shaking. Incubation with the primary antibody was performed over night at 4 °C in TBST, 
containing 5 % (w/v) BSA, unless stated otherwise in chapter 7.8. The membrane was incubated 
with the secondary antibody, conjugated to HRP, diluted in TBST, containing 1 % (w/v) milk 
powder, for two hours at RT. Antibody incubation was always performed on a roller and the 
membranes were washed three times in between and afterwards with TBST for seven minutes 
with vigorous shaking. Proteins were visualized using Enhanced Chemiluminescence ECLTM (GE 
Healthcare) according to manufacturer’s instructions. Signals were detected by the exposition of 
photosensitive films (CEA RP new) using a Cawomat 2000 IR processor (both 
ErnstChristiansen). For reprobing with further antibodies, bound antibodies were stripped from 
the membrane by incubating in stripping buffer (62.5 mM Tris/HCl pH 6.8, 2 % (w/v) SDS, 100 
mM β-mercaptoethanol) at 56 °C for 30 minutes with slightly shaking. 
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Figure S1 Increased T cell numbers and more MZ-like B cells in the inguinal lymph nodes of 
Notch2IC//CD19Cre+/- mice. Absolute numbers of lymphocyte-gated, B220+ B cells, CD3+ T cells, 
B220+CD21intCD23+ Fo B cells, and B220+CD21highCD23- MZ B cells in the inguinal lymph nodes (iLN) 
of Notch2IC//CD19Cre+/- (blank circle) and control (filled circle) mice. Points represent data from 
individual mice and horizontal bars mark the mean value, indicated in numbers above each point column. 
* P < 0.1 ** P < 0.05, in comparison to control, as calculated by the two-tailed student’s t-test. 
 
 
 
 
 
Figure S2 Reduced B cell numbers in the spleen and more Thy1.2+ Notch2IC-expressing cells in 
the bone marrow of Notch2IC//CD19Cre+/+ mice. (A) Notch2IC//CD19Cre+/+ mice have reduced 
splenic B cell numbers compared to CD19Cre+/+ control mice. Absolute numbers of total counted cells, 
lymphocyte-gated, B220+ B cells, and CD3+ T cells in the spleen of Notch2IC//CD19Cre+/+ (blank 
circle) and CD19Cre+/+ control (filled circle) mice are displayed. Points represent data from individual 
mice and horizontal bars mark the mean value, indicated in numbers above each point column. * P < 
0.05, in comparison to control, as calculated by the two-tailed student’s t-test. (B) Higher percentages of 
Thy1.2+ cells within the hCD2+ cell population in the bone marrow of Notch2IC//CD19Cre+/+ mice 
compared to Notch2IC//CD19Cre+/- mice. Mean percentages and SD of Thy1.2 expression on 
lymphocyte-gated, hCD2+ cells in the bone marrow of Notch2IC//CD19Cre+/- (left) and 
Notch2IC//CD19Cre+/+ (right) mice are illustrated. Data are representative for two independent 
experiments. 
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Figure S3 Immunoglobulin titers in non-immunized and immunized Notch2IC//CD19Cre+/- 
mice. Points represent data from individual mice and horizontal bars mark the mean value. Control (filled 
circle); Notch2IC//CD19Cre+/- (blank circle); Non-immunized control (filled triangle); * P<0.1, ** 
P<0.01, in comparison to control. (A) Serum concentrations of total immunoglobulin titers of indicated 
isotypes from 10 to 12 week-old non-immunized mice were determined by ELISA. (B) NP-specific 
antibody response to T cell-dependent antigen. Mice were injected intraperitoneally with 100 μg NP-CGG 
and concentrations of NP-specific antibodies of the indicated isotypes were measured by ELISA at day 14 
after immunization. Four mice were analyzed per group. (C) NP-specific antibody response to T cell-
independent antigen. Mice were injected intraperitoneally with 50 μg NP-LPS and concentrations of NP-
specific antibodies of the indicated isotypes were measured by ELISA at day 14 after immunization. Two 
mice were analyzed per group. 
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